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RIASSUNTO 
 
Il morbo di Parkinson (PD) è la principale malattia neurodegenerativa riguardante 
la funzionalità motoria. L'1% della popolazione sopra i 65 anni è affetto da questa 
malattia. I sintomi principali sono bradichinesia, tremore a riposo, instabilità posturale, 
rigidità muscolare e, talvolta, problemi cognitivi e della personalità. Le principali 
caratteristiche neuropatologiche del PD sono la morte dei neuroni dopaminergici a livello 
della substantia nigra pars compacta e la formazione di corpi d’inclusione citoplasmatici 
composti da aggregati proteici fibrillari di tipo amiloide, Lewy bodies (LBs), il cui 
costituente principale è α-sinucleina (aS) (Spillantini et al., 1998). aS è proteina di 140 
amminoacidi, natively unfolded, la cui funzione, nonostante il suo ruolo chiave nel PD, 
non è ancora completamente chiarita. È espressa in livelli alti nel sistema nervoso 
centrale ed è abbondante nei terminali presinaptici neuronali. Strutturalmente è 
caratterizzata dalla presenza di sette ripetizioni imperfette di sequenza aminoacidica 
(KTKEGV) nella regione N-terminale, da una regione idrofobica centrale (NAC, non-
amyloid component) e da una coda C-terminale con numerosi residui acidi. La 
sovraespressione di aS e mutazioni nel suo gene sono associati a forme precoci della 
sindrome di Parkinson. Il meccanismo con cui un cambiamento nella struttura e 
nell’espressione della proteina possa portare allo sviluppo della malattia non è ancora 
stato chiarito, ma è sempre più accreditata l’ipotesi che siano le forme oligomeriche e 
non gli aggregati finali fibrillari ad essere responsabili della malattia.  
Il progetto di questa Tesi riguarda la caratterizzazione di oligomeri tossici di α-
sinucleina (aS) ottenuti in presenza di acido docosaesaenoico (DHA) e lo studio della loro 
interazione con membrane lipidiche, allo scopo di comprendere il meccanismo con cui 
esercitano la loro tossicità. Il DHA è uno dei principali acido grassi cerebrali, strettamente 
correlato al PD e ad aS. L’esposizione di colture cellulari dopaminergiche a PUFAs porta 
all’accumulo di oligomeri solubili di aS, responsabili della citotossicità associata alla 
neurodegenerazione (Assayag et al., 2007). Esistono poi evidenze dell’implicazione di aS 
nella regolazione del metabolismo degli acidi grassi (Golovko et al., 2007). Inoltre è stato 
osservato che, nei pazienti affetti da PD, la presenza di DHA è maggiore nelle aree 
cerebrali contenenti inclusioni di aS. Studi in vivo, infine, hanno dimostrato che il DHA 
induce la formazione di oligomeri di aS (Sharon et al., 2003). In precedenti studi condotti 
 - 2 - 
nel laboratorio dove è stata svolta questa Tesi è stato analizzato il processo di 
aggregazione di aS in presenza di DHA, utilizzando due diversi rapporti molari 
proteina/acido grasso) (De Franceschi et al., 2009) e gli aggregati proteici ottenuti in 
queste condizioni sono stati caratterizzati da un punto di vista morfologico e strutturale 
(De Franceschi et al., 2011). È stato osservato che la presenza di DHA in rapporto molare 
50:1 rispetto alla proteina, porta alla formazione di oligomeri stabili, off-pathway nel 
processo di fibrillazione, che presentano una significativa attività tossica sulle cellule 
rispetto al monomero di aS.  
Nella prima parte di questa ricerca è stata condotta una caratterizzazione di 
queste specie oligomeriche che sono sufficientemente stabili nel tempo da consentire 
l’uso di diverse tecniche biofisiche. In particolare gli oligomeri sono stati analizzati 
mediante microscopia elettronica a trasmissione (TEM) e a forza atomica (AFM), per 
studiare le dimensioni e la morfologia. Il tipo di struttura secondaria è stata valutata 
mediante dicroismo circolare che ha dimostrato un’altra peculiarità di questi oligomeri, 
ovvero la presenza di struttura parzialmente in α-elica, diversamente dalla maggior parte 
degli oligomeri descritti in letteratura. È stata analizzata anche la capacità degli oligomeri 
di interagire con le membrane, utilizzando liposomi di diversa dimensione e diversa 
composizione e colture cellulari. L’interazione tra gli oligomeri e i liposomi, studiata 
mediante CD e saggi di leakage, causa il rilascio di piccole molecole interne alle vescicole, 
dimostrando così un loro effetto destabilizzante sulle membrane. L’attività degli oligomeri 
è stata anche testata su cellule in coltura che mostrano un’alterata permeabilità in loro 
presenza. Per determinare quale sia il meccanismo di destabilizzazione degli oligomeri, 
sono stati eseguiti vari saggi. Si è dimostrato tramite dynamic light scattering (DLS) e TEM 
che le vescicole, in seguito al legame con gli oligomeri, non vengono distrutte. Inoltre 
mediante studi di aggregazione e analisi su planar lipid membrane portano a ipotizzare un 
meccanismo di tossicità dovuto alla formazione di un’apertura transiente o un aumento 
di flip-flop a livello delle membrane. I risultati di questa parte di tesi sono oggetto di una 
pubblicazione (Fecchio et al., 2013). 
Un altro aspetto che è stato approfondito in questo lavoro di Tesi è lo studio degli 
oligomeri da un punto di vista chimico, allo scopo di caratterizzare le modifiche chimiche 
presenti sulla sequenza della proteina in seguito all’esposizione al DHA. Sono state 
evidenziate diverse modifiche mediante spettrometria di massa tra cui carbonilazioni e 
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presenza di addotti. Quest’ultimo tipo di modifica in particolare avviene a livello 
dell’istidina in posizione 50. Per approfondire il ruolo di questo aminoacido 
nell’interazione con gli acidi grassi è stato  studiato il mutante H50Q di aS. Questa 
proteina modificata è tra l’altro responsabile di forme familiari del PD.  
 Infine è stata studiata anche l’interazione di altre varianti patologiche di aS associate 
a PD, A30P, E46K e A53T con DHA. In particolare, è stata analizzata la loro struttura e la 
loro tendenza ad aggregare in presenza di DHA, nonché la loro capacità di formare 
oligomeri, in confronto ai risultati ottenuti con aS. 
 In conclusione questo studio ha permesso di fornire maggiori informazioni sulla 
struttura e di studiare l’attività di specie oligomeriche che sono potenzialmente molto 
rilevanti per la patogenesi del PD. La struttura e l’attività di questi oligomeri potrà essere 
confrontata con quelle di oligomeri prodotti in diverse condizioni sperimentali o  di 
oligomeri prodotti da altre proteine amiloidogeniche. Questa conoscenza è fondamentale 
per sviluppare agenti terapeutici che prevengano o debellino queste malattie debilitanti 
ed in continuo aumento. 
 
 - 4 - 
SUMMARY 
 
Parkinson disease (PD) is the main neurodegenerative disease that involves motor 
symptoms. About 1% of population above 65 years is affected by PD. Main symptoms are 
bradikinesia, resting tremor, postural instability, muscle rigidity, and sometimes, cognitive 
problems and personality. Neuropathological features of PD are neuronal death in the 
substantia nigra pars compacta and formation of cytoplasmatic inclusion, named Lewy 
bodies, constituted by fibrillar form of α-synuclein (aS). aS is a 140 amino acid protein, 
whose structure and function is yet not well defined. As a consequence of specific genetic 
mutations or environmental factors, it undergoes aggregation and forms amyloid fibrils. It 
is highly expressed in neuronal pre-synaptic nerve terminals. Its sequence is characterized 
by an amphipathic lysine-rich amino terminus, which governs binding to lipids and 
interactions with membranes and contains seven imperfect repetition of the sequence 
KTKEGV; by a hydrophobic central region (NAC, non-amyloid component), responsible for 
protein aggregation and β-sheet formation and a highly acidic C-terminal, rich in Pro and 
acidic residues. Overexpression of aS and mutations in its gene are associated with a 
premature development of PD. Mechanism that make aS a toxic protein has not yet been 
well clarified, but it seems clear that oligomeric forms, and not the final fibrillar forms, are 
the main responsible for the pathogenesis of PD. 
The project of this thesis focuses on the characterization of oligomers of aS that 
form in the presence of docosahexaenoic acid (DHA), and their interaction with 
membrane, to understand the mechanism of toxicity. DHA is one of the most abundant 
fatty acids in neuronal membrane and it has been correlated to PD. It has been 
demonstrated that dopaminergic cell cultures exposed to PUFAs accumulate soluble 
cytotoxic aS oligomers (Assayag et al., 2007). Indeed, aS seems to be involved in fatty 
acids metabolism (Golovko et al., 2007). Moreover, it was reported that, in PD patients, 
DHA concentration is enhanced in those area affected by aS inclusions. In vivo studies 
demonstrated that a DHA enriched diet enhances formation of aS oligomers (Sharon et 
al., 2003). In previous studies in this laboratory, it was analyzed the aggregation process 
of aS in the presence of DHA using different protein to DHA molar ratios (De Franceschi et 
al., 2009; 2011). Oligomers obtained in these conditions were characterized from a 
morphological point of view (De Franceschi et al., 2011). The presence of DHA (50:1 
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lipid:protein molar ratio) leads to the formation of stable oligomers, off-pathway in the 
aggregation process of aS, that have significant toxic activity on cells, suggesting that they 
are potentially relevant in the pathogenesis of PD (De Franceschi et al., 2011).  
In the first part of this thesis a characterization of oligomers have been conducted 
using several biophysical methods, since these oligomers are sufficiently stable to  allow 
the use of these techniques. In particular, transmission electron (TEM) and atomic force 
(AFM) microscopy were used to study oligomers morphology and dimension. The 
secondary structure was evaluated by circular dichroism (CD). This spectroscopic analysis 
reveals that oligomers have a partial α-helix structure, in contrast with the majority of 
oligomeric species described in literature. It was analyzed also the ability of oligomers to 
interact with membrane, using liposomes of different size and composition and cell 
cultures. Interaction of oligomers with membrane, analyzed by CD measurements and 
leakage assays, causes the leakage of small molecule, demonstrating their ability to 
destabilize membranes. Oligomers activity was tested also on dopaminergic cell culture 
that showed an altered permeabilization after treatment. To determine the mechanism 
by which oligomers cause membrane permeabilization, different tests were performed. 
Initially, dynamic light scattering (DLS) and TEM allow to exclude a detergent-like effect.  
Moreover, aggregation studies and planar lipid membrane (PLM) measurements lead to 
hypothesize a toxicity mechanism that depends on the formation of a transient aperture 
or on the enhancement of flip-flop. This part of the thesis is object of a publication 
(Fecchio et al., 2013). 
Another aspect faced in this thesis is the study of chemical modification occurring on 
oligomers after exposition to DHA. Different chemical modification were evidenced by 
mass spectrometry: carbonylation and the formation of adduct with DHA at the level of 
His50. To deepen the role of this residue in the interaction with FA, it was used an aS 
variant, H50Q, that has recently been linked to familiar form of PD.  
 Finally, also the interaction with DHA of other pathological variants of aS (A30P, 
E46K, A53T) was studied. In particular their secondary structure and oligomerization in 
the presence of DHA were analyzed, in comparison with results obtained with aS.  
In conclusion, this study supplied further information about structure and activity 
of oligomeric species that are potentially relevant in PD pathogenesis. These data can be 
compared to oligomers produced in different conditions or formed by different 
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amyloidogenic proteins: this knowledge would be fundamental to the development of 
therapeutic agent that would prevent or defeat these kind of debilitative diseases. 
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Fig. 1.1. substantia nigra: it is 
evident the loss of pigmented 
neurons in PD patients. 
1. INTRODUCTION 
1.1 Parkinson disease  
Parkinson’s disease (PD), after Alzheimer’s disease, is the second most-prevalent 
neurodegenerative disorder, affecting about 1 of peolpe over 60 (Van Den Eeden et al., 
2003). It was first described in 1817 by James Parkinson: it is an irreversible, progressive 
disease that impairs movement causing tremors, bradykinesia, muscular rigidity and 
postural instability, but the disease can be also associated to poorly treatable nonmotor 
symptoms, such as depression, personality changes, dementia, sleep disturbances, 
speech impairments (Lim and Lang, 2010). Aging is the only known definitive risk factor 
for both idiopathic and sporadic PD (Tolleson and Fang, 2013): indeed, incidence 
increases markedly with age. Young-onset Parkinson's disease, defined as occurrence 
before age 40, accounts for just 5% of newly diagnosed cases (Irvine et al., 2008). 
Moreover, upon reaching the 65-69 age range, 0.6% of the population is affected, 
increasing to 2.6 % of those aged 85-89 (De Rijk et al., 2000). The majority of cases of PD 
are believed to be idiopathic and sporadic, except for 5-10% of cases for which there is a 
genetic component, showing both recessive and 
dominant modes of inheritance. An other train of 
thought support that environmental or genetic cause 
for PD are a false dichotomy: many, if not all, cases of 
PD contain contribution of both, albeit in varying 
degrees (Singleton et al., 2013). 
PD is caused by degeneration of dopaminergic (DA) 
neurons that leads to depigmentation of the substantia 
nigra pars compacta (SNpc) (Fig. 1.1).  Pathologically, 
PD is highlighted by the presence of eosinophillic, 
intraneuronal proteinaceous inclusions known as Lewy 
bodies (LBs) and dystrophic Lewy neurites in the 
surviving neurons (Fig. 1.2 B, C). These intraneural 
inclusions were described in 1912 by Friederick H. Lewy, 
after investigation of histological features of sixty PD 
patients’ brain (Lewy, 1912). LBs represent the cardinal 
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hallmark of PD pathology, and have been considered to be a marker for neuronal 
degeneration, because neuronal loss is found in the predilection sites for LBs 
(Wakabayashi, 2007; Lees, 2009). However, it is not clear if the formation of LBs is a 
primary mechanism or a consequence (Tolleson and Fang, 2013). Because patients 
suffering from other neurological disorders can display parkinsonian features, a definitive 
diagnosis of Parkinson’s disease can be confirmed only by post mortem histopathological 
examination of the substantia nigra for the loss of pigmented neurons and presence of 
LBs in remaining neurons. Identification of LBs has been facilitated by immunostaining for 
particular proteins; initially for ubiquitin and more recently for aS, now regarded as the 
major protein constituent (Shults, 2006). Such staining reveals filaments that, when 
purified and examined by immuno-electron microscopy, can be seen to contain aS 
(Spillantini et al., 1998). The recombinant protein forms similar filaments (Fig. 1.2 A) when 
it is allowed to aggregate in vitro (Crowther et al., 1998).  
Fig. 1.2. Schematic representation of neuronal loss in substantia nigra due to aS fibril formation, 
in brain of patience of PD. (reprinted from Ruipérez et al., 2010). Draw of LBs by Dr. Lewy 
(reprinted from Lewy 1923). (B) and (C) Nerve cell with three and two LBs that are double-stained 
for aS and ubiquitin. The halo of each LB is strongly immunoreactive for ubiquitin, whereas both 
the core and the halo of each Lewy body are immunoreactive for α-synuclein (Bar = 10 μm) 
(reprinted from Spillantini et al. 1998). 
A 
B C 
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The motor complications caused by PD appear only after a significant loss of of dopamine 
cells: approximately 50% in the SNpc and 80% in the striatum (Ozansoy and Basak, 2012). 
The role of dopamine (DA) as neurotransmitter was defined in the late 1950s by the 
Swedish scientist Arvid Carlsson, who deserved for this reason the Nobel Prize in 2000. 
His studies were rapidly converted into clinical investigations and resulted within a few 
years in the first clinical treatment of PD, a therapy that is still in wide use today 
(Andersen, 2009). DA neurons operate in a pathway that controls voluntary movement. 
This involves signals being relayed from the cerebral cortex through the basal ganglia back 
to the cortex and then on to 
muscles. Neurons from the 
substantia nigra pars compacta 
project axons that release 
dopamine in synapses on 
interneurons in the striatum. 
As the dopamine containing 
neurons die, failure to 
complete this circuit results in 
inability to coordinate 
movement (Fig. 1.3). 
Neuromelanin, the black 
pigment that gives its name to 
the substantia nigra (SN), is a 
byproduct from the metabolic 
pathway for dopamine 
synthesis. When the 
symptoms of PD first become 
apparent, more than 70% of 
the dopamine containing 
neurons have already been 
lost, releasing their 
neuromelanin and hence 
turning the tissue less black 
Fig. 1.3. DA is synthesized in the cytoplasm by the action of 
tyrosine hydroxylase (TH) and amino acid decarboxylase 
(AADC). 1- As has been shown to regulate the activity of 
these enzymes. 2- Once synthesized, DA is immediately 
sequestered into vesicles by the vesicular monoamine 
transporter 2 (VMAT2). Several lines of evidence suggest 
that α-synuclein is involved in regulating synaptic vesicle 
function and dopamine release into the synaptic cleft. 3- 
Dopaminergic signaling at the synapse is terminated by the 
reuptake of dopamine via the dopamine transporter (DAT), 
with co-transport of two Na+ and one Cl− ions. Studies in cell 
culture systems have shown that α-synuclein is necessary 
for the trafficking of DAT to the cell surface (Reprinted from 
Venda et al., 2010).  
 - 10 - 
(Fig. 1.1). It is now apparent, however, that many regions of the brain are affected in 
Parkinson’s disease, and indeed in the early stages it may affect only a lower region of the 
brain stem called the medulla oblongata, spreading gradually upward through the basal 
ganglia into the cortical areas (Irvine et al., 2008; Braak et al., 2003). Symptoms of PD 
could be reversed temporarily by restoring striatal dopaminergic neurotransmission with 
pharmacologic interventions (LeWitt, 2008; Hornykiewicz, 2002), using DA agonists, 
compounds that directly stimulate postsynaptic receptors. The administration of 
dopamine itself is ineffective because dopamine cannot cross the blood–brain barrier 
(Nutt et al., 1984). Levodopa (3, 4-dihydroxy-L-phenylalanine), a naturally occurring 
amino acid, is an intermediate in the pathway of dopamine synthesis (Fig. 3). After oral 
ingestion, levodopa is actively transported from the upper small intestine into the 
circulation by a mechanism specific for large, neutral L-amino acids. Because of ongoing 
metabolism and the distribution of levodopa throughout the body, only a small fraction of 
the drug reaches the brain after active transport across the blood–brain barrier. Once 
there, dopamine is rapidly formed from levodopa by aromatic L-amino acid decarboxylase 
(AAAD). Moreover, the coadministration of other drugs can improve the efficacy of 
levodopa. In conclusion, current medications only provide symptomatic relief and fail to 
halt the death of DA neurons. A major hurdle in development of neuroprotective 
therapies are due to limited understanding of disease processes leading to death of DA 
neurons (Thomas & Beal, 2007). 
 
1.1.1 Pathogenesis 
 Although the majority of PD cases are idiopathic, about 10% of cases report with a 
family history, and a growing number of mutations have been associated with familial and 
sporadic forms of the disease (Lesage and Brice, 2009; Westerlund et al., 2010). The 
primary pathological change in Parkinson's disease is the destruction of dopamine 
containing cells in the zona compacta of substantia nigra (Jenner, 1989), so one important 
question to study Parkinson’s disease is why dopaminergic neurons are particularly 
vulnerable. One hypothesis is that the metabolic pathways for dopamine synthesis might 
be at the root of the problem (Jenner, 1989). There is evidence that dopamine 
metabolites can increase levels of reactive oxygen species that damage cells, especially 
mitochondria; for example, neuromelanin binds heavy metals that can lead to free radical 
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production (Turnbullet al., 2001). The unique susceptibility of dopaminergic neurons to 
some toxins, such as 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) or 
Rotenone, leads to another hypothesis that postulated exposure to environmental toxins 
as the cause. For example, MPTP is taken up by the dopamine transporter, and this fact 
explains the localization of pathological effects (Langston et al., 1983; Ramsay et al., 
1986; Dauer et al., 2003). However, while there are some cases where a single 
environmental or monogenetic factor may lead to PD (MPTP poisoning or triplication of 
aS, respectively) (Farrer et al., 2004, Przedborski et al., 2001 and Singleton et al., 2003), it 
is more likely that a subtle yet complex interplay exists between genetic and 
environmental factors in the etiology of disease. For example, the autosomal dominant 
G2019S mutation in leucine-rich repeat kinase 2 (LRRK2) is the most common known 
cause of familial and sporadic patients with PD, yet its penetrance is age-dependent, and 
some individuals may never be afflicted (Goldwurm et al., 2007 and Kachergus et al., 
2005). The manifestation of such a predominant mutation as a late onset disorder, where 
it is still not fully penetrant, suggests that genetic defects may serve to predispose 
individuals to certain environmental challenges (Jason et al., 2011). 
Fig. 1.4. Common pathways in PD pathogenesis that involve aS, with promoting (green arrows) or 
inhibitory (red lines) effects (reprinted from Thomas & Beal, 2007).  
 
 In Fig. 1.4 is reported a schematic representation of several different pathways 
that are important in modulating pathogenic events. aS undergoes aggregation either due 
to pathogenic mutations or catechol oxidation which in turn compromise UPS function, 
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induce endoplasmic reticulum stress and cause mitochondrial dysfunction. Mitochondrial 
dysfunction and oxidative damage lead to deficits in ATP which may compromise US 
function promoting abnormal protein aggregation. β-Synuclein is known to prevent aS 
aggregation through activation of Akt signaling. Parkin, an ubiquitin E3 ligase, 
promotesproteasomal degradation, increases mitochondrial biogenesis by activating 
mitochondrial transcription factor A (TFAM) and block PINK1-induced mitochondrial 
dysfunction, while pathogenic mutations, oxidative and nitrosative damage, severely 
compromise its protective function. DJ-1 protects against oxidative stress, functions as a 
chaperone to block aS aggregation and protects against mitochondrial dysfunction. PINK1 
seems to protect against mitochondrial dysfunction which is compromised due to 
pathogenic mutations, although the precise function of PINK1 in mitochondria still needs 
to be determined. L-RRK2 seems to play a role in synaptic vesicle functions, neurite 
outgrowth. Pathogenic mutations in LRRK2 cause abnormal protein phosphorylation 
which induce mitochondria-dependent cell death. In addition, a pathogenic role of 
PI3kinase-Akt (phosphatidylinositol 3-kinase/Akt) and Nrf2/ARE signaling is implicated in 
PD pathogenesis. Familial PD-linked genes namely parkin, DJ-1 and PINK1 activate PI3 
kinase-Akt signaling, while activation of Nrf2/ARE pathway prevents against oxidative 
damage and mitochondrial dysfunction promoting cell survival (Thomas and Beal, 2007). 
 
Genetic factors in PD 
 Ninety per cent of PD cases are sporadic. The remaining minority fraction of PD 
patients carries genetic form of the disease: both autosomic dominant or autosomic 
recessive gene mutations have been found. A distinction has to be done between two 
terminologies. Parkinsonism defines the syndromic features of PD patients movement 
disorders. It is consistent with the loss of dopaminergic neurons in SNpc and consequent 
nigral degeneration. The second term is synucleinopathy that identifies all the pathologies 
linked to aS accumulation in LB. This definition includes PD, dementia with Lewy bodies 
and multiple system atrophy. All PD patients shows parkinsonism, but not all present aS 
accumulation. Generally, these latter cases are directly correlated with autosomic 
recessive PD. While autosomic dominant PD is linked to point mutant of aS A53T 
(Polymeropoulos et al., 1997), A30P (Kruger et al., 1998) E46K (Zarranz et al., 2004), and 
recently with H50Q (Proukakis et al., 2013) and G51D (Kiely et al., 2013) some recessive 
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genes are associated with mitochondria and oxidative-stress related survival pathways, 
other with ubiquitin proteasomal system (Table 1.1). 
 
Table 1.1. Summary of genetic locus and candidate genes for PD (Lai et al., 2012):  
Locus Chromosome Gene Inheritance 
PARK ¼ 4q21.3 SNCA Autosomal dominant 
PARK 2 6q25.2-27 Parkin Autosomal recessive 
PARK 3 2p13 Unknown Autosomal dominant 
PARK 5 4p14 UCHL-1 Autosomal dominant 
PARK 6 1p35-p36 PINK1 Autosomal recessive 
PARK 7 1p36 DJ1 Autosomal recessive 
PARK 8 12q12-q13.1 LRRK2 Autosomal dominant 
PARK 9 1p36 ATP13A2 Autosomal recessive 
PARK 10 1p32 Unknown Susceptibility locus 
PARK 11 2q36-37 GIGYF2 Autosomal dominant 
PARK 12 Xq21-25 Unknown X-linked 
PARK 13 2p13.1 HTRA2/Omi Autosomal dominant 
PARK 14 22q13.1 PLA2G6 Autosomal recessive 
PARK 15 22q11.2-qter FBXO7 Autosomal recessive 
PARK 16 1q32 Unknown Susceptibility locus 
PARK 17 4p16 GAK Susceptibility locus 
PARK 18 6p21.3 HLA-DRA Susceptibility locus 
 
 Till now, linkage studies have identified seventeen loci, named PARK, correlated 
with PD or related disorders (Parkinsonism syndromes and LBD) (table 1.1, from Lai et al., 
2012). The loci include six autosomal dominant genes, the main are aS (SNCA) and 
leucine-rich repeat kinase 2 (LRRK2), and six autosomal recessive genes, parkin, PTEN-
induced putative kinase 1 (PINK1), DJ-1, lysosome ATPase type (ATP13A2), PLA2G6, and 
FBXO7. The ubiquitin carboxyl-terminal esterase L1 gene, (UCHL1, previously known as 
PARK5), has only been found in one small family, and its importance in familial PD is still 
uncertain. Identification of other Mendelian forms of PD still remains a main challenge in 
PD research. PARK1 and PARK4 were initially assigned to different regions on 
chromosome 4, but later ascribed to the same locus. Moreover, other genes, coming 
from different loci, have been linked to PD and Parkinsonism, such as GBA 
(glucocerebroside), MAPT (microtubule associated protein tau), spatacsin, ataxin 3 and 
actasin 2 (Hardy, 2010). Unsurprisingly, the application of new techniques such as next 
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generation sequencing (NGS), genome-wide association studies (GWAS) and meta-
analyses have allowed for the discovery of new genes and genetic risk factors for 
Parkinson disease and also other movement disorders, such as dystonia, essential tremor 
and restless legs syndrome (RLS) (Kumar et al., 2012). As an example, two independent 
studies utilized exome sequencing in a Swiss and an Austrian kindred to identify the same 
p.D620N (c.1858G>A) mutation in the vacuolar protein sorting  5 homolog (VPS35) gene 
as the cause of autosomal dominant Parkinson disease in these families (Vilarino-Guell et 
al., 2011; Zimprich et al., 2011). 
 
PARK1: aS gene 
 The discovery that aS is the main component of LBs is subsequent to the 
recognition of a mutation linked to PD in the SNCA gene (Polymeropoulos et al., 1997). 
Autosomal dominant early-onset PD has been linked to several point mutations (A30P, 
A53T, E46K, H50Q and G51D) in the gene encoding aS (Polymeropoulos et al., 1997; 
Kruger et al., 1998; Zarranz et al., 2004; Proukakis et al., 2013; Kiely et al., 2013. All 
mutations are reported in Fig. 1.5. 
1              10               20    30     40      50        60 
MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK  
            70               80               90              100   110     120 
EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP  
        130            140 
DNEAYEMPSE EGYQDYEPEA  
 
Fig. 1.5. Sequence of aS. The point mutations linked to autosomal dominant early-onset PD are 
colored. 
 
 A53T was the first mutation to be identified: it causes earlier onset of the disease 
(about 7-10 years earlier), and much lower prevalence of tremor compared with patients 
with sporadic PD (Papapetropuolus et al., 2001). PD patients with A30P and E46K 
mutation display as well earlier onset of the disease. Moreover, also duplications and 
triplications of PARK1 locus cause autosomal dominant, early onset PD (Singleton et al., 
2003; Chartier-Harlin et al., 2004). The age of onset and severity of the disease phenotype 
seems to correlate with SNCA copy number, suggesting a gene-dosage effect (Cookson, 
2005). PD patients who carry duplications, which generate three copies of the gene, tend 
to have PD which develops slowly from the 40s. Locus triplications, which produce four 
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copies of the SNCA gene, are responsible of earlier onset disease (mid 20-mid 30) (Farrer 
et al., 2004; Wood-Kaczmar et al. 2006).  
AS variants differ for the kinetics of fibrillation: the rate is increased for the A53T 
and the E46K substitutions (Conway et al., 1998; Greenbaum et al., 2005), while it is 
decreased in the case of A30P (Conway et al., 2000). Moreover, both the A53T and the 
A30P mutations promote accumulation of prefibrillar oligomeric species (Conway et al., 
2000), while the E46K protein reduces the formation of such aggregates (Fredenburg et 
al., 2007). Deep structural studies on the point-mutated aS variants have been performed 
for the first mutants discovered, while poor data are available for the latest, i.e. H50Q and 
G51D. NMR analyses have shown, for A30P, A53T and E46K, that these mutations have no 
global effects on the structural properties of the protein or on the dynamic behaviour of 
the aS backbone (Bussell & Eliezer, 2001, Fredenburg et al., 2007). Nevertheless, the 
secondary structure propensity for the free disordered state of the wt protein is different 
the three PD-linked variants. Specifically, the analysis of the Cα secondary shifts revealed 
that the A30P mutation decrease the helical propensity found in the N-terminal region of 
wt aS. The A53T mutation induces a more subtle and local preference for extended β-
sheet like conformations around the site of mutation (Bussell & Eliezer, 2001). The study 
on E46K indicated that this mutation results in only very minor conformational changes in 
the free state of aS (Fredenburg et al., 2007). Bertoncini et al. (2005b) analyzed the 
perturbation induced by A30P and A53T mutantion in aS conformers ensemble. The two 
variants show increased backbone flexibility and the absence of the long-range 
interactions that were previously observed in the wt protein. In these mutants the 
number of conformation available are larger and possibly there is a reduced shielding of 
hydrophobic NAC. The possibility to an easier overcome of the energetic barrier for self-
association is reported as apossible cause for the increased propensity of these variants 
to aggregate. Of interest, aS mutations have effect on the interactio of aS with lipids and 
membranes: the A53T mutation seems to have little effect on membrane binding (Perrin 
et al., 2000; Bussell & Eliezer, 2004). Instead, the A30P mutation decreases the extent of 
lipid interactions in vitro and in vivo (Perrin et al., 2000; Jo et al., 2002; Jensen et al., 
1998), beacouse of the presence of a pro residue that act as a helical breaker. Specifically, 
a N-terminal helix is interrupted at level of A27 to A37, leading to the formation of two 
antiparallel helix (Ulmer and Bax, 2005). In contrast, E46K mutation increases the ability 
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of the protein to bind to negatively charged liposomes (Choi et al., 2004), since Lys 
residue shift the net charge of the first 100 residues from +4 to +6 (Bodner et al., 2010). 
Several different study have been conducted to study the consequence of aS variants 
expression. Theei presence in cells seems to promote mitochondrial defects and cell 
death and enhance susceptibility to oxidative stress. On the other hand, mice deficient in 
aS are resistant to toxicity induced by MPTP and other mitochondrial toxins (Klivenyi et 
al., 2006). 
 
Post translational modification on aS 
 There are >300 different protein posttranslational modifications (PTMs), which 
include such diverse processes as proteolysis, phosphorylation, lipidation, S-nitrosylation, 
nitration, oxidation, glycosylation, methylation, adenosine diphosphate (ADP)-
ribosylation, acylation (acetylation, isoprenylation, myristoylation), ubiquitination, 
sumoylation, sulfation, farnesylation, dityrosine crosslinking, methionine oxidation, 
crosslinking by transglutaminase, truncation, and N-terminal acetylation and many others 
(Aebersold et al., 2001). PTMs change the size, charge, structure and conformation of 
proteins. As a result, characteristics of proteins, such as enzyme activity, binding affinity, 
and protein hydrophobicity, are altered. PTMs cannot only directly change the proteins’ 
function but also indirectly affect function by leading to cell compartmentalization, 
sequestration, degradation, elimination, and protein–protein interactions. Individual 
proteins can undergo multiple and different PTMs (Aebersold et al., 2001). Protein 
aggregation is a highly cooperative process, and even a small subpopulation of modified 
aS could have a substantial impact on kinetics and product distribution. It has been 
pointed out that only few post-translational modification have been described for aS. This 
includes phosphorilation, methionine oxidation, dityrosine crosslinking, crosslinking by 
transglutaminase, truncation, and N-terminal acetylation (Beyer, 2006). The known sites 
of main PTMs in α-synuclein and their known effects on its conversion into disease-
related forms are discussed below. 
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- Phosphorylation 
 In human α-synuclein in vivo, serine 129 was established as a major 
phosphorylation site, with a second phosphorylation site located at serine 87. The major 
phosphorylation site was found to be located within a consensus recognition sequence of 
casein kinase 1 (CK-1). In vitro experiments and two-dimensional phosphopeptide 
mapping provided further evidence that serine 129 was phosphorylated by CK-1 and CK-2, 
both highly conserved sites (Okochi et al., 2000). About 90% of α-synuclein in LBs is 
phosphorylated at Ser-129 (Fujiwara et al., 2002). 
 The effect of phosphorylation at Ser-129 on aggregation of α-synuclein has been 
studied by expressing the S129A, to abolish phosphorylation at this site. Expression of 
S129A alpha-synuclein instead of wild-type alpha-synuclein decreased the parkin-
mediated ubiquitination of synphilin-1 and the formation of ubiquitinated inclusions. 
Moreover, treatment of SH-SY5Y cells with H2O2 increased alpha-synuclein 
phosphorylation and enhanced the formation of inclusions, whereas treatment with the 
casein kinase 2 inhibitor 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole had the 
opposite affect. (Smith et al., 2005). This data shows that Ser-129 phosphorylation 
promotes aggregation of α-synuclein. Phosphorylation at Ser-87, on the other hand, 
expands the structure of α-synuclein, increases its conformational flexibility, and blocks 
its aggregation in vitro. Furthermore, phosphorylation at S87, but not S129, results in 
significant reduction of alpha-syn binding to membranes. (Paleologou et al., 2010) 
 
- Oxidative modifications 
 The primary targets for oxidative modifications in α-synuclein are its methionine 
and tyrosine residues. The α-synuclein primary sequence contains four tyrosine residues: 
Tyr-39, Tyr-125, Tyr-133, and Tyr-136. These tyrosine residues are conserved in all α-
synuclein orthologs and in β-synuclein paralogs, suggesting that these residues might play 
important functional roles (Dev et al., 2003). Studies have shown that exposure to 
oxidative and nitrative species stabilizes alpha-synuclein filaments in vitro, and this 
stabilization may be due to dityrosine cross-linking. (Norris  et al., 2003). However, in a 
cellular model of PD, only a significant increase in nitration of Tyr-39 was detected while 
nitration levels of other tyrosine residues were unchanged (Danielson et al., 2009). The 
difference could be due to a higher accessibility of Tyr-39 to a nitrating agent.  
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Methionine residues are also susceptible to oxidation to sulfoxide and ultimately sulfone 
(Fig. 1.6). All four methionines in α-synuclein (Met-1, Met-5, Met-116, and Met-127) 
located outside the repeat-containing region are highly susceptible to oxidation to 
methionine sulfoxide MetO. Their oxidation inhibits fibrillation of this protein in vitro and 
MetO protein also inhibits fibrillation of unmodified alpha-synuclein. Moreover, the 
degree of inhibition of fibrillation by MetO alpha-synuclein is proportional to the number 
of oxidized methionines (Hokenson et al., 2004). 
 
Fig. 1.6. Methionine and tyrosine oxidation scheme. A — Tyr nitration, B — Tyr dimerization, and 
C — Met oxidation. 
 
 Since PD pathology is associated with dopaminergic neurons, the interaction 
between aS and dopamine has been extensively investigated. Dopamine is known to bind 
to α-synuclein non-covalently, inhibiting its fibrillation and stabilizing the oligomers 
(Herrera et al., 2008). However, dopamine is highly susceptible to oxidation, and its 
oxidation products can inhibit aS fibril formation, because DAQ might stabilize aS 
protofibrils. These adducts drive aggregation of α-synuclein into aS/DAQ adducts that 
retain an unfolded conformation. Only a small fraction of aS molecules interacts with DAQ 
in a covalent way (Bisaglia et al., 2010). 
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Overall, oxidative modification can significantly alter the aggregation pathway of α-
synuclein, usually toward oligomer formation. The structure and toxicity of these 
oligomers depend on the nature of modification and other experimental variables 
(Breydo et al., 2012). 
 
- Ubiquitination 
 Ubiquitin is a small protein that can be enzymatically attached to lysine residues of 
various cellular proteins. Ubiquitination is used to target proteins for proteolytic 
degradation. Although α-synuclein contains 15 lysine residues, Lys21, Lys23, Lys32, and 
Lys34 are the major ubiquitination sites in vitro. Notably, filamentous alpha-synuclein is 
less ubiquitinated than the soluble form and the major ubiquitination sites are localized 
to Lys6, Lys10, and Lys12 at the amino-terminal region of filamentous alpha-synuclein in 
vivo (Nonaka et al., 2005). Since ubiquitination is not required for the degradation of the 
α-synuclein monomer, it appears that α-synuclein ubiquitination occurs after its 
aggregation (Sampathu et al., 2003). The effect of monoubiquitination of aS on its 
aggregation depends on the site of modification. However, monoubiquitination of aS by 
SIAH ligase at multiple lysine residues promotes its aggregation in vitro and in vivo, which 
is toxic to cells. Mass spectrometry analysis demonstrates that SIAH monoubiquitylates aS 
at lysines 12, 21, and 23, which were previously shown to be ubiquitylated in Lewy 
bodies. SIAH ubiquitylates lysines 10, 34, 43, and 96 as well (Rott et al., 2008).   
 
- Modification by lipid-derived aldehydes 
 Highly reactive aldehydes (for example, 4-hydroxy-2-nonenal and 
malondialdehyde) are produced by lipid peroxidation (H. Esterbauer, R.J. Schaur, H. 
Zollner, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related 
aldehydes, Free Radic. Biol. Med.11 (1991) 81–128). aS has been shown to have affinity 
for unsaturated fatty acids and membranes enriched in polyunsaturated fatty acids, 
which are especially sensitive to oxidation under conditions of oxidative stress . One of 
the most important products of lipid oxidation is 4-hydroxy-2-nonenal (HNE), which has 
been implicated in the pathogenesis of Parkinson disease. Incubation of aS with HNE 
resulted in covalent modification of the protein. HNE modification of alpha-synuclein led 
to inhibition of fibrillation, due to the formation of stable oligomers toxic to cells. 
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Oligomers formed after reactions with 4-hydroxy-2-nonenal and 4-oxo-2-nonenal could 
have different structures and morphologies. (Nasstrom et al., 2003; Qin et al., 2007; 
Nasstrom et al., 2011). Overall, lysine modification of α-synuclein tends to promote the 
formation of oligomers at the expense of fibrils. This is likely due to the ability of more 
flexible structures of oligomers to accommodate these modifications. Similar behavior 
has been observed for other amyloidogenic peptides and proteins (Bieschke et al., 2006). 
 Lipid induced modification of aS and relative pathological implications will be 
further described in section 3.3. 
 
Oxidative stress  
Parkinson's disease (PD) is related to excess production of reactive oxygen species 
(ROS) or inadequate and impaired detoxification by endogenous antioxidants, alterations 
in catecholamine metabolism, alterations in mitochondrial electron transfer function, and 
enhanced iron deposition in the substantia nigra (Reale et al., 2012). The formation of 
reactive oxygen and nitrogen species damages also other cellular component such as 
lipids, DNA and proteins. Oxidized proteins may not be adequately ubiquitinate or 
recognized by the proteosome and may accumulate (Jenner, 2003). The concept that 
oxidative stress is an important mechanism underlying the degeneration of dopaminergic 
neurons is reinforced by data documenting that high levels of lipid peroxidation, 
increased oxidation of proteins and DNA and depletion of glutathione are observed in 
postmortem studies of brain tissues of PD patients (Reale et al., 2012). Lipid peroxidation 
leads to the production of toxic species, such as 4-hydroxynonenal (HNE), detected by 
immunocytochemistry in SN and cerebrospinal fluid of PD patients (Yoritaka et al., 1996). 
HNE may act by covalently modifying proteins and impairing their function, disrupting 
neuronal calcium homeostasis and perturbing mitochondrial function, through caspase 
activation. Activated caspases, in turn, induce activation of JNK, resulting in stimulation of 
AP-1 DNA-binding protein production. This transcriptional pathway induced by HNE may 
modulate the cell death process. Moreover HNE has NF-kB inhibitor action that cause the 
reduction of glutathione levels and the inhibition of complexes I and II of the 
mitochondrial respiratory chain (Camandola et al., 2000; 2000b). Actually, plenty of 
evidences underline the prominent role of oxidative stress as cellular damage mechanism 
in PD.  Synucleinopathies are usually associated with inflammation and elevated levels of 
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oxidative stress in affected brain areas, that could modify aS, especially when it binds to 
biological membranes. The important aspect is that oxidative modifications can affect aS 
aggregation. aS is such sensitive to oxidative stress because it could act physiologically as 
a catalytically regenerated scavenger of oxidants in healthy cells (et al., 2013) with Cu, Zn-
SOD and H2O2, then the amount of oligomerization increased, especially for A53T mutant 
form. This process was inhibited by radical scavenger and antioxidant molecules (Kang et 
al., 2003). Another reported consequence of oxidative stress in dopaminergic neuron is 
that of oxidation of Dopamine. It has been demonstrated that oxidation leads to the 
formation of dopamine-derived orthoquinone (DAQ) that could react and bind to aS. This 
modification seems to be inhibitory of the fibril formation process, causing accumulation 
of aS protofibrils. Adduct formation provides an explanation for the dopaminergic 
selectivity of α-synuclein–associated neurotoxicity in PD. Interestingly, these effects are 
eliminated by antioxidants. Thus, three established risk factors—oxidative stress, DA, and 
aS—may, in combination, stabilize protofibrillar aS and promote the pathogenesis of PD 
(Conway et al., 2001). As  a prerequisite, aS levels must exceed the critical concentration 
for oligomerization. In rare familial forms of PD, that threshold may be lowered by aS 
point mutations (Conway et al., 2000). Once the critical concentration of aS has been 
exceeded, the cytoplasmic concentration of DAQ may be one of several factors that 
determine the amount and lifetime of potentially pathogenic aS protofibrils (Conway et 
al., 2001). DAQ results from a combination of oxidative stress and elevated cytoplasmic 
DA concentration, both of which are independently associated with PD (Dunnett et al., 
1999).  
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1.2 α-SYNUCLEIN 
 aS is a small (140 amino acids) cytoplasmic protein, expressed in all the central 
nervous system, especially in the neocortex, hippocampus, striatum, thalamus, and 
cerebellum (Iwai et al., 1995). It represents 0.5–1% of the total cytosolic protein in brain 
(Kruger, 2000). It is highly expressed at the presynaptic level (Kahle et al., 2004), and 
locally it is estimated to reach the concentration of 70-140 μM (van Raaij et al., 2008).  
 aS family is composed of four proteins: aS, β-synuclein (bS), μ-synuclein (mS) and 
synoretin (synr) (Fig. 1.1). aS and bS have similar level of cellular expression and 
distribution, while mS and synr are prevalently expressed in peripheral terminals. The 
proteins in the family show a high degree of homology, however only aS is found in LB. bS 
is not included in amyloidogenic fibrils because it does not contain aa 71-82 of aS, 
believed to drive fibrillogenesis (Giasson et al., 2001). The function of these proteins is 
still unknown. The location and some experimental data suggest an association with 
presynaptic vesicles (Murphy et al., 2000). aS is proposed to regulate dopamine 
neurotransmission by modulation of vesicular dopamine storage and catecholamine 
release from the synaptic vesicles (Lotharius and Brundin, 2002). In particular, the 
potential function of aS in DA regulation and storage is correlated with its ability to 
interact with membranes and regulate vesicular trafficking (Lotharius and Brundin, 2002): 
aS over-expression inhibits a vesicle ‘priming’ step that occurs after secretory vesicle 
trafficking to ‘docking’ sites but before calcium-dependent vesicle membrane fusion 
(Larsen et al., 2006). In addition, aS seems to be involved in synaptic plasticity and 
learning (Clayton & George, 1998), indeed it is upregulated in songbirds, during the 
periods of song-learning, this is a function related with synaptic plasticity (George et al., 
1995). Interestingly, knockout mice for aS are quite normal, showing only an increase of 
dopamine release in response to electrical stimuli (Abeliovich et al., 2000). Genome wide 
screening in yeast showed that nearly one-third of genes that enhance the toxicity of aS 
are functionally related to lipid metabolism and vesicle trafficking (Willingham et al., 
2003).  An analysis of a yeast PD model with dosage sensitivity for aS expression (Outeiro 
& Lindquist, 2003) revealed that the earliest defects following aS expression were an 
inhibition of the endoplasmic reticulum to Golgi vesicular trafficking and an impairment 
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of the endoplasmic reticulum associated degradation (Cooper et al., 2006). Finally, it was  
revealed that aS regulates.  
 Another possible hypothesis, on the base of its abundance in the cytosol, its 
unfolded structure, and its prevention of protein aggregation induced by heat shock or 
chemical treatment, concerns a putative role of aS as chaperone (Souza et al., 2000). 
Actually, aS can act as a molecular chaperone assisting in the folding and refolding of 
synaptic proteins called soluble NSF (N-ethylmaleimide sensitive factor) attachment 
receptors (Chandra et al., 2005). A recent proteomic study evidenced 587 proteins as aS-
binding partners in a neuronal-hybrid cell line (Jin et al, 2007). Even considering the 
possibility of an overestimation, the chaperone activity could well fit with the huge 
number of protein-interactions. aS overexpression rescues lethality associated with the 
lack of CSPα, a co-chaperone (HSP40 kind) associated with synaptic vesicles and 
implicated in folding of SNARE proteins, confirming that aS may act as an auxiliary 
chaperone preserving the function and integrity of the synapse (Chandra et al., 2005).  
 
1.2.1 Primary structure 
 aS is a 140 amino acid protein with four tyrosine residues, four methionine 
residues and one residue of histidine, deprived of cysteine as well as tryptophan residues. 
The primary sequence divides the protein in three regions: the N-terminal region (amino 
acid 1–60), the central region (61–95) and the C-terminal region (96–140) (Fig. 1.7). The 
N-terminal region, residues 1–60, includes the sites of three familial PD mutations and 
contains six imperfect repeats of the motif KTKEGV that is involved in the binding of 
detergents micelles and liposomes. This region adopts an amphipathic α-helix structure 
when the protein binds to phospholipids (Davidson et al., 1998), that it is comparable to 
A2 helix type of apolipoproteins (Clayton &George, 1998). At the interface between the 
hydrophobic half and the hydrophilic one lysine residues are present to mediate the 
interaction, as the amine is positively charged and the aliphatic chain can interact with 
lipids. This is why aS prefers negatively charged vesicle to interact with. The central 
region, residues 61–95, comprises the highly aggregation-prone NAC sequence (Ueda et 
al., 1993; Han et al., 1995) and contains the remaining three imperfect repeats. NAC is the  
acronym of Non β- Amyloid Component, as this part of the molecule is also found in 
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amyloid plaques of Alzheimer’s disease patients brains (Ueda et al., 1993; Weinreb et al. 
1996, Goedert, 1997; Jo et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7. Schematic representation of aS structure. Most important characteristics about 
aggregation (blue), KTKEGV repeats (light-blue), acidic residues (black), mutations (red) and 
phosphorilation sites (green) are reported.  
 
This region is highly hydrophobic, and it can acquire β-sheet structure as it is the leader of 
amyloid fibril formation. In particular, aa 71-82 was described to be the responsible 
(Giasson et al., 2001) of aS aggregation, as deletion mutants do not form β-sheet 
structured fibrils, neither do bS, which lacks this region. 
The C-terminal region is an acidic segment rich in glutamic, aspartic and proline residues. 
This region determines the acidic isoelectric point of the α-syn (pI = 4.7) (Hoyer et al., 
2002). The C-terminal region, residues 96–140, is highly dynamic in most conditions: it 
does not acquire structure in any condition. A regular repetition of the acidic residues can 
be observed: The region has a mM affinity for the binding of metals like Ca2+, Fe2+/3+, Al3+, 
Co2+ and Mn2+ (Uversky et al., 2001). Divalent metal binding has been shown to increase 
fibril formation rate. Ser129 is site of phosphorylation (Takahashi et al., 2003) and 
phosphorylated aS forms fibrils slower than wild type protein (Paleologou et al., 2008); 
phosphorylated aS is also found in PD patients LB (Takahashi et al., 2003). Also C-terminal 
tail seems to be involved in intermolecular interaction with the N-terminal part of the 
region, just for electrostatic interactions. Observing the primary sequence, it becomes 
evident that all the missense mutations diseases-associated, reside in the N-terminal 
region.  
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1.2.2 Secondary structure of aS 
Since the discovery of aS amyloid fibrils as main component of LBs inclusions, the 
protein has been deeply examined in a massive number of structural studies. aS has been 
cloned and produced in bacteria for the first time in 1994 (Jakes et al., 1994), and 
recombinant aS was shown to be able to form amyloid fibrils in vitro (Conway et al., 
1998). Until recently, aS was valued as a heat-stable protein, with a monomeric natively 
unfolded structure (Weinreb et al., 1996). In vitro studies on recombinant aS show that 
the aS monomer lacks of ordered secondary structure under physiological conditions, 
detectable by far-UV circular dichroism (CD), Fourier transform IR (FT-IR) and NMR 
spectroscopy. For this reason, aS is considered a typical intrinsically disordered (or 
natively unfolded) protein, which possesses little or no ordered structure under 
physiological conditions in vitro (Uversky et al., 2001). Intrinsically disordered proteins 
have been recognized as a protein class, which are gaining considerable attention due to 
their capability to perform numerous biological functions despite the lack of unique 
structure (Wright and Dyson 1999; Uversky et al. 2000, 2005, 2007). These proteins exist 
as dynamic and highly flexible ensembles that undergo a number of distinct 
interconversions on different time scales. In general, one of the main physical 
characteristic of this set of protein is the combination of low overall hydrophobicity and 
large net charge. However, aS does not fit this general trend. In its case, N- and C-terminal 
regions possess charge of opposite sign and are separated by an extended hydrophobic 
region (Uversky et al., 2000). Indeed, this monomer could assume different 
conformational structures that hinder the amyloidogenic region. There are long-range 
interactions between both the N- and C-terminal with the non-amyloid component region 
(NAC). In particular, a long-range intramolecular interaction between the C-terminal 
region (residues 120–140) and the central part of aS (residues 30–100) was noted 
(Bertoncini, et al., 2005; Dedmon et al., 2005). These interactions avoid NAC–NAC contact 
between different monomers, which is the basis for the oligomerization and aggregation 
of α-syn. This is an intrinsic autoinhibitory mechanism that should be disrupted in order 
to favor aS oligomers and fibrils formation (Bertoncini, et al., 2005; Bernardo et al., 2005). 
Small angle X-ray scattering analysis showed that the radius of gyration, Rg, which is used 
to describe the dimensions of polypeptide chain, is ~ 40 Å of native aS, which is much 
larger than that predicted for a folded globular protein of 140 residues (15 Å), but 
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significantly smaller than that for a fully unfolded random coil (52 Å). Paramagnetic 
relaxation enhancement (PRE) NMR spectroscopy  (Dedmon et al., 2005; Bertoncini et al., 
2005) and fluorescence based studies (Lee et al., 2004; 2005) gave a molecular 
characterization of this partial condensation suggested the presence of the numerous 
long-range interactions, forming a hydrophobic cluster that comprised the C-terminal part 
of the highly hydrophobic NAC region (residues 85–95) and the C terminus (residues 110–
130), probably mediated by M116, V118, Y125, and M127. Region 110-130 in the 
negatively charged C-terminal tail can contact residues 85-95 in the centre of the protein. 
Within the C-terminal region, residues 120-130 can contact residues 105-115, and the 
region about residues 120 also can interact with the N-terminus about residues 20 
(Bertoncini et al., 2005). The forces involved singnificantly decrease in high salt 
concentration (Hoyer et al., 2004). These long-range interactions was suggested to inhibit 
the spontaneous aS oligomerization and aggregation. The autoinhibitory conformations 
fluctuate in the range of nanoseconds to micro-seconds, corresponding to the time scale 
of secondary structure formation during folding. This highly dynamic tertiary structure 
could explain the influece of such conditions that favour aS aggregation, as for example 
temperaure increase (Bertonici et al., 2005). Indeed, this kind of interaction are important 
for the shielding of NAC region, which has been proposed to lead protein aggregation. So, 
all the conditions that favour the shielding action of the C-terminal tail result in a faster 
protein aggregation. The conformational behavior of aS under a variety of conditions was 
extensively analyzed (Uversky, 2003). The structure of aS is extremely sensitive to its 
environment and can be easily modulated by a change in conditions. Beside an extended 
state, aS can acquire a pre-molten globule state in several conditions such as low pH, high 
temperature, in the presence of various metal ions and as a result of spontaneous 
oligomerization both in vitro and in vivo (Uversky, et al., 2001; Uversky, 2007). Moreover, 
in vitro studies demonstrate that recombinant aS can assume various -helical structures 
interacting with lipid vesicles (Davidson et al., 1998). Eliezer et al. (2001) documented the 
tendency of the first 100 residues of aS towards α-helical torsion angles, and the 
following paper of the same group quantified this trend to exists for the about the 10% of 
the time (Bussell & Eliezer, 2001). Kim et al. (2007) found that region comprehending aa 
39–98 of aS polypeptide chain is able to populate β-sheet conformations in solution at 
supercooling temperatures. This finding is relevant for the understanding of the first steps 
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leading to amyloid fibril formation by aS. In addition, other works confirmed that aS is 
present in solution as an ensemble of conformers able to interchange each other in the 
microsecond timescale (Maiti et al., 2004; Lee et al., 2004; 2005). aS can also move from a 
fibrillation prone partially folded conformation to β-sheet species both in monomeric and 
oligomeric states. Its aggregates can be morphologically different, including spheres or 
ring oligomers, insoluble amorphous aggregates and amyloid fibrils (Uversky, 2003; 
Uversky, 2007). Based on this conformational behaviour, Uversky proposed the concept 
of chameleon protein, which holds that the structure of aS is modulated by its 
environment to a dramatic degree. That is, the choice among all the above mentioned 
conformations is determined by the peculiarities of protein surroundings (Uversky, 2003; 
Uversky et al., 2007). Because of its plasticity, aS chameleon protein could be able to 
perform multiple functions. Indeed, Wright and Dyson proposed a reassessing of the 
structure-function paradigm due to the peculiarities of natively unfolded proteins (Wright 
and Dyson, 1999). 
Data summarized so far refers to structural in vitro studies on recombinant aS. 
Some drawbacks of using recombinant are forcing non-physiological conditions, depriving 
the protein of the physiological modification it could be affected and of physiological 
binding partners and local ion environment. The native-unfolded paradigm was disputed 
by the work of Selkoe’s laboratory, which showed that aS in its native state is a folded 
tetramer, rich in α-helix, with greater lipid-binding affinity than the monomer and 
resistant to fibril formation. In addition this tetrameric aS is N-acetylated in vivo, at least 
in human erythrocytes where most of the characterization was done (Bartels, J.G. Choi, 
D.J. Selkoe, Nature 477 (2011) 107–110]. Tetrameric state was hypothesized on the base 
of native gels results (about 48 kDa) and scanning transmission electron microscopy 
(STEM) measurements (55 kDa average). STEM imaging yielded a homogenous 
distribution of roughly spherical particles measuring about 3-3.5 nm in diameter, and CD 
measurement demonstrate that this particles have α-helical structure. Purified tetramers 
show higher affinity for negatively charged lipids than recombinant aS, and, most of all, 
less ability to aggregate. Soon, this work was challenged and laboratories from different 
places concluded that aS is a native monomeric and unstructured protein in erythrocytes 
and in the nervous system (Fauvet et al., 2012). These findings are in disagreement with 
most of published results obtained studying recombinant aS, and, if confirmed, would 
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lead to several functional implications on aS physiological role. Authors explain the 
divergence with the use of denaturing agents, including sample heating, during the 
standard purification of recombinant aS from bacteria (Bartels et al., 2011). A second 
study published by Wang and colleagues sustains the thesis of α-helical folded tetramer 
as native state of aS, that can be present in physiological conditions, while the unfolded 
structure can be a precursor of the aggregation-prone conformation. 
 
1.2.3 Mutations on aS gene 
 The first missense mutation found in aS was A53T, followed by two additional 
disease-causing missense mutations: A30P mutation in a German family (Kruger et al., 
1998), and an E46K mutation in a Spanish family (Zarranz et al., 2004). In vitro, aS can 
readily form fibrils similar to those seen in LBs (Conway et al., 1998, Giasson et al., 
1999 and Wood et al., 1999) and the mutations can influence the kinetics of aS 
fibrillation: E46K and A53T can both increase rate of fibril formation, while A30P 
decreases it (Conway et al., 1998 and 2000, Giasson et al., 1999 and Greenbaum et al., 
2005). Focusing on oligomeric species, A30P and A53T show a higher accumulation of pre-
fibrillar species, while E46K reduces them (Conway et al., 2000; Fredenburg et al., 2007). 
Interestingly, A53T and A30P mutants are able to form prefibrillar intermediates with 
pore-like activity, providing explanation for their toxicity (Conway et al., 2001; Volles & 
Lansbury, 2002). AS mutants were analyzed for their secondary structure futures, 
resulting different from aS WT. Specifically, the analysis of A30P reveals that it has a 
minor helical propensity compared to that found in the N-terminal region of wt aS, 
whereas the A53T mutation induce a more subtle and local preference for extended β-
sheet like conformations around the site of mutation (Bussell & Eliezer, 2001). These two 
variants show increased backbone flexibility, while E46K do not. The important long-
range interactions that prevent aSWT to assume an aggreation-prone confomration, are 
absent, so In these mutants the number of conformation available are larger and this 
could lead to a reduced shielding of hydrophobic NAC. The possibility to an easier 
overcome of the energetic barrier for self-association has been suggested by the authors 
as the cause for the increased propensity of these proteins to aggregate (Bertoncini et al., 
2005b).  
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Recently, a new missense mutation have been reported: H50Q (Proukakis et al., 
2013; Appel-Cresswell et al., 2013). H50Q’s characteristics are still under study, but 
authors assert that their protein modeling provide additional support for pathogenicity as 
the amino acid perturbs the same amphipathic alpha helical structure as the previously 
described pathogenic mutations. The mutation of H50Q was found to significantly 
accelerate the aggregation and amyloid formation of aS in vitro. This mutation, however, 
did not alter the overall secondary structure as suggested by two-dimensional nuclear 
magnetic resonance and circular dichroism spectroscopy. The initial oligomerization study 
by cross-linking and chromatographic techniques suggested that this mutant oligomerizes 
to an extent similar to that of the wild-type (Ghosh et al., 2013). Link between aS 
aggregation and PD was further strengthened with the identification of several PD 
kindreds with triplication (Farrer et al., 2004 and Singleton et al., 2003) or duplication of 
the aS gene (Chartier-Harlin et al., 2004). In vitro, increased concentrations of aS have 
been shown to promote the polymerization into fibrils (Wood et al., 1999), and patients 
with a gene triplication have greater disease severity and younger age of onset than those 
with gene duplication, suggesting a possible “SNCA gene dosage effect” leading to PD 
(Singleton and Gwinn-Hardy, 2004). Furthermore, these findings indicate that a 50% 
increase in the expression of aS due to gene duplication is sufficient to cause disease and 
is consistent with the aggregation of α-synuclein contributing to disease (Jason et 
al.,2011).  
 
1.2.4 Aggregation process  
 Some pathologies, as for example Alzheimer disease, PD and Prion diseases are 
associated with the formation of protein aggregates that form large deposits (Koo et al., 
1999; Serpell, 2000). Each amyloid disease involves predominantly the aggregation of a 
specific protein, although a range of other components including are incorporated into 
the deposits in vivo. The aggregation process of aS was extensively studied as aS amyloid 
fibrils were observed in LBs (Fig. 1.1).  
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Fig. 1.8. Conformational states of a protein in a cell and subsequent destinies (From Dobson, 
2003). The unfolded polypeptide chain can assume 3D structure after translation or it can be 
degraded or form amorphous aggregates. Intermediates can be assemble into prefibrillar species 
that lead to amyloid fibril formation. 
 
 Those macromolecular structures were reproduced in vitro, to be studied in order 
to identify their 3D structure. The in vitro kinetics of aS fibril formation show an initial lag-
phase followed by an exponential growth phase and a final plateau, usually attributed to 
a nucleation-dependent polymerization. aS fibrils obtained in vitro, are formed by two or 
more filaments (Fig. 1.8). They typically vary in length from about 500 nm to 3 μm and, 
based on AFM analyses, have an average height of 9.8 ±1.2 nm (Fink, 2006; Khurana et al., 
2003). The core region of aS, defined by proteolysis studies, encompass the central, highly 
amyloidogenic NAC region (Miake et al., 2002; Quin et al. 2007). EPR and site-directed 
spin labelling studies indicate that the fibril core is formed by parallel, in-register 
arrangement of multiple β-strands that run perpendicular to the fibril axis, where each 
layer contain a new molecules (Chen et al., 2003). The fibril core is actually supposed to 
be constituted by five β-strands, as revealed by D/H exchange experiments (Vilar et al., 
2008; Karyagina et al., 2011).  
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 Even though the ability to form amyloid fibrils seems to be generic (Dobson, 
2001), the propensity to do so under given circumstances can vary markedly between 
different sequences. The relative aggregation rates for a wide range of peptides and 
proteins correlates with the physicochemical features of the molecules such as charge, 
secondary-structure propensities and hydrophobicity (Chiti et al., 2003). As already said, 
the in vitro kinetics of aS fibril formation show an initial lag-phase followed by an 
exponential growth phase and a final plateau (Fink, 2006). The lag-phase is due to the fact 
that the process is nucleation-dependent, meaning that the rate limiting step is the 
formation of a nucleus composed of a critical numbers of monomers (Wood et al., 1999; 
Murphy, 2007). The constitution of the nucleus is hosted, as monomers has to be in those 
rare and limited conformations prone to a stable interaction once contact has occurred 
each other. However, once this passage has been achieved, elongation or enlargement is 
a thermodynamically favoured process. Uversky and coworkers showed that early stages 
of fibril formation involve the partial folding of aS into the highly fibrillation-prone pre-
molten globule-like conformation, which represents a key intermediate on the fibrillation 
pathway (Uversky et al. 2001, Fink, 2006).  Hence, factors that shift the equilibrium in 
favor of this partially folded conformation facilitate fibril formation. Thus, an increase in 
protein concentration is predicted to increase the concentration of the intermediate, and 
so the rate of fibrillation (Uversky et al., 2001). Since, as previuosly reported, the 
unstructured monomer presents long-range interactions between the C-terminal and the 
central NAC regions (Bertoncini et al., 2005), an event that leads to the formation of an 
unfolded state should be expected prior to the aggregation. Moreover, it has been 
recently suggested that aS could be folded as an α-helical tetramer (Bartel et al., 2011; 
Wang et al., 2011). The aggregation-prone conformation may be attained early in the 
aggregation pathway, through the exposition of the hydrophobic NAC region and 
facilitating aggregation (Paleček et al., 2008). To favor the aggregation prone 
conformation, structural perturbations are necessary. They could be caused by different 
conditions, including for example the presence of positively charged ions able to interact 
with the C terminus, a decrease in pH that reduce the net charge of the C-terminal region, 
and the deletion of the C terminus, result in a more rapid aggregation reaction (Hoyer et 
al., 2004). Even when the partially unfolded states is reached, the probability of 
interaction of two of pre-molten globule species is low, but it may occur the case in which 
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stable hydrogen bonds formation is established. Later, dimers can form stable contacts 
with other units, and oligomers start to grow. Soluble oligomers convert to fibrillation 
intermediates, designated protofibrils (Harper et al., 1997). Analysis by TEM and AFM has 
revealed that different final product may arise from the aggregation of aS depending on 
the experimental conditions: fibrils, oligomers, and insoluble amorphous aggregates (Fink, 
2006). Although the central role of aS fibrillation in the pathogenesis of PD is well 
established, it has been demostrated that aS fibrils may not be the toxic species, but may 
also have a protective role. On the contrary, soluble oligomers and protofibrils seem to be 
the toxic species (Volles et al., 2002). The oligomeric species of aS present during the lag-
phase of the aggregation process are relatively unstable, transient and present at very 
low steady-state concentrations (Goldberg et al., 2000). As a result of the unstable and 
transient nature of these intermediates, the direct detection and characterization of 
prefibrillar oligomeric species oculd be extremely difficult. Several oligomeric prefibrillar 
species with various morphologies have been described (Conway et al. 1998, 2000; Ding 
et al. 2002; Lashuel et al. 2002, Apetri et al. 2006).  These  species are usually 
characterized by extensive β-structure and sufficient structural regularity to bind 
Thioflavin-T (ThT) and Congo Red (CR) (Chiti & Dobson, 2006). However, some types of 
oligomers are unable to bind Thioflavin T ThT and CR (Apetri et al., 2006). Indeed several 
oligomeric species have been identified by different techniques: photo-induced cross-
linking of aS (Li et al., 2006); electrochemical techniques (Paleček et al., 2007); intrinsic 
tryptophan fluorescence of Y39W aS (Dusa et al., 2006) and FRET measurements (Kaylor 
et al., 2005); fluorescence of pyrene-labeled aS (Thirunavukkuarasu et al., 2008). 
Structured protofibrillar species could form from the reorganization or assembly of small 
and relatively disorganized oligomers that are formed rapidly after the initiation of 
aggregation process. In Fig. 1.8 a schematic representation of the hypothetical 
aggregation pathways of aS is reported. Moreover, also stable oligomers with very slow 
rates of dissociation, have been decribed. These oligomers could arise as a consequence 
of different mofications, sucha as oxidation of the four methionine residues to 
methionine sulfoxide (Hokenson et al., 2004), specific nitration of the tyrosine residues 
(Uversky et al., 2005) and covalent modification by 4-hydroxynonenal (Qin et al., 2006). 
Typically these oligomers are formed more rapidly than fibrils and, as a consequence, no 
significant fibrillation occurs from these modified forms of aS.  
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1.2.5 Factors that influence aS aggregation process 
Even if the comprehension of the aggregation and fibril formation processes is 
incomplete, several factors have been reported to have an influence on the aggregation 
pathway and kinetic, with inhibiting or promoting effects. As previously said, aS 
undergoes a nucleation dependent mechanism of aggregation, so that every factor that 
can increase the probability of the acquisition of an aggregation-prone conformation, 
enhance fibrillogenesis. For example, a promoting factor could be the increase in 
temperature, that is directly correlated with kinetic energy of molecules and also to 
enhanced reactivity of species. Also a high protein concentration could increases the 
probability of oligomers formation because   conformers able to form the critical nucleus 
are more concentrated, and this explain the effect of a familiar form of PD due to the 
triplication of aS, that leads to autosomal dominant PD (Singleton et al., 2004). As a 
consequence of the partial stability due to the interaction between different regions of 
aS, proteolytic cleavage of aS, revealed to occur naturally in neuronal cell (Li et al., 2005), 
increases fibrillogenesis. Specifically, by in vitro studies, C-terminal truncation has been 
reported to enhance fibril formation of aS by exposition of hydrophobic NAC region 
(Crowther et al., 1998; Hoyer et al., 2004). Also ionic strength enhances fibrillogenesis, 
since it masks C-terminal negative charges, disrupting tertiary contacts between N-
terminal and the C-terminal of the protein, thus leading to exposition of hydrophobic 
patches (Hoyer et al., 2004). Other mechanisms that involve charge and so the tertiary 
contacts, is pH. The isoelectric point of aS is 4.6: so more acidic pH leads to disruption of 
contacts between C-terminal tail and positive charges N-terminal region (Uversky et al., 
2001b). Among molecules that enhance aggregation propensity of aS, there are lipids, 
expecially in the case of polyunsaturated fatty acids like arachidonic acid and 
docosohexaenoic acid (Perrin et al., 2001). High protein:lipid molar ratio increases fibril 
formation probabilities (Zhu et al., 2003): lipid membranes could recruite aS molecules 
and, enhancing local protein concentration, favor protein-protein interaction. Other 
involved molecules could be proteins that have been identified to stimulate aS in vitro 
aggregation at substoichometric concentrations, like tau (Norris & Giasson, 2005), 
histones (Goers et al., 2003), brain specific protein p25α (Lindersson et al., 2005) and 
tubulin (Alim et al., 2002). Some post-trasductional modifications seem to enhance aS 
fibril formation propensity. As an example, aS is predominantly present as non-
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phosphorylated in normal in vivo conditions, but Ser129 phoshorylation forms occur in aS 
inclusions in post-mortem patients brains (Fujiwara et al., 2002). In vitro, Ser129 
phoshorylation was found to increase the formation of aS mature fibrils.  The 
demonstration of oxidatively nitrated aS in the syucleinopathic inclusions suggests that 
oxidative insults may be relevant to the pathogenesis (Duda et al., 2000b; Giasson et al., 
2000). Moreover, aS modified by oxidative attachment of a dopamine adduct results in a 
stabilization and subsequent accumulation of aS oligomers (Conway et al., 2001).  
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1.3. SYNUCLEIN AND LIPIDS  
 Although the regognized role of aS in neurodegeneration, its physiological 
function remains poorly understood (Bendor et al., 2013). Recent studies pointed out that 
aS interferes with vesicles-trafficking pathways (Lashuel et al., 2013). Scott and 
colleagues, coupling α-synuclein overexpression and knock-out model-system, reported 
that aS attenuates the mobility of recycling pool vesicles and maintains the overall size of 
these vesicles. Specifically, overexpression of aS leds to smaller vesicles and inhibited 
intersynaptic trafficking, while an absence of aS leads to larger vesicles size and enhanced 
intersynaptic trafficking. (Scott et al., 2012). aS seems to have a chaperone activity, since 
it directly binds SNARE-protein synaptobrevin-2/vesicle-associated membrane protein 2 
(VAMP2) and promotes SNARE-complex assembly (Burrè et al., 2010). Moreover, in triple-
knockout mice, lacking synucleins, the absence of the proteins cause the development of 
age-dependent neurological impairments, consinsting in decreased SNARE-complex 
assembly, and premature death (Burrè et al., 2010). On the contrary, also membranes 
seem to have an effect on aS, especially influencing its aggregation kinetic, with 
difference depending on the membrane composition (Beyer et al., 2007).  
 
1.3.1 Structural features 
 A variety of observations suggest that aS, in the cytosol, is normally divided 
between a helix-rich, membrane-bound and a disordered cytosolic form, a behaviour 
apparently conferred by structural similarity to the exchangeable apolipoproteins (Perrin 
et al., 2000). Indeed, aS contains class A2 lipid-binding helices: similarly to this "class A2" 
helical binding mechanism, lipid association is disrupted by introduction of charged 
residues along the hydrophobic face of the predicted alpha-helix and also by biotinylation 
of conserved lysines (which line the interfacial region). aS is able to undergo a large 
conformational change in the presence of specific phospholipids, ability that is presumed 
to be related to its functions (Perrin et al.,2000). Structural features of aS allow it to bind 
to synthetic vesicles containing acidic phospholipids and to cellular membranes with 
preferences towards acidic detergents like sodium dodecyl sulphate, and phospholipids, 
like phosphatidylserine (PS), phosphatidylglycerol (PG) and phosphatidyc acid (PA) 
composed vesicles, or mixture with neutral phospholipids (phosphatidylcholine (PC) and 
phosphatilylethanolamine (PE)) (Davidson et al., 1998; Zhu & Fink, 2003; Zhu et al., 2003; 
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Rhoades et al., 2006). In presynaptic termini, monomeric α-synuclein exists in equilibrium 
between free and membrane- or vesicle-bound states (McLean et al., 2000). This 
equilibrium is tightly regulated, and it has been estimated that approximately 15% of α-
synuclein is membrane-bound within the synaptic termini (Lee et al., 2002). aS binding to 
the membranes is accompanied by an increase in α-helix content (Perrin et al., 2000; 
Davidson et al., 1998): different helical structures form upon membrane binding, 
depending on the composition of the membrane. One well-studied form occured in the 
presence of SDS micelles that led to the formation of two anti-parallel curved α-helices 
(Val3-Val37 and Lys45-Thr92) connected by a well-ordered, extended linker, and followed 
by another short extended region (Gly93-Lys97) (Ulmer et al., 2005). The well ordered 
conformation of the helix-helix connector indicates a defined interaction with lipidic 
surfaces. Other α-helix structure have been reported, such as a single curved α-helix 
encompassing residues 1–90 (Jao et al., 2008; Lokappa and Ulmer, 2011). Also a non-
canonical α-helix model has been reported, characterized by a periodicity of 11/3 (Figure 
1.9 incollata qui sotto), to better arrange to membrane placing lysine residues on the 
interface between solvent and membrane surface: in this model lysine’s ε-amino groups 
are responsible of the electrostatic interaction with negative charged headgroups of 
phospholipids, while the acylic chain suits well in the hydrophobic environment due to 
lipids tails (Bussell & Eliezer, 2003; Bussell et al., 2005; Jao et al., 2004; 2008).  
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Fig. 1.9. aS binding model to lipid vesicles. A and B are representations of the interaction of aS 
with a curved membrane. C is a more detailed view of this protein -lipid interaction. D schematic 
representation of aS structure on SUV or on micelles, that differs from large vesicles because 
highly curved micelles can not accomodate the extended helical structure as in A and B. E helical 
wheel in wich 11 amino acid residues make up three turns. In this way, a lipid-exposed side (red) 
and solvent-exposed side (green) are formed. F view of the overlaid structures from above the 
lipid surface. In blue, te 11 lysine residues, that are oriented approximately perpendicular to the 
helical axis (reprinted from Jao et al., 2008). 
 
 
1.3.2 aS influence on lipid bilayers 
 aS interaction with membranes strogly influences the lipid bilayer structure 
(Madine et al., 2006). Using 2H- and 31P-NMR spectroscopy it has been shown that the 
association of aS with negatively charged membranes can disrupt the integrity of the lipid 
bilayer, while it has little effect on membranes of zwitterionic phospholipids. (Madine et 
al., 2006). Two different region of aS show preference for different membrane surface 
charge: the peptide aS (10−48), a lysine-rich peptide of the N-terminal region, associates 
with negative lipid, while peptide aS(120−140), a glutamate-rich peptide in the C-terminal 
region, weakly associates with lipid headgroups but with a slightly higher affinity for 
membranes with no net surface charge than for negatively charged membrane surfaces. 
Binding of these peptides to lipid vesicles do not disrupt the lamellar structure of the 
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membranes, but both peptides induce the lateral segregation of the lipids into clusters of 
acidic lipid-enriched and acidic lipid-deficient domains. This finding is really important 
because it could reveal the function of aS: it has been speculated that the N-terminal and 
C-terminal domains of aS might act in concert to organize membrane and play a role in 
presynaptic vesicle synthesis, maintenance, and fusion (Madine et al., 2006). Another 
consequence of aS bound to lipids that could be related to aS function, is the prevention 
of lipids oxidation (Breydo et al., 2012). The antioxidant function of aS could be attributed 
to its facile oxidation via the formation of methionine sulfoxide. Monitoring the lipid 
oxidation kinetics in the absence and in the presence of aS, Zhu et colleagues find that 
monomeric aS prevent unsaturated lipid oxidation while aS fibrils do not (Zhu et al., 
2006). The inhibition of lipid oxidation by aS may be a physiological function of the 
protein (Zhu et al., 2006). 
 
1.3.3 Lipids influence on aS properties 
 Membranes and aS fibrillogenesis are correlated in two ways: lipids influence aS 
aggregation and, viceversa, oligomeric species of aS seem to exert their toxic activity on 
membranes. aS-lipids interaction, causing rearrangement of the structure of aS, 
influences aS aggregation kinetic. Indeed, it has been reported that the interaction of α-
synuclein with the membranes alters the kinetics and pathways of its aggregation in vitro 
(Breydo et al., 2012). Lipids seem to act as anti-chaperones facilitating protein transition 
into partially folded states more prone to aggregate. The effects of membrane binding 
varied, from inhibition (Zhu and Fink 2003) to acceleration (Necula et al., 2033) of aS 
aggregation, (Zhu et al., 2003a; Zhu et al., 2003b)and (Jo et al., 2000). These opposite 
effects primarly depend on the protein-lipid molar ratio. Low concentration of fatty acids 
accelerate aggregation of aS (Necula et al., 2003), probably because membrane-bound α-
synuclein can generate nuclei that seed the aggregation of the more abundant cytosolic 
form (Lee et al., 2002). On the contrary, higher fatty acids concentration induces total aS 
conversion to the α-helical membrane-bound form, that is unlikely to contribute to 
aggregation and fibril formation (Zhu et al., 2003b). These observations suggest that the 
initial phases of aS aggregation may occur on the surfaces of membranes and thus 
pathological conditions that induce cross-linking of synuclein, such as oxidative stress, 
may enhance the propensity for aggregation (Cole et al., 2002). Indeed, detection of 
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oligomeric form of aS formed in the presence of lipids has been reported both in vivo and 
in vitro (Sharon et al., 2003; De Franceschi et al., 2011). Specifically, polyunsaturated fatty 
acid (PUFA), such as arachidonic and docosahexaenoic acids, have been linked to aS 
oligomerization, also at physiological concentrations (Perrin et al., 2001). However, it has 
been reported that experimental conditions strongly influenced the structure and 
heterogenicity of oligomers of aS formed in the presence of lipids (Haque et al., 2010).  
 
1.3.4 Role of fatty acids  
 Multiple studies have documented interactions of aS with free fatty acids, but the 
physiological consequences are still not fully understood (Ruipérez et al., 2010). Perrin 
and coworkers (2001) showed that in vitro exposure to vesicles containing certain 
polyunsaturated fatty (PUFAs) causes the formation of aS oligomers at physiological 
concentrations. It has been reported that aS interacts with PUFAs in vivo to promote the 
formation of highly soluble oligomers that precede the insoluble aS aggregates associated 
with neurodegeneration . Indeed, soluble oligomers of aS were found in the cytosol of 
mesencephalis neuronal cells derived from murine (normal or aS-transgenic) and human 
(normal or PD affected) brains. Interestingly, exposure of cells to PUFAs increased aS 
oligomers levels, while saturated or monounsaturated FAs did not. In addition to the 
degree of saturation, the length of the carbon chain was important for alpha-synuclein 
oligomerisation (Sharon et al., 2003). These results have been confirmed in vitro: PUFAs, 
depending on unsaturation and carbon chain length, influence aS aggregationlead to the 
formation of cytotoxic oligomers (Assayag et al., 2007). Upon interaction with DHA, the 
normally unstructured α-synuclein rapidly adopts an α-helical conformation. This effect 
has been observed in the presence of both arachidonic acid or docosahexaenoic acid, but 
not in the presence of saturated fatty acids (Broersen et al., 2006). The study of DHA is 
especially important since DHA accounts for 60% of all esterified fatty acids in neuronal 
plasma membrane (Lukiw et al., 2008). Moreover, the levels of this fatty acid in a non-
esterified form appear to be elevated in patients affected by Parkinson’s disease (Sharon 
et al., 2003) and it has also been reported that DHA intake increases expression of aS 
gene, and in turn aS allows DHA to be present in a soluble rather than micellar form. For 
these reasons, interest growth on the study of the mode of interaction of aS and DHA: It 
has been reported that the N-terminal alpha-synuclein fragment of approximately 70–80 
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amino acids was most resistant to proteolysis in the presence of docosahexaenoic acid, 
suggesting that PUFAs interact with the N-terminus of the protein (De Franceschi et al., 
2009). Recent studies implicated aS specifically in regulation of fatty acid metabolism. 
Mice lacking the alpha-synuclein gene exhibited reduced incorporation of arachidonic 
acid  (AA) into brain phospholipids, and a simultaneous riseof about 50% in incorporation 
of docosahexaenoic acid (Golovko et al., 2007). Because AA and DHA are the major 
polyunsaturated fatty acids in the brain, the increase in DHA incorporation into brain 
phospholipids is considered to be compensatory for the reduction in rate of AA 
incorporation into these lipid pools, since both FAs use the same sn-2 position of 
phospholipids. Further genetic studies in mice have suggested a role for alpha-synuclein 
in substrate presentation to acyl-CoA synthetase (ACSL), a critical enzyme in the fatty acid 
re-acylation pathway. The ablation of alpha-synuclein decreased ACSL activity (Golovko, 
et al., 2006). Importantly, addition of physiologically relevant concentrations (3.15–6.3 
nM) of aS WT, but not mutant aS, restores AA-CoA formation in aS KO mice: mutant 
forms of aS (A30P, E46K, and A53T) fail to modulate acyl-CoA synthetase (Acsl) activities, 
indicating that expression of these forms may cause a loss of function. Alpha-synuclein 
was shown to specifically modulate activity of the ACSL6 isoform which is responsible for 
arachidonic acid incorporation into phospholipids (Golovko et al., 2009). Since aS is a FA 
binding protein, several studies analyzed consequences on FA incorporation in the 
absence of aS. Barcelo and colleagues reported that in ethanolamine 
glycerophospholipids and phosphatidylserine, docosahexaenoic decreases of about 7% 
(Barcelo-Coblijn et al., 2007). Into astrocytes of WT and aS-KO mice (68), aS deficiency 
decreased PA and AA incorporation of about 31% and 39%, respectively, while DHA 
incorporation was unaffected. In the phospholipid fraction, a decreased distribution into 
this lipid pool of these fatty acids, including DHA, was found (Castagnet et al., 2005). In 
cells treated with high concentrations of fatty acids, aS WT was found to associate also 
with lipid droplets, specifically it seems to accumulate on phospholipid monolayers 
surrounding triglyceride-rich lipid droplets and was able to protect stored triglycerides 
from hydrolysis (Cole et al., 2002). Treatment of aS-expressing HeLa cells with high levels 
of oleic acid, determined an increase in the formation of lipid droplets and translocation 
of aS from the cytosol to the surface of lipid droplets. Interestingly, PD mutant synucleins 
showed variable distributions on lipid droplets and were less effective in regulating 
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triglyceride turnover. Also small aS oligomers detected in cells, primarily dimers and 
trimers, were associated with lipid droplets and cell membranes, suggesting that the 
initial phases of synuclein aggregation may occur on the surfaces of membranes (Cole et 
al., 2002). Another important aspect involving FA is the oxidative stress damage. Neurons 
are particularly susceptible to injury by oxidative stress beacuse of low defence 
mechanisms and the high rate of oxygen consumption (Ruiperez et al., 2011). Among 
brain lipids, PUFAs are particularly vulnerable to oxidation due to their unsaturated bonds 
(Fig. 1.10). Of note, several studies suggest that aS may be neuroprotective toward 
oxidative stress. Indeed, aS levels increase in neurons exposed to chronic oxidative (Quilty 
et al., 2006) However, these study do not expalin whether these aS changes are cytotoxic 
or neuroprotective. It was 
also proposed that aS 
could directly prevent 
oxidation of PUFA, via the 
formation of methionine 
sulfoxide, acting as 
scavengers of ROS (Zhu et 
al., 2006). These findings 
suggest that the inhibition 
of lipid oxidation by α-
synuclein may be a 
physiological function of 
the protein.  Fig. 1.10. Metabolism of polyunsaturated fatty acids (PUFAs). 
PUFAs are released from phospholipid membranes through 
the action of PLA2. Alpha-synuclein (αS) binds free PUFAs 
changing its conformation. PUFAs are reincorporated into 
phospholipids through the action of acyl-CoA synthetases 
(ACSL) and lysophosphatidyl acyltransferases (LPAT). PUFAs 
are also transported into mitochondria (bottom left) for 
degradation generating ATP with a minor production of 
reactive oxygen species (ROS). PUFAs can be oxidized into 
eicosanoids through enzymatic actions and also converted into 
oxidized species in uncontrolled ROS reactions. The interaction 
of alpha-synuclein with PUFAs (oxidized or not) could lead to 
mitochondrial changes. Proteins Parkin, DJ-1, PINK1 and LRKK2 
are implicated in the regulation of mitochondrial functions. 
Mutations in these proteins lead to inherited Parkinson’s 
disease (reprinted from Ruiperez et al., 2011). 
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2. Materials and Methods 
 
2.1 Materials 
 DHA and fluorescein isothiocyanate dextran (FITC-Dextran) of average molecular 
weight of 10,000 Da were purchased from Sigma Chem. Co. (St. Louis, MO). Trypsin from 
bovine pancreas, and thioflavin-T (ThT) were purchased from the Sigma Chemical 
Company (St. Luis, MO), whereas acetonitrile and triluoroacetic acid (TFA) from Fluka 
(Buchs, Switzerland). All other chemicals were of analytical reagent grade and were 
obtained from Sigma or Fluka. 
The lipids, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-
glycero-3-phospho-(1'-rac-glycerol) (DOPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-
serine (POPS), 1-palmitoyl-2-oleoyl-sn-glycero-3 phosphoethanolamine (POPE) and Brain 
Total Lipid Extract, were obtained from Avanti Polar Lipids (Alabaster, AL) as chloroform 
solution and used without further purification. 
 
2.2 Methods 
2.2.1 Expression and purification of recombinant aS and aS mutants 
 Human aS cDNA was amplified by PCR with synthetic oligonucleotides (Sigma-
Genosys) containing NcoI and XhoI restriction sites and designed to obtain the entire 
sequence of the protein (aS/E46K/A30P/A53T/H50Q 1-140). After digestion with 
restriction enzymes, the two PCR products were subcloned into the NcoI-XhoI-linearized 
pET28b expression plasmid (Novagen) and introduced into an Escherichia coli BL21(DE3) 
strain.  
Overexpression of proteins was achieved by growing cells in LB medium (1% Bacto 
tryptone, 0.5% yeast extract, 0.5% NaCl) at 37 °C to an OD600 of 0.6-0.8 followed by 
induction with 0.5 mM isopropyl β-thiogalactopyranoside for 4 h. 
The purification of aS and its mutants was conduced following this procedure. After 
osmotic rupture of cells, centrifugation was used to separate lipid and contaminants. 
After boiling of cell proteic content for 15 min, the soluble fraction, containing the 
protein, was treated with 55% ammonium sulphate. The pellet was then resuspended, 
dialyzed and loaded into a Resource Q 6-ml column (Amersham Biosciences) and then 
eluted using 20 mM Tris buffer, pH 8, with a linear gradient 0-500 mM NaCl. 
Further purifications were obtained by RP-HPLC. aS was purified in a Jupiter-C4 column 
(4.6 x 150 mm) (Phenomenex, CA, USA) eluted with a linear gradient of water (0.1 % TFA), 
versus acetonitrile (0.085 % TFA) from 5% to 38% in 5 min and from 38% to 43% at a flow 
rate of 0.6 ml/min. All aS mutants were expressed and purified following the same 
protocol. Finally, the proteins were lyophilized and stored at -20 °C. 
 
2.2.2 Aggregation studies 
 In order to analyze the aggregation process of aS, lyophilized protein obtained 
from purification was dissolved in PBS phosphate buffer (8 mM Na2HPO4, 137 mM NaCl, 
2 mM KH2PO4, 2.7 mM KCl), pH 7.4, and filtering the protein solution with a 0,22 μm 
pore-size filter (Millipore, Bedford, MA, USA). Dissolved samples were incubated at 37 °C 
at a protein concentration of 50 μM (0.723 mg/ml), under shaking at 500 rpm with a 
thermo-mixer (Compact, Eppendorf, Hamburg, DE). The same experiment has been 
conduced in parallel for A30P, A53T, E46K and H50Q mutants, with or without DHA. 
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2.2.3 Circular Dichroism 
  Protein concentrations were determined by absorption measurements at 
280 nm using a double-beam Lambda-20 spectrophotometer from Perkin Elmer (Norwalk, 
CT). The extinction coefficients at 280 nm were 5960 M-1 for aS and mutants, as evaluated 
from their amino acid composition by the method of Gill and von Hippel (1989).  
Circular dichroism spectra were recorded on a Jasco J-710 (Tokyo, Japan) 
spectropolarimeter. Far-UV CD spectra were recorded using a 1 mm path-length quartz 
cell and a protein concentration of 5 µM. The mean residue ellipticity [θ] (deg⋅cm2⋅dmol–
1) was calculated from the formula [θ] = (θobs/10) ⋅(MRW/lc), where θobs is the observed 
ellipticity in deg, MRW is the mean residue molecular weight of the protein, l the optical 
pathlength in cm and c the protein concentration in g/mL. The spectra were recorded in 
PBS buffer, pH 7.4, both in the presence of different concentration of DHA (ranging from 
0-400 µM) and during aggregation studies.  
 
2.2.4 Gel filtration 
 Gel filtration chromatography (or size exclusion chromatography) was performed 
with a Superdex 75 10/300GL column (Amersham Biosciences, Uppsala, Sweden), using 
an ÄKTA FPLC system (Amersham Biosciences, Uppsala, Sweden). The matrix is composed 
of cross-linked agarose and dextrane with an average particle size of 13 μm and a 3-70 
KDa separation range for globular proteins. The hydrodynamic volume of analytes was 
determined on the base of the the distribution coefficient, Kd, calculated as the following 
formula: Kd= (Ve-Vo)/(Vt-Vo), where Ve, Vt and Vo are respectively the analyte elution 
volume, total and void volume. If the analyte is large and completely excluded from the 
mobile phase within the gel, Kd = 0 whereas, if the analyte is sufficiently small to gain 
complete access to the inner mobile phase, Kd = 1. Due to variation in pore size between 
individual gel particles, there is some inner mobile phase that will be available to analytes 
of intermediate size; hence Kd values vary between 0 and 1. It is this complete variation 
of Kd between these two limits that makes it possible to separate analytes within a 
narrow molecular size range on a given gel. 
A calibration controls with globular proteins of known MW was performed. 50 µg of each 
of the following standard calibration proteins were loaded: bovine α-lattalbumine (MW= 
14 kDa), carbonic anhidrase (MW= 29 kDa), ovoalbumin (MW= 45 kDa), BSA(MW= 66 
kDa), thyroglobulin (MW= 440 kDa) , β-amilase (MW= 200 kDa)  and ferritin (MW= 669 
kDa). 200 µg of blue dextran and 0.05% dimethyl sulfoxide (DMSO) were loaded to 
estimate the void and total volume of the column, respectively. The elution was 
monitored by recording on-line the absorbance at 214 nm. In order to characterize aS and 
its mutants behaviour in solution, 144 µg of proteins at different time of incubation were 
loaded. 
 
2.2.5 RP-HPLC 
 Reversed-phase high-performance liquid chromatography (RP-HPLC) involves the 
separation of molecules on the basis of hydrophobicity. The separation depends on the 
hydrophobic binding of the solute molecule from the mobile phase to the immobilized 
hydrophobic ligands (n-butyl, n-octyl and n-octadecyl) attached to the stationary phase. 
This one usually consists of an n-alkylsilica-based matrix from which the solutes are eluted 
with gradients of increasing concentrations of organic solvent such as acetonitrile. A 
charged ion-pairing reagent (TFA, trifluoroacetic acid) with an opposite charge to that of 
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the protein is added to the mobile phase to form a noncharged complex. TFA increases 
the idrophobicity and consequently the retention of the protein, indeed if it is added in a 
concentration of 0.085% (v/v), the pH is around 2.5. At this pH, the carboxylic groups of 
protein are protonated and the trifluoroacetic anion binds to the positively charged 
amino groups of proteins. Elution proceeds by application of a gradient of increasing 
organic solvent concentration, which competes with the stationary phase for hydrophobic 
interaction with the analyte. 
The HPLC analyses of aggregated samples were conducted using a Jupiter C4 column (4.6 
mm × 150 mm; Phenomenex, CA, USA), eluted with a gradient of water/0.1% TFA vs 
acetonitrile/0.085% TFA from 5% to 38% in 5 min, from 38% to 43% in 15 min. The elution 
was monitored by recording the absorbance at 226 nm. The identity of the eluted 
material was assessed by mass spectrometry. 
 
2.2.6 SDS-PAGE 
 SDS-PAGE was conducted following the method of Laemmli (1970). In SDS 
polyacrylamide gel electrophoresis (SDS-PAGE), charged proteins migrate in response to 
an electric field. Their rate of migration depends on the strength of the field and on the 
net charge, size and shape of the molecules. Since different proteins with similar 
molecular weights may migrate differently due to their differences in secondary, tertiary 
or quaternary structure, sodium dodecyl sulphate (SDS), an anionic detergent, is used in 
SDS-PAGE to reduce proteins to their primary (linearized) structure and coat them with 
uniform negative charges. Polyacrylamide gels restrain larger molecules from migrating as 
fast as smaller molecules. Because the charge-to-mass ratio is nearly the same among 
SDS-denatured polypeptides, the final separation of proteins is dependent almost entirely 
on the differences in relative molecular mass of polypeptides. Electrophoresis 
experiments were conducted with the Mini-Protean II electrophoresis system purchased 
from Biorad using plates of 5 x 8 cm and spacer of 0.75 mm thickness. For the separation 
of proteins the gel was composed by 13 % T (% total acrylamide and bis-acrylamide). The 
electrophoretic buffer (Laemmli buffer) composition was: 25 mM Tris-HCl, 0.25 M glycine, 
0.1% SDS, pH 8.5. The acrylamide polymerization was obtained by adding TEMED and 10% 
solution of ammonium persulfate (APS). Samples were dissolved in 50 mM Tris-HCl, pH 
6.8, containing 2% SDS, 2% β-mercaptoethanol, 10% glycerol, traces of bromophenol blue 
and denaturated by heating at 100 °C for 5 minutes. The electrophoresis was performed 
at room temperature at 25 mA.  
 
2.2.7 Native-PAGE 
 Native (non-denaturing) polyacrylamide gel electrophoresis was conducted with 
the Mini-Protean II electrophoresis system purchased from Biorad using plates of 5 x 8 cm 
and spacer of 0.75 mm thickness. For the separation of proteins the gel was composed by 
13 % T (% total acrylamide and bis-acrylamide). The electrophoretic buffer composition 
was: 25 mM Tris-HCl, 0.25 M glycine, pH 8.5. Samples were dissolved in 50 mM Tris-HCl, 
pH 6.8, containing 10% glycerol and traces of bromophenol blue. The electrophoresis was 
performed at room temperature at 25 mA.  
 
 
 
 
 - 46 - 
2.2.8 Liposomes preparation 
 To prepare large and small unilamellar vesicles (LUV, SUV), lipids were transferred 
in glass tubes. Chloroform was dehydrated by gentle helium stream and then warmed at 
45°C to remove residual organic solvent. The lipid film was hydrated with PBS pH 7.4 in 
the absence or presence of calcein (50 mM) or FITC-dextran (1.6 mM) at 40°C for 2 hours 
with frequent vortexing. Then it was subjected to 5 cycles of freezing and thawing. The 
suspension vesicles was extruded 11 times through a 400 nm or 30 nm pore size 
polycarbonate membrane on lipid extruder (Northern Lipids Inc, Vancouver, BC), in order 
to obtain LUVs or SUVs. Calcein-loaded and FITC-dextran-loaded vesicles were purified by 
gel filtration chromatography (Sepharose G-25) to remove unencapsulated dye. The final 
lipid concentration, determined as total phosphorus, was conducted according to Chen et 
al.2003.  
 
2.2.9 Thioflavin T binding assay (ThT) 
 The ThT binding assays were performed accordingly to LeVine (1993) using a 
freshly prepared 25 µM ThT solution in 25 mM sodium phosphate (pH 6.0) that had been 
passed through 0.45 µm filters. Aliquots (30 µl) of protein samples from the aggregation 
incubation were taken at specified times and diluted into the ThT buffer (final volume 500 
µl). Fluorescence emission measurements were conducted at 25°C using an excitation 
wavelength of 440 nm and recording the ThT fluorescence emission at 480 nm. 
 
2.2.10 Dynamic Light Scattering (DLS) 
 DLS measurements were carried out with a Zetasizer Nano-S instrument (Malvern 
Instrument, UK). This apparatus, which uses the backscattering detection (scattering 
angle θ=173°) and an avalanche photodiode detector (APD), is equipped with a Helium–
Neon laser source (wavelength 633 nm; power 4.0 mW), and a thermostated sample 
chamber controlled by a thermoelectric Peltier. DLS measurements were performed at 
25°C in PBS pH 7.4 in duplicate. During every measurement 12 runs were collected. 
DLS was used to check the size distribution and the stability of vesicles.  DOPG LUV and 
SUV size distributions were measured for vesicles alone and after 30 min of incubation 
with oligomers.  
 
2.2.11 Transmission Electron Microscopy  
 In order to evaluate the morphology and the size of the species deriving from the 
self-assembly of DHA and from the aggregation process of aS, aliquots of the samples 
were examined by transmission electron microscopy (TEM). The samples relative to 
aggregation of the proteins were diluted 3 times with PBS. A drop of the samples solution 
was placed on a Butvar-coated copper grid (400-square mesh) (TAAB-Laboratories 
Equipment Ltd, Berks, UK), dried and negatively stained with a drop of uranyl acetate 
solution (1%, w/v). TEM pictures were taken on a Tecnai G2 12 Twin instrument (FEI 
Company, Hillsboro, OR, USA), operating at an excitation voltage of 100 kV.  
 
2.2.12 Mass spectrometry 
Mass determinations were obtained with an electrospray ionization (ESI) mass 
spectrometer with a Q-TOF analyzer (Micro) from Waters Micromass (Manchester, UK). 
The measurements were conducted at a capillary voltage of 3 kV and a cone voltage of 35 
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V. The molecular masses of protein samples were estimated using the Mass-Lynx 
software 4.1 (Micromass).  
 
2.2.13 Proteolysis  
 Proteolysis experiments were carried out on monomeric aS and aS mutants to 
analyze interaction with DHA, using proteinase K (Ebeling et al., 1974) at E/S ratio of 
1:1000 (by weight). Experiments of proteolysis were conducted also on oligomeric 
samples of aS/DHA and H50Q/DHA, to identify aminoacidic residues modified by DHA, 
using Trypsin at a E/S ratio of 1:100 (by weight). All experiments were conduced in PBS, 
pH 7.4 and the reactions were quenched at specified times by acidification with TFA in 
water (4%, v/v) or by direct injection in RP-HPLC. All the proteolysis mixtures were 
analyzed by RP-HPLC. For all the proteins, the RP-HPLC analyses were conducted using a 
Vydac C18 column (4.6 mm x 250 mm; The Separations Group, Hesperia, CA), eluted with 
a gradient of water/0.1% TFA vs. acetonitrile/0.085% TFA from 5% to 25% in 5 min, from 
25% to 28% in 13 min, from 28% to 39% in 3 min, from 39% to 45% in 21 min at a flow 
rate of 1 ml/min. Column was provided by a HPLC security guard column SAX 
(Phenomenex, USA). The sites of cleavage along the polypeptide chains were identified by 
mass spectrometry analyses of the protein fragments purified by RP-HPLC.  
 
2.2.14 Ion exchange chromatography 
 Separation in ion exchange chromatography depends upon the reversible 
adsorption of charged solute molecules to immobilized ion exchange groups of opposite 
charge. Separation is obtained since different substances have different degrees of 
interaction with the ion exchanger due to differences in their charges, charge densities 
and distribution of charge on their surfaces. An ion exchanger consists of an insoluble 
matrix to which charged groups have been covalently bound. The charged groups are 
associated with mobile counter ions which can be reversibly exchanged with other ions of 
the same charge without altering the matrix. After sample injection, solute molecules 
carrying the appropriate charge displace counter-ions and bind reversibly to the gel, 
whereas unbound substances are washed out from the exchanger bed using starting 
buffer. Desorption of solute molecules is achieved by increasing the ionic strength of the 
eluting buffer. 
The analyses of aS and aS/DHA were conducted using a Resource-Q column (Amersham 
Pharmacia), a strong anion column pre-packed with SourceTM. SourceTM is based on 
monodisperse, hydrophilized and rigid polystyrene/divinyl benzene beads, produced by 
substitution of the base matrices with quaternary amino groups (-O-CH2-CHOH-CH2-O-
CH2-CHOH-CH2-N+(CH3)3). The eluting buffer used was 20 mM Tris pH 8 with a 30-
minutes linear gradient 150-500 mM NaCl. 
 
2.2.15 DNPH assay 
 2,4-Dinitrophenylhydrazine (DNPH) or Brady's reagent is a substituted hydrazine 
used to detect, in lateral chain of aminoacids,  carbonyl groups such as aldehydes and 
ketones. aS monomers and aS/DHA oligomers purified by RP-HPLC were dried and 
resuspended in 2M HCl + 10mM DNPH, and then incubated for 1h at room temperature 
in the dark. To stop reaction, proteic material was precipitated with 15% trichloroacetic 
acid. After centrifugation, pellets were washed 3 times with a solution of ethanol:ethyl-
acetate 1:1 and then dried. For RP-HPLC analysis, samples were re-hydrated in 0.1% TFA 
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and chromatograms were recorded both at 226 nm (to detect the proteic material) and 
366 nm (to detect DNPH). Eluted fractions were analyzed by mass-spectrometry. For UV-
Vis analysis, samples were resuspended in 6M Guanidinium chloride overnight and 
spectra were recorded from 380to 240 nm.  
 
2.2.16 Atomic Force Microscopy 
 aS/DHA oligomers were diluted 500 times using Milli-Q water and 10 µl aliquots 
were deposited on freshly cleaved mica and dried under mild vacuum. Tapping mode 
AFM images were acquired in air using a Multimode scanning probe microscope equipped 
with an “E” scanning head (maximum scan size 10 µm) and driven by a Nanoscope IV 
controller (Digital Instruments, Bruker, Germany). Single beam uncoated silicon 
cantilevers (type Olympus OMCL-AC160TS, Olympus, Tokyo, Japan) were employed. The 
tip of the probe was of 7 nm.The drive frequency was between 280 and 300 kHz, and the 
scan rate was between 0.5 and 1.0 Hz. TEM pictures were taken on a Tecnai G2 12 Twin 
instrument (FEI Company, Hillsboro, OR, USA), operating at an excitation voltage of 100 
kV. Samples for TEM were diluted 2 times and a drop of the solution was placed on a 
Butvar-coated copper grid (400-square mesh) (TAAB-Laboratories Equipment Ltd, Berks, 
UK), followed by a drop of uranyl acetate solution (1% w/v). 
 
2.2.17 Release Assays 
 For calcein release assay, SUV or LUV were diluted to 50 µM of lipids. After 30 
minutes of incubation in the presence of different protein species (monomers, oligomers, 
fibrils), fluorescence emission at 515 nm was recorded after excitation at 490 nm. 
Maximum fluorescence emission was obtained by the addition of 0.1% Triton X-100 to 
disrupt vesicles. The average values of experiments, performed in triplicate, were 
expressed as a percentage of the maximum effect due to total vesicles disruption. FITC-
dextran-loaded SUVs or LUVs were incubated for 30 minutes in the presence of the 
protein species at a final lipid concentration of 100 M. Released dye was detected by 
fluorescence measurement with excitation at 490 nm and emission at 515 nm, after 
purification of the incubated solution through Microcon (cutoff 50000) to allow FITC-
Dextran elution. The minimum and maximum effect was obtained by measurement of a 
liposome solution respectively with or without 0.1% Triton X-100. The average values of 
experiments, performed in triplicate, were expressed as a percentage of the maximum 
effect calculated as total vesicles disruption obtained with Triton X-100. 
 
2.2.18 Cell Permeabilization Assay 
 To examine whether aS/DHA oligomers can permeabilize cell membranes, we 
exploited the ability of propidium iodide (PI; MW 668.4 Da) to bind DNA as indirect 
reporter of membrane damage. Dopaminergic SH-SY5Y cells were cultured in 24-well 
plates (seeding density ~50000 cells/well) and twenty-four hours after seeding treated 
with 0.5 µM of aS monomer or aS/DHA oligomers. Impermeant dye PI (2 µg/ml) and 
counterstain dye Hoechst 33242 (2 µg/ml) were added to cells simultaneously to the 
treatment. After a 30 min-incubation at 37°C, PI-positive cells were counted in three 
replicate cultures, acquiring an average of 5 fields per culture (250-350 cells/field). The 
experiment has been repeated 3 times independently. Saponin (50 µg/ml) was used as 
positive control of membrane permeabilization. 
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2.2.19 Planar Lipid Membrane 
 Solvent-free Planar Lipid Membrane (PLM) was composed of equimolar mixture of 
1,2-dioleyl-phosphatidyl-glycerol (DOPG) and 1,2-dioleyl-phosphatidyl-ethanolamine 
(DOPE) and formed on an aperture in a 25 µm thick Teflon septum separating two 
chambers, as described in Dalla Serra et al. [26]. Ionic currents were recorded by a patch 
clamp amplifier (VA-10X npi, Tamm, Germany), filtered at 100 Hz, digitalized and acquired 
at 2 kHz by the computer using DigiData 1322 A/D converter and pClamp software (Axon 
Instruments, Sunnyvale, CA).  
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3. aS/DHA OLIGOMERS CHARACTERIZATION 
Multiple studies have documented interactions of aS with phospholipid 
membranes and free fatty acids even if the physiological consequences are not still 
understood. In vivo, almost the 15% of aS is supposed to be bound to lipid membranes 
(Lee et al., 2002). This binding leads the protein to acquire α-helix structure and can have 
consequences on its aggregation kinetic, inducing protein oligomerization or preventing 
amyloid formation (Breydo et al., 2012). As previously reported (Sharon et al., 2003; De 
Franceschi et al., 2011), aS is able to bind brain fatty acid, such as DHA. We and others 
have shown that in the presence of DHA aS acquires α-helix structure and undergoes 
aggregation that rapidly leads to the formation of stable oligomers, that are toxic to cells 
(De Franceschi et al., 2011). A study on the kinetic of aggregation and on the properties of 
the species formed in the presence of DHA has been conducted by our group in a 
previous work, but some aspects remained unclear. Considering that the main objective 
of the present research was to define the activity of the oligomers formed in presence of 
DHA, a further characterization has been conducted. In particular, a new method for the 
isolation of the oligomers based on ion exchange chromatography have been proposed as 
alternative to the gel filtration. Other relevant aspects of this study regard the chemico-
psysical characterization of the oligomers by using microscopy and spectroscopic 
techniques. Finally a large part of the research is dedicated to the analysis of the activity 
of oligomers on model membranes and cells to the aim to propose a possible mechanism 
of toxicity. 
 
3.1 Aggregation process of aS in the presence of DHA and isolation of 
oligomers 
 aS aggregation is conducted in the presence of DHA, using a molar ratio 
protein:fatty acid of 1:50. Previously it was found that it was possible to monitoring the 
aggregation and to isolate oligomeric aS from monomeric one using gel filtration 
chromatography. In Fig. 3.1 the main points of the purification and chemical 
characterization are reported. The mixture of aS and DHA corresponding to 48 hours of 
incubation was used for the studies conducted here. The monomeric species elutes at 24 
min, (Fig. 3.1 A). The oligomeric species (Fig. 3.1 A, dashed line), that elutes at 20 min, 
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increases on time. This fraction was analyzed by RP-HPLC for its identification and to 
provide further information about the chemical properties of oligomers (Fig. 3.1 B).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. Gel filtration (A) and RP-HPLC (B) chromatograms of aS/DHA mixture. (A) Gel filtration 
of aS in the absence (solid line) and in the presence (dashed line) of DHA in a molar ratio 
protein:lipid of 1:50. (B) RP-HPLC analyses were conducted using a Jupiter C4 column (4.6 x 150 
mm; Phenomenex, CA, USA), eluted with a gradient of acetonitrile/0.085% TFA vs water/0.1% TFA 
from 5% to 38% in 5 min, from 38% to 43% in 15 min, recording the absorbance at 226 nm. The 
identity of the eluted material was assessed by mass spectrometry and the spectrum of oligomers 
(RT 29.5) is reported (inset). 
 
 RP-HPLC chromatograms of aS/DHA mixture after 48 hours of incubation shows 
the presence of the peak relative to oligomer eluting at 29.5 min and two peaks at higher 
retention time corresponding to DHA and DHA by-products. Oligomeric fraction eluted by 
gel filtration, shows the same species at 29.5 min but the other two peaks are absent, 
indicating that the GF step removes the free fatty acid. Mass spectrometry analysis of 
species eluted at 29.5 min (Fig. 3.1 B, inset) shows that aS contains methionine oxidations 
and a covalent bound DHA molecule as indicated by the mass increase of 326 Da on the 
expected mass (14460 Da). The modification is not present in all molecules but from 
electrospray mass spectrometry data a modification of about 3% can be hypothesized.  
 
Gel filtration is resulted highly suitable for the purification of aS oligomers since 
that it is possible to remove aS in monomeric form and the excess of DHA. Moreover the 
native elution conditions, phosphate buffer at pH 7.5, seems to not induce chemical 
stress of the protein species. The main drawback of this type of method is the dilution of 
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the sample in the purified fraction. This could affect the dynamic equilibrium between the 
monomeric and aggregated form of aS. Due to the too low protein concentration in the 
purified sample, further analyses, such as structural characterizations and functional 
tests, are sometimes difficult to perform. So we tried another method of isolation based 
on ion exchange chromatography (IEX). The benefits of IEX are that it has a high 
throughput, the column has a long lifespan and it has a high resolving power allowing the 
separation of proteins having isoelectric points differing about 0.5 units of pH. So in this 
case we can have also information about change in the charge properties of the 
oligomers. In general separations can be fast, recoveries are high, buffer components are 
non-denaturing and frequently compatible with further downstream chromatographic 
separation or assay systems. Moreover this technique provides information on the 
possible charge modifications on the polypeptide chain of aS. Finally, it can be used as a 
concentration step, to recover proteins from a dilute solution.  
aS/DHA mixture were loaded in an anion-exchanger column and to compare 
elution pattern also the monomeric aS was analyzed as reference (Fig. 3.2). aS elutes at 
12 min and after 48 hours of incubation there is no further peak in the chromatogram 
(Fig. 3.2 A). The analysis of the mixture aS/DHA just after its preparation shows the same 
peak at 12 min, but after incubation, there are two main peaks at 12 and 20 min 
corresponding to 44% of NaCl in the chromatogram (Fig. 3.2 B). In order to identify the 
material under the peaks, these two main fractions were analyzed by RP-HPLC (Fig. 3.2 C) 
and they correspond respectively to monomeric and oligomeric aS. The late elution of the 
oligomers can be explained as higher affinity of these species for DEAE resin than the 
monomer. The resin is positively charged, so the affinity of aS presumably derives from 
the negatively charged C-terminal tail. The oligomers are formed by several monomer aS 
molecules, whose negatively charged C-terminal tails are not expected to be involved in 
the oligomer structure (De Franceschi et al., 2009), but they are free to interact with the 
anion exchanger. Moreover, also the presence of bound DHA could provide additional 
negative charge. The peak corresponding to oligomer seems narrow suggesting that the 
purified population of oligomers might be almost homogenous in terms of net charge. 
Unfortunately technical problems hampered the extensive use of this chromatography. 
Indeed it is resulted partially non-reproducible especially in terms of yield. For this reason 
we decided to continue to purify oligomers by gel filtration.  
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Fig. 3.2. IEX chromatography of aS (A) and aS/DHA 1:50 (B). The IEX chromatograms were 
obtained from samples just prepared (dashed line)) and after 48 hours of incubation (solid line). 
IEX analyses were conducted using a DEAE column, eluted with a gradient of NaCl from 0 to 1M in 
30 minutes, recording the absorbance at 214 nm. (C) RP-HPLC chromatogram of fractions eluted 
at 12 min (dashed line) and 20 min (solid line) in IEX of aS/DHA after 48 hours. (C) RP-HPLC 
analyses were conducted using a Jupiter C4 column (4.6 x 150 mm; Phenomenex, CA, USA), eluted 
with a gradient of acetonitrile/0.085% TFA vs water/0.1% TFA from 5% to 38% in 5 min, from 38% 
to 43% in 15 min, recording the absorbance at 226 nm. 
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3.2 Chemico-physical characterization of aS/DHA oligomers  
 aS/DHA oligomers were characterized by far-UV CD. The mixture corresponding to 
different times of incubation was analyzed. aS acquires α-helix structure in the presence 
of DHA and this type of secondary structure is maintained during oligomerization process 
(Fig. 3.3 A). Upon incubation, a small decrease of signal is detectable, as a consequence of 
aggregation and probable precipitation of the protein material. 
Fig. 3.3. Far-UV CD spectra. (A) aS/DHA mixture during the aggregation process. The spectra were 
recorded at a protein concentration of 5 mM in PBS pH 7.4, immediately after addition of DHA, 
and after 3, 24 and 48 hours. (B) Far UV CD of oligomers after purification by gel filtration (red 
line). The spectra of monomeric aS and aS in the presence of DHA (protein/DHA 1:50) are also 
reported as reference. (C) Titration experiment by far UV CD of oligomers in the presence of 
increasing amount of DHA. The numbers close to the spectra indicate the amount (µM) of DHA.  
 
The secondary structure of oligomers was checked also after the purification step by 
gel filtration. Oligomers show a CD spectrum typical of a protein in a partly folded state 
with a moderate content of α-helix structure (Fig. 3.3 B, red line). The spectrum of 
oligomers is shown in comparison with CD spectra of monomeric aS (Fig. 3.3 B, 
continuous line) and of the mixture of aS/DHA before gel filtration (Fig. 3.3 B, dashed line, 
from De Franceschi et al., JBC 2011). The loss of α-helix structure can derive from the fact 
that part of DHA was removed by gel filtration step. Interestingly, further addition of DHA 
to oligomers, isolated by gel filtration, induces again an increase of their α-helical 
structure (Fig. 3.3 C), as observed for monomeric aS. The transition between partly folded 
state and α-helix follows a two-state model, for the presence of an isodichroic point at 
203 nm in the titration experiment. Since in monomeric aS is the N-terminal region the 
responsible for membrane recognition and for cooperative formation of helical domains 
(Bartels et al., 2010), it is reasonable to assume that in the partly folded state, the N-
aS/DHA 1:50
Wavelength (nm)
200 210 220 230 240 250
[θ ]
 
x 
10
-
3  
(de
g.
cm
2 .
dm
o
l-1
)
-25
-20
-15
-10
-5
0
0h
3h
24h
48h
Wavelength (nm)
200 210 220 230 240 250
[ θ]
 
x 
10
-
3  
(de
g·
cm
2 ·
dm
o
l-1
)
-30
-20
-10
0
Wavelength (nm)
200 210 220 230 240 250
[θ]
 
x 
10
-
3  
(de
g·
cm
2 ·
dm
o
l-1
)
-10
-8
-6
-4
-2
0
Oligomers
25 µM DHA
100 µM 
250 µM
50 µM
Oligomers
aS
aS/DHA 1:50
A C B 
 - 56 - 
terminal region or part of it is still free to drive the association of oligomers with 
membranes and lipids. 
Oligomers were then observed by transmission electron microscopy (TEM), atomic 
force microscopy (AFM) and DLS (Fig. 3.4). These analyses provide information about an 
average size distribution of the oligomers. As previously reported by De Franceschi et al. 
(2011), TEM analysis shows that the chromatographic fraction corresponding to 
oligomers has a spherical morphology, with diameters ranging from 12 to 35 nm. In Fig. 
3.4 B the number size distribution from aS/DHA oligomers obtained by DLS analysis is 
shown, indicating a mean size of 22 ± 8 nm. AFM measurement based on height 
differences, shows the presence of two main populations, one is smaller (1.1 ± 0.1 nm) 
and the other is larger (4.1 ± 0.1 nm). To better compare AFM and DLS results, the profile 
peaks of two section containing oligomers of different size are also reported. The 
diameter of smaller oligomers (Fig. 3.4 D and E, black arrows) is about 20 nm, in 
agreement with the average value calculated by DLS measurements. Bigger oligomers 
(Fig. 3.4 D and E, red arrows) have diameter of about 50-60 nm, values still included in the 
size distribution curve obtained from DLS. 
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Fig. 3.4. Structural characterization of aS/DHA oligomers after their isolation by gel filtration. 
(A) Transmission electron microscopy and (B) DLS for particle size estimation of aS/DHA 
oligomers. (C) Tapping mode AFM image of oligomers and relative XZ profile of sections indicated 
by dotted line (D) and dashed line (E). 
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4. INTERACTION WITH MEMBRANES  
4.1 Morphological analyses of liposomes  
Liposomes were used to obtain membrane-mimetic systems to study oligomers 
interaction with membrane. Different phospholipid composition vesicles were prepared: 
DOPG, DOPG-POPE, POPS-POPC, POPC, POPE, TBE, as small unilamellar (SUV) and large 
unilamellar (LUV) vesicles. Different phospholipids were tested to check aS/DHA 
oligomers binding preference. Indeed, it is generally recognized that aS has a strong 
preference for binding to anionic membranes (Davidson et al., 1998; Zhu & Fink, 2003), 
but this information is lacking for aS/DHA oligomers. Thus, liposomes with -1, -0.5 and 0 
net charge were used. Immediately after preparation, dynamic light scattering (DLS) and 
electron transmission microscopy (TEM) were used to confirm the formation of liposomes 
of the desired size. Liposomes were tested for their stability on time measuring the 
average diameter by DLS immediately and after one week of storage at 4°C. The mean 
diameter for LUV and SUV, measured immediately after extrusion, is different for all the 
different phospholipid composition, as reported in Table 4.1: the smaller values were 
obtained with 1POPC:1POPS and the larger with POPE. After one week of storage at 4°C, 
there are no relevant differences in the average diameter, except for POPE vesicles. 
Immediately after extrusion with a polycarbonate membrane with pore of 30 nm, POPE 
SUV appear large as LUV. Moreover, after one week storage, the average diameter of 
POPE LUV increases of about +1096.8 nm (Table 4.1). This instability is due the tendency 
of phosphatidylethanolamine to self-aggregate after re-hydration and to form aggregates 
and floccules. Since other phospholipidic compositions allow to obtain more stable 
liposomes, POPE was not used for experiments. However, vesicles were always used 
within few days after preparation. In Fig. 4.1 the three main composition, corresponding 
to 100% and 50% negatively-charged phospholipids and total brain extract (with less than 
40% negative charged lipids) are reported. These three conditions were used also for the 
experiments as they provide, on the base of far-UV CD measurements, conditions for high 
(DOPG), middle (1POPC:1POPS) and low (TBE) interaction with aS/DHA oligomers (data 
reported in §4.2). Also POPC and POPE correspond to 100% zwitterionic or neutral lipids, 
but the use of an extract (TBE) was preferred, compared to single-phospholipid 
compositions. DLS and TEM (Fig. 4.1, inset) show comparable diameter size (average 
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values reported in Table 4.1). From TEM is possible also to control the morphology of 
liposomes: DOPG and 1POPC:1POPS have more regular distribution, and present the 
typical aspect of liposomes on mica, due to the drying of the samples. TBE liposomes, that 
show a larger size distribution with DLS, have also a different morphology on TEM picture, 
probably due to the unknown components of the extract.  
 
Fig. 4.1 DLS and TEM of SUV of different composition DOPG, 1POPC:1POPS AND TBE liposomes 
were diluted to a final lipid concentration of 0.5 mM and observed immediately after preparation.   
 
4.2 aS/DHA oligomers interact with membranes 
 Spectroscopic analyses by CD were conducted in order to study the interaction of 
oligomers with vesicles. It has been reported in literature that aS adopts an α-helical 
conformation induced by interactions with membranes, particularly those containing 
acidic phospholipids, and also with detergent micelles. The N-terminal and NAC regions 
include the imperfect repeats, xKTK(E/Q)GVxxxx, highly conserved in orthologous genes 
that can adopt an amphiphilic helical structure, a classical motif for membrane-interacting 
proteins. So we use this criteria to verify if oligomers are able to interact with 
membranes. aS/DHA oligomers were diluted to a final concentration of 5 µM, and 
analyzed by far-UV CD in the absence and in the presence of vesicles with different size 
and composition. Oligomers, as previously reported, after gel filtration, have a partly α -
helix folded state (Fig. 4.4 A, red line). The CD spectra are reported in Fig. 4.2 and show 
that vesicles containing negative charged phospholipids induce a structural transition of 
aS/DHA oligomers in a dose dependent manner. DOPG vesicles strongly induce α-helix 
structure acquisition of aS/DHA oligomers, while vesicles containing 50% of negative 
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charged lipids such as 1POPS:1POPC and 1DOPG:1POPE have less effect. POPE, POPC 
(zwitterionic phospholipids) and TBE (mixture with less than 40% negative charged 
phospholipids) do not induce structural transition. No significant difference was observed 
using LUV and SUV with the same composition, lacking information about a membrane 
curvature preference of aS/DHA oligomers. 
Fig. 4.2. Far-UV CD of aS/DHA oligomers in the absence (red line) and in the presence (black lines) 
of vesicles. Vesicles of  different composition were used, as reported in figure. Both LUV (dashed-
dotted lines) and SUV (dotted and dashed lines) were tested. 
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4.3 Aggregation in the presence of lipids and membranes  
 Membrane-induced or lipid-accelerated fibril formation of amyloidogenic proteins 
was frequently observed. Zhu and colleagues (2003) demonstrated that the fibrillation of 
aS is very significantly affected by acidic phospholipids vesicles in a concentration-
dependent fashion. By CD spectra it was demonstrated that, at high lipid/protein ratios, 
PA/PC and PG/PC vesicles induce α-helical structure in aS, whereas lower ratios of about 
5:1 mass ratio of protein to lipid induce a partially folded α-synuclein intermediate (Zhu et 
al., 2003). The presence of this intermediate has been previously correlated with 
enhancement of formation of aS fibrils (Uversky et al., 
2001). More recently, also Reynolds and colleagues 
reported that aS aggregates when applied on lipid 
bilayer surface at nanomolar concentrations, causing 
the extraction of lipid molecules and subsequent 
membrane thinning, as represented in Fig. 4.3 
(Reynolds et al., 2011). aS and A53T fibrils formation 
detected in the presence of synaptosomal lipid 
vesicles appeared to be associated with vesicles 
suggesting a partial insertion of aS into the bilayer, 
which could act as an anchor for site-directed fibril 
assembly (Jo et al., 2004). 
Fig. 4.3. Schematic drawing showing the proposed mechanism of membrane damage caused by 
aggregation of aS on membrane. (a) Monomeric aS adsorbed to the membrane. (b) Aggregation 
of aS monomers initiates membrane thinning and lipid extraction around the growing aggregates. 
(c) A 24 h period of incubation results in the presence of mature aS fibrils. Subsequently, 
membrane integrity is lost (from Reynolds et al., 2011). 
 
To analyze the effect of membranes on the aggregation properties of aS/DHA 
oligomers, aS and aS oligomers were incubated in the absence and in the presence of 
vesicles (molar ratio protein/lipid of 1:20 and 1:50). The aggregation was conducted in 
the presence of DOPG SUV, since oligomers preferentially interact with negatively 
charged membranes and DHA (molar ratio protein/fatty acid 1:50), as control. The effect 
of the lipids on protein aggregation was monitored by ThT fluorescence assay (Fig. 4.4). 
The aggregation process of aS results sped up in the presence of DOPG SUV (1:20) (Fig. 
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4.4 A, empty circles), while in the presence of DOPG SUV (1:50) is inhibited (Fig. 4.4 A, 
empty triangles). TEM analysis shows that in the mixture corresponding to aS incubation 
for 9 days in the presence of SUV DOPG (1:20) there are aS amyloid-like fibrils associated 
to the surface of SUV (Fig. 4.4 A, inset). The size and morphology of these fibrils are 
similar to those of aS fibrils formed in the absence of SUV. In both cases, aS forms 
straight, unbranched fibrils with a width of 10–15 nm. An additional feature is that the 
shape of vesicles in contact with fibrils is not changed. In the presence of DHA, as 
previously observed, there is not formation of aS aggregates that bind ThT dye (Fig. 4.4 A, 
inverted black triangles). In the case of aS/DHA oligomers, their incubation in the 
presence or the absence of SUV or DHA does not result in any increase of the 
fluorescence of ThT dye (Fig. 4.4 B), confirming their nature of off-pathway intermediates 
(De Franceschi et al., 2011). The aggregation process was further monitored by CD 
spectroscopy, confirming the presence of 
β-sheet structure only for ThT-positive 
fibrils (Fig. 4.5).  
 
 
Fig. 4.4. Aggregation studies monitored by 
ThT assay. aS (A) and aS/DHA oligomers (B) 
aggregation processes were conducted at 
37°C in the presence of lipids and followed by 
ThT binding assay. aS or aS oligomers were 
dissolved in 20 mM Tris, 150 mM NaCl pH 7.4 
at a 50 µM concentration in order to induce 
aggregation, in the absence (black circles) 
and in the presence of DOPG SUV, at molar 
ratio 1:20 (empty circles), 1:50 (empty 
triangles) and in the presence of DHA (molar 
ratio 1:50, inverted black triangles). The 
excitation wavelength was fixed at 440 nm, 
and the fluorescence emission was collected 
at 485 nm. To better visualize the 
aggregation trend of aS and aS in the 
presence of DOPG (molar ratio 1:20), the 
data points are fitted with a sigmoidal 
equation (SigmaPlot software). Inset: TEM 
images of protein material relative to aS and 
aS/DHA oligomers samples after 9 days of 
incubation in the presence of DOPG SUV 
(molar ratio 1:20). 
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Fig. 4.5. Aggregation studies monitored by far-UV CD. aS or aS oligomers were dissolved in 20 
mM Tris, 150 mM NaCl pH 7.4 at a 50 μM concentration in order to induce aggregation, in the 
absence (solid lines) and in the presence of DOPG SUV, at molar ratio 1:20 (dotted lines), 1:50 
(dashed-dotted lines) and in the presence of DHA (molar ratio 1:50, dashed lines). 
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4.4 aS/DHA oligomers induce permeabilization of synthetic membranes 
 Since aS/DHA oligomers are able to interact with negative charged phospholipids, 
the effect of this interaction on liposomes was investigated. A standard test to evaluate 
the lipid disruption properties of oligomers is the calcein-leakage test. Fluorescence 
emission of liposomes loaded with calcein is measured before and after oligomers 
addition. Because of the self-quenching effect due to the high concentration of calcein in 
the liposomes, the initial fluorescence emission depends only by traces of external dye. 
After addition of oligomers, if the dye leaks as a consequence of altered permeabilization 
of membranes, the fluorescence emission of calcein results enhanced because of the 
dilution in the external environment. aS/DHA oligomers effects were measured 30 min 
after their addition to different vesicles (Fig. 4.6 A) and we have tested vesicles composed 
by DOPG, 1POPC:1POPS and TBE. These compositions differ for the percentage of 
negative charged phospholipids: DOPG and 1POPC:1POPS, composed by 100% and 50% 
negative-charged phospholipids respectively, and TBE with less than 40% negative 
charged phospholipids, but the detailed composition is not available. We observed that 
only DOPG liposomes were permeabilized by oligomers, while the other two tested 
composition do not show significant difference between aS oligomers, monomers and 
fibrils. So phospholipids that do not induced structural transition on aS oligomers are not 
even destabilized by oligomers. Also in the case of 1POPC:1POPS, that induces a minor 
effect on the oligomer structure (Fig. 4.2), there is no release of calcein from vesicles. 
Thus, binding of oligomers to membranes not necessarily lead to membrane 
permeabilization. 
aS/DHA oligomers effect on DOPG liposomes were measured at different 
concentration of protein species, in comparison with aS monomers, fibrils and also DHA 
alone (Fig. 4.6 B). Oligomer effect is significantly different from those of other species, 
since they are able to permeabilize vesicles in a dose dependent manner, while aS and 
fibrils do not, even at that concentration (2.5 μM) that allows aS/DHA oligomers to cause 
the maximum effect. 
Since aS/DHA oligomers are able to destabilize membrane, it is important to 
characterize the mechanism of action. A critical parameter to understand the type of this 
destabilization is to verify the presence and eventually the dimension of a pore or 
membrane aperture. Indeed calcein used for the previous study is a really small molecule 
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(622.5 Da), that gives no information about the kind of destabilization: pore formation, 
transient destabilization due to oligomers insertion or even detergent effect on 
membranes would be not discernible with this test. To deeper characterize oligomers 
effect on membranes, first step was a supplemental leakage test performed with 
fluorescein-isothyocianate-dextran loaded vesicles. Dextran, that has an average 
molecular weight of 10,000 Da, could leak only if a pore/aperture of almost 4 nm occurs. 
aS/DHA oligomers or aS monomers were 
added to DOPG SUV and LUV (Fig. 4.5 C): 
both species show no difference in inducing 
leakage of Dextran, indicating a size 
selection of molecule that could leak in the 
presence of aS/DHA oligomers, and defining 
an aperture size between 1 and 4 nm 
(Mazzucca et al., 2010). 
 
 
 
 
 
 
 
 
 
Fig. 4.6. Calcein-leakage test on liposomes. (A) 
Fluorescence measurement of calcein-loaded 
LUV of different composition after 30 min 
incubation with monomeric aS, aS fibrils and 
aS/DHA oligomers at a final concentration of 1 
μM. (B) Fluorescence measurement of calcein-
loaded SUV after 30 min incubation with 
increasing concentration of DHA alone, 
monomeric aS, aS fibrils and aS/DHA oligomers. 
Final protein concentration was 0.1, 0.5, 1 and 
2.5 μM. (C) Fluorescence measurement of FITC-
dextran loaded SUV and LUV after 30 min 
incubation with aS/DHA oligomers and 
monomeric aS at a final concentration of 2.5 
μM.  
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4.5 aS/DHA oligomers permeabilize cellular membranes 
Previously, it was reported that aS/DHA oligomers are toxic to dopaminergic cells 
(De Franceschi et al., 2011). To correlate this assumption with leakage test, oligomers 
permeabilization activity was studied also on cells. Standard methods to analyze cells 
viability or permeabilization consist in a previous phase of exposure to potential toxic 
species, and then detection of effect with fluorescent dye. This approach would limit the 
detectable permeabilizing effect only to a stable pore formation that will still be active 
after the incubation phase. Other mechanism such as transient aperture due to oligomers 
insertion, detergent effect or flip-flop temporary enhancement would not be detectable 
adding dye after long time incubation. For this reason, a different method was developed: 
aS/DHA oligomers, propidium iodide (PI) and Hoechst dye were added simultaneously to 
cells. In this way, every single event that will cause membrane destabilization would allow 
PI to enter the cells. After 30 minutes of incubation, fluorescence signal of cells 
permeabilized to PI were merged with Hoechst-evidenced nuclei. aS/DHA oligomers 
effect was measured in comparison with aS monomers (Fig. 4.7). Oligomers are able to 
permeabilize cells, even if in a really minor extent than that exerted on liposomes. The 
lower effect is due to the complexity of cells membrane toward vesicles and to the minor 
content of negative-charged phospholipids that allows the higher effect on DOPG 
vesicles. Moreover, aS/DHA oligomers at the same concentration (0.5 µM) are able to 
induce the apoptotic death of 2.5% of cells after 24h (De Franceschi et al., 2011), a 
percentage consistent with this extent of permeabilization. 
 
 
Fig. 4.7. PI influx in dopaminergic cells.  SH-SY5Y cells 
were treated with aS/DHA oligomers and the number of 
PI-positive cells was calculated as a percentage of the 
total counterstained cells. Quantization (n = 3 cultures, 
with 5 fields analyzed per culture, 250-300 cells per 
field; error bars indicated the S.E.) indicated that 
aS/DHA oligomers increased the percentage of PI-
positive cells. Statistical significance was calculated by 
one-way ANOVA (p < 0.05) compared with mock control 
or monomeric aS.  
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4.6 Mechanism of permeabilization of aS/DHA oligomers of membranes 
Oligomers can induce permeabilization by several different mechanism (Lashuel 
and Butterfield, 2013). Indeed, different kind of oligomers could exert different effect on 
membrane, depending on their chemical properties. The most common mechanisms are 
pore formation, flip-flop enhancement, detergent effect and transient destabilization 
subsequent to oligomers insertion in the lipid bilayer or to lipid extraction caused by 
aggregation on membranes. Thus, it is necessary to investigate how aS/DHA oligomers 
destabilize membranes. Since several different kind of aS oligomers have been produced, 
there are standard method reported in literature, used to confirm or exclude a possible 
mechanism of action. In order to define the mechanism of aS/DHA oligomers, different 
analysis were performed for aS/DHA oligomers and will be discussed below.  
 
4.6.1 Detergent activity  
Detergent-like effect has been reported as mechanism of toxicity on membrane 
for mellitin, a lytic peptide of bee venom (Chaari et al., 2013), and for aggregated species 
of IAPP that form small micelle-like protein-lipid aggregates (Sciacca et al., 2012). To 
analyze this possibility for aS/DHA oligomers, TEM and DLS measurement of vesicles 
before and after addition of aS/DHA oligomers were conducted, to provide information 
about  the morphology and average size of vesicles after treatment with oligomers (Fig. 
4.8 and 4.9). Number relative size distributions of LUV and SUV change upon interaction 
with oligomers, resulting in a smaller average diameter size (Fig. 4.8 A and B). Comparison 
with Triton X-100 effect revealed that it was not a detergent effect, also in the 
concentration of oligomers able to induce 100% of calcein release. On the contrary, 
intensity relative size distributions revealed even an increment of average diameter size 
of vesicles (Fig. 4.8 C and D). DLS size distribution of vesicles was measured also after 
addition of monomeric aS for comparison. Moreover, also 1POPC:1POPS and TBE vesicles 
were used. Data are reported in Tables 4.2, 4.2, 4.4 and 4.5. Table 4.5 summarized data 
from Fig. 4.8, obtained using a final molar ratio aS/lipids of 1:20, providing information 
also for vesicles of different composition. Tables 4.2, 4.3 and 4.4 relate to experiment 
conducted with aS monomers and aS/DHA oligomers in a molar ratio aS/lipids 1:50. In 
every case the effect induced by Triton X-100 is remarkably different from that induced 
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by the protein species. For vesicles composed of TBE or 1POPC:1POPS, the effects 
induced by aS or aS/DHA oligomers are similar. 
Fig. 4.8. DLS measurement of liposomes. Number (A, B) and Intensity (C, D) relative DOPG LUV (A, 
C) and SUV (B, D) in the absence (solid line) and in the presence of aS/DHA oligomers (grey bars) 
and Triton X-100 (black bars). aS/DHA oligomers (dotted line) size distribution is reported for 
comparison. 
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 In addition to measurement of size distribution of vesicles, also morphology 
changes were studied, observing sample of vesicles in the absence and in the presence of 
aS/DHA oligomers by TEM. The images do not show significant difference between 
liposomes morphology with or without aS/DHA oligomers (Fig. 4.9), allowing to exclude a 
detergent effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9. TEM of SUV (0.5 mM) in the absence (left column) and in the presence (right column) of 
aS/DHA oligomers. Vesicles with different composition were observed, from the top: DOPG, 
POPS-POPC, TBE. 
- oligomers                       + oligomers 
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Fig. 4.10. Schematic representation of PLM chambers. Cis 
and Trans 2-ml chambers are separated by a 25-μm-thick 
Teflon septum containing a 180-μm hole, where the lipid 
bilayer is formed. 
4.6.2 Pore formation 
 aS/DHA oligomers activity was tested also on planar lipid membrane (PLM). Lipid 
bilayer was formed by drying a lipid solution of 1DOPG:1DOPE in pentane. Two 2-ml 
chambers, separated by a 
1DOPG:1DOPE bilayer as 
represented in Fig. 4.10, were filled 
with 100 mM KCl, 5 mM HEPES pH 
7.00 buffer. After application of 
current, aS/DHA oligomers were 
added to the buffer and current 
alterations were measured on real time. Results show that oligomers induce alteration in 
the permeability of membrane bilayer to ions, but preferentially in a unstructured 
manner (Fig. 4.11). About 50% of the cases give weak activity (about 10 pA). Remaining 
experiments show in the same frequency a stronger (hundreds of pA) or absence of 
activity. In 25% of the experiments formation of a stable channel was observed, from few 
seconds to minutes. Relative conductance was not ohmic, as major conductance was 
recorded with application of negative tension. Rarely, other behaviours were observed, as 
flickering of single channel or opening of 
several consecutive channels. As a control, also 
monomeric aS and DHA alone were tested. The 
fatty acid addition does not induces any 
membrane perturbation, while aS causes 
formation of structured channel, as reported in 
literature (Tosatto et al., 2012). 
 
 
 
Fig. 4.11. PLM experiments. Electrophysiological 
activity of aS/DHA oligomers on 1DOPG:1DOPE 
lipid membranes. Buffer composition was KCl 100 
mM, Hepes 5 mM, pH 7.0. Protein concentration 
was 68 nM. Applied potential +80 mV (A) or +100 
mV (B). 
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Table 4.1. LUV and SUV stability on time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Average diameters obtained from two DLS measurements of freshly prepared 
vesicles solutions.  
b 
Average diameters obtained from two DLS measurements of vesicles solutions 
stored for one week at +4°C. 
c 
Difference between mean diameters of freshly prepared and stored vesicles. 
d
 Net charge of relative phospholipids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
LUV 
composition 
Diameter 
(nm)
a
 
Diameter1w 
(nm)
b
 
Δ diameter 
(nm
)c
 
DOPG 370.1 417.6 +47.5 
DOPG-POPE 372.3 367.7 -4.6 
POPC 135.5 150.5 +15.5 
POPS-POPC 289.8 303.3 +13.5 
POPE 578.7 1684.5 +1096.8 
TBE 381.5 376.3 -5.4 
SUV 
composition 
Diameter 
(nm)
a
 
Diameter1w 
(nm)
b
 
Δ diameter 
(nm)
c
 
DOPG 108.2 118.7 +10.7 
DOPG-POPE 112.9 156.9 +44 
POPC 108.1 99.4 -8.7 
POPS-POPC 99.6 102.1 +2.5 
POPE 526.2 506.6 -19.4 
TBE 170.4 162.2 -8.2 
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Table 4.2. Diameter size (nm) of DOPG LUV and SUV in the absence and in the presence 
of monomeric aS and aS/DHA oligomers in a molar ratio protein/phospholipids of 1:50 
and in the presence of Triton X-100 (0.1%) Measured were performed immediately after 
aS addition and after 30 minutes and 1 hour. Values are the mean average of two 
different measures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Relative number of particles, multiplied for their light scattering intensity 
b 
Relative number of particles, multiplied for their volume. 
c
 Relative number of particles of defined size. 
Composition Intensity
a
 Volume
b
 Number
c
 
LUV DOPG 355.3 ± 22.1 441.3 ± 55.6 195.9 ± 76.5 
oligomers 
94.72 
510.2 ± 77.6 
87.10 
567.6 ± 94.6 
77.29 
426.65 ± 50.4 
oligomers, 30 
min 
435.2 ± 107.8 450.4 ± 116.1 416.1 ± 97.2 
oligomers, 1 h 397.4 ± 36.3 413.9 ± 38.2 375.8 ± 34.1 
aS 
81.82 
357.2 ± 12.9 
75.14 
431.7 ± 31.2 
97.33 ± 43.09 
306.6 
aS, 30 min 336.3 ± 10.2 369.25 ± 6.0 294.9 ± 16.3 
aS, 1h 339.9 ± 37.5 448.2 ± 81.8 88.2 ± 72.5 
Triton X-100 
11.4 ± 1 
68.0 ± 7.9 
9.1 ± 0.5 7.6 ± 0.3 
SUV DOPG 118.7 ± 8.6 96.2 ± 1.5 69.1 ± 12.4 
oligomers 218.6 ± 21.5 
58.6 ± 0.6 
295.1 ± 51.4 
45.04 ± 2.3 
oligomers, 30 
min 
33.7 
204.0 ± 12.6 
36.3 ± 5.7 
268.5 ± 21.8 
29.26 ± 2.3 
oligomers, 1h 
31.8 
205.3 ± 11.0 
27.8 
218.2 ± 15.9 
24.6 
126.3 ± 15.7 
+aS 101.9 ± 1.7 65.1 ± 1.3 41.7 ± 1.7 
aS, 30 min 95.5 ± 1.2 
17.9 
67.5 ± 3.1 
17.4 
47.4 ± 2.6 
aS, 1h 77.9 ± 1.6 59.5 ± 3.3 47.2 ± 4.7 
Triton X-100 
16.0 ± 0.1 
272.3 ± 85.1 
11.2 ± 0.01 8.9 ± 0.05 
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Table 4.3. Diameter size (nm) of 1POPS:1POPC LUV and SUV in the absence and in the 
presence of monomeric aS and aS/DHA oligomers in a molar ratio protein/phospholipids 
of 1:50 and in the presence of Triton X-100 (0.1%). Measured were performed 
immediately after aS addition and after 30 minutes and 1 hour. Values are the mean 
average of two different measures. 
 
Composition Intensity
a
 Volume
b
 Number
c
 
LUV POPS-POPC 352.6 ±3.7 373.5 ±3.2 326.4 ±3.1 
oligomers 
56.6 ±7.7 
398.4 ±21.7 
51.05 ±5.8 
460.9 ±34.8 
45.8 ±3.9 
314.5 ±1.5 
oligomers, 30 
min 
308.7 ±10.2 322.7 ±10.0 293.2 ±9.6 
oligomers, 1h 376.0 ±7.3 419.3 ±7.2 319.25 ±7.4 
aS 329.8 ±31.4 360.8 ±38.9 290.15 ±19.9 
aS, 30 min 304.4 ±5.2 312.8 ±5.3 296.5 ± 4.7 
aS, 1h 
86.6 ±12.4 
428.7 ±5.9 
80.40 ±13.6 
481.25 ±9.7 
72.26 ±12.6 
355.1 ±10.0 
Triton X-100 
11.7 ±0.8 
201.5 ±43.5 
9.8 ±1.1 8.5 ±1.2 
SUV POPS-POPC 
33.9 
163.5 ±5.4 
31.6 
120.3 ±43.2 
40.8 ±16.6 
oligomers 131.3 ±6.5 
33.0 
94.2 ±16.0 
32.7 ±4.3 
oligomers, 30 
min 
116.6 ±6.0 86.1 ±5.8 56.0 ± 1.9 
oligomers, 1h 118.4 ±2.2 96.2 ±2.8 68.7 ±6.8 
aS 156.1 ±6.9 138.4 ±8.4 78.07 ±0.3 
aS, 30 min 110.4 ±8.7 75.7 ±4.9 49.19 ±0.5 
aS, 1h 94.2 ±1.6 73.2 ±2.4 55.91 ±4.5 
Triton X-100 9.1 ±1.40 8.0 ±0.9 7.22 ±0.6 
 
a ,b, c 
see reference table 4.2. 
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Table 4.4. Diameter size (nm) of TBE LUV and SUV in the absence and in the presence of 
monomeric aS and aS/DHA oligomers in a molar ratio protein/phospholipids of 1:50 and 
in the presence of Triton X-100 (0.1%) Measured were performed immediately after aS 
addition and after 30 minutes and 1 hour. Values are the mean average of two different 
measures. 
 
Composition Intensity
a
 Volume
b
 Number
c
 
LUV TBE 418.8 ±34.1 432.8 ±35.8 401.9 ±33.4 
oligomers 423.3 ±44.5 506.2 ±81.3 314.8 ±0.5 
oligomers, 30 
min 
77.2 
456.2 ±1.62 
70.8 
549.8 ±9.1 
63.4 
326.9 ±2.1 
oligomers, 1h 397.3 ±14.1 438.1 ±15.3 343.5 ±11.6 
aS 444.7 ±10.5 478 ±17.2 398.7 ±0.6 
aS, 30 min 410.6 ±3.1 454.95  12.1 351.75 ±8.1 
aS, 1h 426.25 ±34.0 439.2 ± 37.3 411.1 ±30.7 
Triton X-100 
5.0 
224.7 ±7.4 
4.8 
239.2 
4.7 
220 
SUV TBE 220.4  16.6 
74.9 
262.5 ±58.2 
114.9 ±75.4 
oligomers 
49.9 
    209.1 ±16.6 
52.4 ±9.8 
243.4 ±52.7 
45.1 ±5.3 
oligomers, 30 
min 
193.8 ± 14.9 
92.3 ± 27.6 
299.4 ±0.8 
70.2 ±22.4 
oligomers, 1h 
32.5 
151.7 ±3.2 
29.7 
134.05 ±0.9 
27.6 
83.5 ±7.4 
aS 213.3 ±21.1 
88.9 
286.3 ±110.0 
103.6 ±55.5 
aS, 30 min 
55.0 
196.9 ±9.7 
50.7 ±3.1 
206.3 ±13.1 
50.5 ±2.7 
aS, 1h 
36.8 
197.3 ±7.3 
42.1 ±12.6 
203.4 ±7.3 
43.0 ±17.8 
104.6 
Triton X-100 
6.8 ±0.5 
92.2 ±10.7 
6.0 5.8 ±0.3 
 
a ,b, c 
see reference table 4.2. 
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Table 4.5. Diameter size (nm) of different composition LUV and SUV in the absence and in 
the presence of monomeric aS and aS/DHA oligomers in a molar ratio 
protein/phospholipids of 1:20 and in the presence of Triton X-100 (0.1%). Measurements 
were performed after 30 minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a ,b, c 
see reference Table 4.2. 
 
 
 
 
 
 
Composition Intensity
a
 Volume
b
 Number
c
 
LUV DOPG 301.1 ±16.6 326.5 ±21.2 269.0 ±9.8 
oligomers 42.9 ±1.0 40.9 ±1.3 38.9 ±1.4 
oligomers, 30 min 109.65 ±36.7 98.355 ±33.7 89.61 ±35.3 
Triton X-100 10.5 ±0.6 9.1 ±0.4 8.13 ±0.3 
SUV DOPG 170.5 ±3.1 51.0 ±0.5 82.9 ±7.9 
oligomers 203.5 ±6.6 214.9 ± 10.2 160.2 ± 4.4 
oligomers, 30 min 27.2 ±11.4 24.95 ±8.6 22.06 ±7.7 
Triton X-100 8.9 ±0.3 8.1 ±0.1 7.47 ±0.1 
LUV POPS-POPC 92.9 86.2 ±0.8 78.21 ±7.8 
oligomers 68.2 ±19.4 58.9 ±16.2 50.7 ±12.9 
oligomers, 30 min 43.2 ±5.3 41.3 ±4.8 39.3 ±4.2 
Triton X-100 9.0 ±0.3 8.29 ±0.03 7.6 ±0.2 
SUV POPS-POPC 95.7 ±5.3 69.08 ±0.02 50.1 ±2.9 
oligomers 138.6 ±4.0 107.5 ±16.9 44.6 ±42.5 
oligomers, 30 min 144.0 ±10.5 63.9 ±6.2 31.7 ±1.1 
Triton X-100 11.4 ±1.0 8.8 ±0.4 7.3 ±0.1 
LUV TBE 356.3 ±4.9 375.25 ±4.0 331.6 ± 5.8 
oligomers 345.5 ±41.3 366.85 ±47.4 318.4 ±31.5 
oligomers, 30 min 348.9 ±43.1 418.8 ±42.9 238.8 ±63.1 
Triton X-100 8.5 ±0.4 8.1 ±0.3 7.6 ±0.2 
SUV TBE 219.8 ±3.4 84.95 ±3.9 55.7 ±8.6 
oligomers 137 ±2.1 104.3 ±5.1 43.9 ±23.9 
oligomers, 30 min 168.8 ± 22.6 104.5 ±31.5 60.1 ±7.9 
Triton X-100 9.4 ±1.1 8.1 ±0.4 7.2 ±0.01 
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5. CHEMICAL MODIFICATIONS ON aS/DHA OLIGOMERS 
5.1 DHA induces oxidative modifications on aS 
In aS aggregates formed in the presence of DHA several oxidative modifications 
were found, in terms of oxidation of Met residues, covalent addition of allylic radical 
(+326 Da) and hydroperoxide radical (+358 Da) of DHA (De Franceschi et al., 2011) and 
the presence of carbonyl groups that should result from the reaction of Lys, Pro or Thr 
with reactive oxygen species (ROS) or from the reaction of Lys and His with lipid 
peroxidation products (Thakur and Nehru, 2013). An important goal would be to obtain a 
complete chemical characterization of the oxidative modifications in aS aggregates by 
both the identification of modified residue(s) and the evaluation of the extent and the 
randomness of these several modifications. This study would be of utmost importance to 
understand the role of lipid peroxidation in oligomers formation in synucleinopathies. 
 The first type of modification is due to the presence of four Met residues, in 
position 1, 5, 116 and 127 in the aS sequence. Met residues are easily oxidized to 
methionine sulfoxide by ROS, but generally these residues are particularly susceptible to 
undergo oxidation even under acid conditions in the presence of oxygen. Mass 
spectrometry analysis shows aS containing from 1 (+16 Da), 2 (+32 Da), 3 (+48 Da) to 4 
(+64 Da) oxidations. Both monomer and oligomer contain this pattern of Met oxidation 
and the corresponding RP-HPLC peaks are almost resolved. This type of modification is 
not easy to control, so it is difficult to say whether it has a role in oligomerization or the 
activity of the oligomers.  
 The presence of other chemical modifications was investigated. To this aim the 
derivatization of modified aS with dinitrophenylhidrazine (DNPH) coupled with MS 
analysis was tried. DNPH reacts with carbonyls groups that form in the lateral side chain 
of specific amino acidic residues (lysine, proline, arginine, and threonine) in oxidative 
conditions as represented in Fig. 5.1 (Linares et al., 2011).  
 
 
Fig. 5.1. Schematic representation of reaction of DNPH on carbonyls of lateral chain of 
aminoacidic residues. 
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The idea is to distinguish carbonyl contributions derived from reactions of Lys, Pro, Thr 
with ROS (Δmass from 0/-1 to +180) and from addition of allylic or hydroperoxide radicals 
of DHA. To this aim aS/DHA mixture corresponding to 24-hr of incubation was purified by 
RP-HPLC and the fraction relative to oligomers (RT of 29.5 min, Fig. 1.1) was collected and 
dried. This species was incubated in the presence of DNPH, to allow the reaction with 
carbonyls. Exceeding DNPH was washed with ethanol-ethylacetate extraction and UV 
absorbance was measured. The same reaction was conducted on monomeric form of aS. 
In Fig. 5.2 the UV-vis spectra of aS and aS/DHA oligomers reacted with DNPH were shown 
in comparison with spectra of the same species not reacted.  All species absorbe at 280 
nm, but only oligomers show a specific UV signal at wavelength 366 nm. This wavelength 
corresponds to the maximum DNPH absorbance, indicating the presence of an increased 
amount of carbonyl in oligomers. DNPH labelled-proteins were analyzed by RP-HPLC, 
monitoring the chromatogram at 226 nm and 366 nm. It was possible to detect the 
presence of protein and the protein reacted with the fluorescent dye. The chromatogram 
relative to the analysis of aS does not show any peaks at 366 nm (Fig. 5.3 B), while for 
aS/DHA oligomers a peak co-eluting with oligomers at 29.5 min is detectable (Fig. 5.3 D). 
This result shows that carbonyls are present in the oligomeric form of aggregated aS, but 
non in the monomeric protein. The peak at 366 nm is visible just upon 1 hr incubation 
(data not shown). This provides an important conclusion: the carbonylation is an early 
event, being within 1 hr of incubation of aS with DHA. We can speculate that the 
presence of DHA enhances the oxidative stress on aS as a consequence of its  suggested 
physiological function, as inhibitor of lipid oxidation (Zhu et al., 2006).  
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Fig. 5.2. UV-Vis spectra. (A) aS and (B) aS/DHA oligomers spectra of protein before (black lines) 
and after (red lines) reactions with DNPH. Spectra were recorded in PBS pH 7.4. 
 
 
Fig. 5.3. RP-HPLC analyses. aS in the absence (A,B) and in the presence (C,D) of DHA was analysed 
by RP-HPLC before (A,C) and after (B,D) reaction with DNPH. Samples were eluted with a gradient 
of acetonitrile and 0.085% TFA and elution was followed at 226 nm (black line) and 366 nm (red 
line) to detect protein reacted with DNPH. 
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We made a tentative to identify the amino acid residue(s) modified by 
carbonylation. We used a standard approach consisting in subjecting the protein samples 
to proteolysis by trypsin and derivatizing the peptides with DNPH (Fig. 5.4). Unfortunately 
by this procedure only a fragment containing the Δ mass of 180 Da was found and it 
corresponds to the sequence 24-32. This peptide contains a Lys residue in position 32 and 
this could be a possible target of carbonylation. However the presence of a single 
modification does not justify the signals obtained in UV and RP-HPLC analyses. It could be 
happen that some peptides can be lost in the extraction step of DNPH being too small and 
hydrophobic. Moreover the oligomeric species is quite resistant to proteolysis and the 
yield in peptide is very low. Finally it is reasonable that residues in the protein are 
randomly modified and so it is difficult to detect them. 
 
 
Fig. 5.4. RP-HPLC analyses of proteolysis. aS/DHA oligomers proteolyzed with Tripsin and 
derivatized with DNPH was analyzed by RP-HPLC. Samples were eluted with a gradient of 
acetonitrile and 0.085% TFA and elution was followed at 226 nm (black line) and 366 nm (red line) 
to detect fragments containing DNPH. 
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5.2 Detection of DHA covalent adduct on aS 
Mass spectrometry analysis has revealed the presence of a covalent adduct on aS 
oligomers formed in the presence of DHA (De Franceschi et al., 2011). A series of signals 
with a mass increase of 326 and 358 Da was observed. These mass differences are 
consistent with the covalent modification of the protein for the addition of allylic radical 
of DHA (326 Da) and hydroperoxide radical (358 Da), the earlier products of DHA 
autoxidation. In order to identify the site(s) of modification on aS, a proteolysis followed 
by mass spectrometry analysis was performed. aS/DHA oligomers were purified by RP-
HPLC (cfr. Fig. 1.1 B) after 3 hours of aS incubation in the presence of DHA (P/DHA 1:50). 
HPLC fractions at 29.5 min of retention time containing oligomers were collected then 
digested with trypsin for 3 hr, using an enzyme to substrate ratio of 1:100. Proteolytic 
fragments were analyzed in RP-HPLC (Fig. 5.5). Mass spectrometry identification were 
performed for all eluted peaks, to find DHA-adduct containing fragments (Table 5.1). In 
the chromatogram several peaks are detectable. Found fragments span all aS sequence. 
Met-containing peptides are present also in oxidized form (+16 Da) as previously 
observed. Fragments corresponding to sequence 1-80, 1-60, 35-80, 46-80 and 46-58 were 
found with a mass increase of 326 Da (Fig. 5.5). The residue that reasonably is modified is 
His in position 50. Another possible site of modification would be Lys58, but we can 
exclude it since if Lys58 were modified, it wouldn’t be recognized by trypsin. The peptides 
containing the Δ mass of 326 Da are 1-60 (6475.2 Da), 35-80 (4923.2 Da), 46-80 (3760.9 
Da) and 46-58 (1621.5 Da). There are two aspects of particular interest to evidence in this 
analysis. One is the degree of modification. In fact, the modified peptide constitutes 
about 2-3% of the unmodified one, making very challenging its identification. Moreover 
ms-ms analysis on double-charged ions relative to modified peptides causes the removal 
of the covalent adduct, also using very low collision energy. Ms-ms analysis of double 
charged ion at m/z 811 relative to peptide 46-58 +326 Da forms again the peptide 46-58 
without the modification, while the analysis of the double charged ion at m/z 648 give 
rise to a ms-ms spectrum of peptide 46-58 (Fig. 5.6). The same behaviour was observed 
for other DHA-modified peptides. In the light of these considerations and overlapping the 
sequences (Fig. 5.7) of the indentified peptides we concluded that the modification is 
located on His50. 
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Fig. 5.5. RP-HPLC analysis. A. Chromatogram of the proteolysis mixture of aS/DHA oligomers with 
trypsin before (black lines) and after (red lines) reaction. Proteolysis was conduced in PBS pH 7.4 
buffer with a E:S ratio 1:100 (by weight). B. Detail of the chromatogram from 10 to 30 min to 
better see the identified fractions Numbers close the peak indicate the fragments identified by 
mass spectrometry. Peaks relative to species containing DHA adduct are labelled in red. 
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Fig. 5.6. MS-MS of peptide 46-58. MS-MS analysis of peptide 46-58 of aS, eluted from RP-HPLC 
results in the whole fragmentation of the fragment (top). MS-MS analysis of peptide 46-58 
modified by DHA (bottom) was performed in order to detct the precise residue modified by DHA. 
Spectrum reveals that the adduct dissociate and formation of unmodified 46-58 fragment occurs.  
 
 
1            35   46                            58 60                    80 
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTK 
                               EGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQK 
                                                                               EGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQK 
                                                 EGVVHGVATVAEK 
Fig. 5.7. Sequences of peptides characterized by a Δ mass of 326 Da. The hypothesised His 50 as 
site of modification is highlighted. 
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5.3 Role of His50 in oligomerization 
Histidine and lysine are nucleophilic amino acids and therefore vulnerable to 
modification by lipid peroxidation derived electrophiles, such as 2-alkenals, 4-hydroxy-2-
alkenals, and ketoaldehydes, derived from lipid peroxidation. Histidine shows also a 
specific reactivity toward 2-alkenals and 4-hydroxy-2-alkenals, whereas lysine is a 
ubiquitous target of aldehydes, generating various types of adducts (Uchida, 2003). 
Covalent binding of reactive aldehydes to histidine and lysine is associated with the 
appearance of carbonyls and antigenecity of proteins. In our case His50 is resulted the 
most frequent site of formation of an adduct with DHA. It is of great interest after that to 
investigate the importance of the position of the DHA adduct for aS oligomerization. To 
this aim we have studied a mutant of aS containing in position 50 a glutamine residue 
(H50Q). Moreover this species is naturally occurring mutant, found in familiar form of PD 
(Proukakis et al., 2013). The protein was obtained by recombinant technique and it was 
characterized by mass spectrometry, after purification by RP-HPLC (Fig 5.8). 
 
Fig. 5.8. (A) RP-HPLC of H50Q after purification by ion exchange and (B, C) MS spectra of the 
major fraction. Further details are described in Methods section. 
 
To investigate the influence of H50Q variant on the interaction with DHA, far-UV 
CD measurement were performed (Fig. 5.9), in the presence of increasing amount of 
DHA. In comparison with aS, H50Q shows a similar extent of acquisition of a-helical 
A 
B 
C 
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structure. To further investigate the possible occuring differences, aS and H50Q were 
proteolyzed with pK in the presence of saturating amount of the FA. After 5 min of 
reaction, the first fragments were detectable. RP-HPLC and mass spectrometry analysis 
(Fig. 5.10) (Table 5.2) of obtained species reveal that the same cleavage sites were 
present in the two protein, suggesting a really similar interaction mode of aS and H50Q.  
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Fig. 5.9. CD measurements. Far-UV CD spectra of aS and H50Q in the absence and in the presence 
of DHA at different molar ratio. Spectra were recorded in PBS pH 7.4, at a protein concentration 
of 5 µM, and in the absence or in the presence of DHA in a final molar ratio protein:lipid of 1:25, 
1:50, 1:60, 1:70 and 1:80. 
 
 
Fig. 5.10. RP-HPLC chromatograms of the proteolytic mixture of aS and H50Q with pK in the 
presence of DHA with a molar ration protein:lipid 1:70, after 5 min of incubation. Proteolysis were 
conducted with proteinase K in a E:S ratio of 1:1000. The fractions are collected and analyzed by 
mass spectrometry to identify the peaks. 
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H50Q was incubated with DHA under the same conditions used to obtain aS/DHA 
oligomers and its aggregation process was monitored by GF (Fig. 5.11) and RP-HPLC (Fig. 
5.12). The aggregation process of H50Q in the presence of DHA shows a comparable 
extent of oligomerization. The retention volume of oligomers is the same for the two 
species, meaning that they have the same hydrodynamic volume.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.11. Gel filtration analysis. Chromatograms of the mixtures of H50Q (left) and aS (right) 
with DHA in a molar ratio 1:50 during aggregation. The number on the left refers to the time of 
incubation. 
 
The mixture of H50Q in the presence of DHA was also analyzed by RP-HPLC (Fig. 5.10 and 
Table 5.3) and the behaviour of oligomers compared to aS. The patterns are quite similar 
and just after 3 hours H50Q oligomers form with similar RT of 29.5 min, indicative of very 
hydrophobic species.  Moreover after 48 hours most of the monomeric protein is 
converted in oligomer.  
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Fig. 5.12. RP-HPLC analysis. Chromatograms of H50Q (A) or aS WT (B) in the presence of DHA in a 
molar ratio 1:50 during aggregation. The colour indicate the time of incubation: 0 (red), 3- 
(orange), 24- (yellow) and 48- (green) hours. 
 
The most important feature of H50Q oligomers to compare to aS ones is the 
presence, and eventually the position, of DHA adducts. For this reason, H50Q/DHA 
oligomers were purified by RP-HPLC and analyzed by mass spectrometry (Fig. 5.13). 
Analysis showed that DHA still binds to the protein and moreover more than one DHA 
adduct was present on single protein molecules. As done for aS, proteolysis experiments 
were conducted in order to identify possible favourite sites of modification.  
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Fig. 5.13. Mass spectrometry analysis. Mass spectrum of H50Q/DHA oligomers purified by RP-
HPLC after 3 hours incubation. 
 
Proteolysis was conducted using trypsin, in a E:S ratio 1:100 by weight. Proteolytic 
solutions were analyzed in RP-HPLC after 30 min (Fig. 5.14). Mass spectrometry 
identification were performed for all eluted peaks, to find DHA-adduct containing 
fragments (Table 5.4). We identify the same peptides as aS, and those containing Q50 
show the correct mass decrease of 9 Da due to substitution of His with Gln (table 5.4). 
Since His50 had been removed, different modified fragments were sought. We were not 
able to find modified peptides. This means that probably a favoured site for modification 
is absent and this leads to spread DHA between the several lysine present on the protein. 
As a consequence, a single  specific lysine is rarely modified, thus it is not detectable with 
this kind of analysis. 
 To further characterize H50Q/DHA oligomers, their ability to affect synthetic 
membranes was tested. As already done for aS (§ 3.6), calcein test was used. DOPG LUV 
loaded with calcein were treated with 1 µM solution of H50Q oligomers (Fig. 5.15). 
Oligomers show to be able to destabilize vesicles at the same extent of aS oligomers. 
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Fig. 5.14. RP-HPLC analysis. Chromatogram of H50Q/DHA oligomers after 30 minutes of 
proteolysis with trypsin. Proteolysis was conducted in PBS pH 7.4 buffer at 37°C with a E:S ratio 
1:100 (by weight). 
 
 
Fig. 5.15. Calcein-leakage test for H50Q/DHA oligomers. Fluorescence measurement of calcein-
loaded DOPG LUV after 30 min incubation with oligomers of H50Q or aS formed in the presence 
of DHA 1:50.  
 
This result allows us to deduce that the specific position of the modification in aS 
sequence by DHA is not essential for oligomers formation and activity. Considering that 
we never obtained unmodified oligomers, we can not exclude a role of this adduct 
considering that it not possible to obtain oligomers without modification.  
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Table 5.1. Chemical characterization of fragments corresponding to mayor peaks of the 
chromatogram relative to the fragmentation of aS/DHA oligomers with trypsin after 3 hr 
of incubation. 
 
Molecular Mass (Da) RT
a
 
(min) Found
b
 Calculated
c
 
Peptide 
species
d
 
11.2 830.43 829.91 24-32 
13.2 
1524.16±0.01 
1294.99±0.05 
1294.8±0.1 
1754.37±0.02 
1523.74 
1294.68 
1621.46 
1754.02 
44-58 
46-58 
46-58+326 
44-60 
13.8 
1406.9±0.1 
1179.93±0.05 
1409.65 
1180.37 
33-45 
35-45 
14.1 950.7±0.01 951.09 35-43 
14.7 2157.17±0.04 2157.45 59-80 
14.9 1607.16±0.01 1606.84 81-97 
15.1 2148.14±0.11 2148.44 81-102 
15.4 1928.41±0.05 1928.17 61-80 
15.6 
1478.05±0.04 
4923.6±0.13 
1478.66 
4923.25 
81-96 
35-80 +326 
17.9 
4847.06±0.38 
6472.55±0.75 
4846.03 
6475.19 
98-140+1ox 
1-60+326 
19.3 4958.66±0.01 4958.20 97-140 
19.9 
4288.74±0.34 
4830.5±0.1 
4288.43 
4830.03 
103-140 
98-140 
21.2 
6434.93±0.04 
6451.22±0.46 
6434.86 
6450.86 
81-140+1ox 
81-140+2ox 
23.4 6418.65±0.13 6418.86 81-140 
28.2 
3434.52±0.05 
3760.8±0.05 
3664.32±0.01 
3434.89 
3760.89 
3664.18 
46-80 
46-80+326 
44-80 
 
a 
Peptides or proteins were purified by RP-HPLC and listed in order of 
retention times (RT). 
b 
Experimental molecular masses determined by ESI-MS. 
c 
Molecular masses calculated from the amino acid sequence of aS. 
d
 Species containing Met residues are present also as oxidized form. 
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Table 5.2. Chemical characterization of peptide material corresponding to mayor peaks of 
the chromatograms relative to the fragmentation of aS and H50Q bound to DHA with 
proteinase K after 5 min of incubation. 
 
 
 
 
 
 
 
 
 
 
 
a ,b, c, d 
see reference Table 5.1 
Table 5.3. Chemical characterization of protein material corresponding to mayor peaks of 
the chromatogram relative to the aggregation of aS and H50Q in the presence of DHA. 
Molecular Mass (Da) RT
a
 
(min) Found
b
 Theoretical
c
 
Species
d
 
14508.13 ±0.05 14508.1 aS 3ox 19.5 
14491.8 ±0.5 14492.1 aS 2ox 
21 14459.92 ±0.01 14460.1 aS 
14817.1 ±0.7 14818.1 aS 2ox 326 
31.5 
14831.3 ±0.9 14834.1 aS 3ox 326 
14522.4±1.1 14522.2 H50Q 2ox  
17.8 
14554.6 ±0.2 14554.2 H50Q 4ox 
18.5 14506.3 ±0.6 14506.2 H50Q  1ox 
18.9 14490.5 ±0.3 14490.2 H50Q 
31.5 14824.0±1.13 14825.2 H50Q 3ox 326 
e
32 326.28 ±0.08 326.24 DHA (-2H) 
33 328.29 ±0.16 328.24 DHA 
a ,b, c, d
 see reference Table 5.1 
e
 Peaks eluted at 32 and 33 min correspond to DHA for all analyzed protein. 
 
 
Molecular Mass (Da) RT
a
 
(min) Found
b
 Theoretical
c
 
Species
d
 
18.4 
 
5633.10±0.11 
5390.01±0.11 
5633.0 
5389.7 
90-140 
93-140 
29.7 7174.57±0.06 7173.7 73-140 
30.1 8846.32±0.74 8845.2 1-89 
30.4 9088.98±0.59 9088.5 1-92 
30.8 14477.41±0.4 14476 1-140+1ox 
31.5 14460.05±0.27 14460 1-140 
18.4 
 
5633.14±0.12 
5389.77±0.48 
5633.0 
5389.7 
90-140 
93-140 
29.6 8837.24±0.36 8836.2 1-89 
29.9 9079.42±0.42 9079.45 1-92 
30.4 14452.58±0.40 14451.2 1-140 
aS 
H50Q 
H50Q 
aS 
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Table 5.4. Chemical characterization of peptide material corresponding to mayor peaks of 
the chromatograms relative to the fragmentation of H50Q/DHA oligomers with trypsin 
after 30 min of incubation.  
 
Molecular Mass (Da) RT
a
 
(min) Found
b
 Calculated
c
 
Species
d
 
11.3 
829.42 
1058.59 
829.43 
1058.57 
24-32 
22-32/24-34 
12.5 
1071.6 
872.47 
1300.78 
1071.59 
872.46 
1300.74 
11-21 
13-21 
11-23 
12.7 1101.63 1101.60 13-23 
13.2 801.37  801.35 1-6 2ox 
13.7 
1179.74 
1285.66 
1179.65 
1285.69 
35-45/33-43 
46-58 
13.9 1744.10 1743.97 44-60 
14.1 
950.56 
785.39 
950.51 
769.35 
35-43 
1-6 1ox 
14.3 
1514.97  
1170.68 
950.5 
1688.82 
1285.78 
1514.83 
1170.58 
950.51 
1685.97 
1285.69 
46-60 
1-10 1ox 
35-43 
7-23 
46-58 
14.7 1605.98 1605.87 81-97 
15.1 
1910.64±0.46 
2157.36 
1927.04 
2156.18 
61-80 
59-80 
15.5 
4862.2 
1477.3 
4862.03 
1478.7 
98-140 2ox 
81-96 
17.1 4972.99±1.57 4974.20 97-140 1ox 
18.9 4958.46±0.03 4958.20 97-140 
19.4 
4288.07±0.39 
4829.38±0.75 
4288.43 
4830.03 
103-140 
98-140 
22.8 6418.11±0.51 6418.86 81-140 
29.1 
3655.36±0.07 
4819.30±0.19 
5629.74 
3655.17 
4817.52 
5629.41 
44-80 
33-80 
24-80 
29.4 3425.1 3423.80 46-80 
a ,b, c, d 
see reference Table 5.1 
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6. aS FAMILIAR VARIANTS AND DHA 
 Genetic studies of the aS gene in familial cases of PD have demonstrated that 
overexpression of normal aS is associated with this disease. However also pathogenic 
missense mutations, A53T (Polymeropoulos et al., 1997), A30P (Kruger et al., 1998), and 
E46K (Zarranz et al., 2004) and multiplication (Chartier-Harlin et al., 2004; Farrer et al., 
2004; Fuchs et al., 2007; Singleton et al., 2003) of the aS gene have been identified in 
kindreds of autosomal dominantly inherited familial PD and DLB (Fig. 6.1). Recently other 
missense mutations have been found, such as H50Q (Proukakis et al., 2013) and G51D 
(Kiely et al, 2013). 
 
1             10               20    30     40      50        60 
MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK  
        P        K   Q   D  T 
            70              80               90              100   110     120 
EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP  
        130            140 
DNEAYEMPSE EGYQDYEPEA   
Fig. 6.1. Schematic representation of the localization of main aS mutations. 
 
It is not yet fully clear how these mutations affect the pathogenesis of PD. It is seems that 
E46K mutation produces aS peptides displaying an increased propensity to form relatively 
large oligomers, whereas the A30P mutation produces aS peptides displaying decelerated 
secondary structure transitions and a decreased propensity to form oligomers (Ono et al., 
2011). Another aspect concerns the ability of aS mutants to bind phospholipids and fatty 
acids. The mutant A30P is defective in binding to phospholipid vesicles, while the A53T 
substitution displays a normal membrane-binding activity, comparable to wild-type aS (Jo 
et al., 2002).  Bodner and coll. (2010) have reported the phospholipid binding properties 
of the variants, viewed by solution NMR. They show overall decreased lipid affinity for the 
A30P mutation, comparable affinity for A53T, and an increased level of binding of E46K, 
relative to wild-type aS.  
We investigated the ability of a group of aS mutants to bind DHA by circular dichroism 
and proteolysis experiments. Further we have evaluated the propensity of these protein 
species to oligomerize in the presence of DHA. This study could help to get more 
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information about the interaction between aS and fatty acids and the role of this 
interaction in the pathogenesis of PD.  
 
Fig. 6.2. Scheme depicting the increased vulnerability of aS to self-association when engaged in 
the SL1 binding mode vs SL1. SL1 and SL2 refer to two different bound state to phospholipids: SL1 
comprise a short bound α-helix followed by dynamic disordered residues ~25-140; SL2 engages 
the full N-terminal domain, up to residue ~100, in the α-helical conformation, while the 40 
residues of the C-terminal tail remain flexible in solution. All variants increase the relative 
population of SL1, for which a long unstructured stretch of N-terminal residues is exposed 
(reprinted from Bodner et al., 2010). 
 
6.1. Conformational analysis. 
 The secondary structure of A30P, A53T and E46K in the presence of DHA was 
analyzed by far UV circular dichroism (CD). All mutants are unfolded in solution while 
increasing the amount of DHA, the appearance of the two typical minima at 2008 and 222 
nm is observed, indicating the acquisition of α-helical secondary structure (Fig. 6.3). 
The overall behaviour of the proteins is similar and they show a similar susceptibility to 
acquire α-helix conformation upon addition of the fatty acid. The presence of an 
isodichroic point at 203 nm in the titration experiments  suggest a two state transition 
from random coil to α-helix. To further analyze the interaction the ellipticity was shown as 
a function of the molar ratio between the proteins and DHA. Especially the ellipticity at 
208 nm or the ratio between the ellipticity at 208 in the presence of DHA and at 208 nm 
in the absence of the fatty acid as a function of protein/DHA ratio was reported (Fig. 6.4). 
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Fig. 6.3. CD measurements. Far-UV CD spectra of aS, A53T, E46K, A30P in the absence and in the 
presence of DHA at different molar ratio. Spectra were recorded in PBS pH 7.4, at a protein 
concentration of 5 µM, and in the absence or in the presence of DHA in a final molar ratio 
protein:lipid of 1:25, 1:50, 1:60, 1:70 and 1:80 for all proteins. 
 
A30P shows a slight reduced ellipticity and requires more DHA to complete its 
conformational transition. Indeed, while aS, E46K and A53T CD signals at 208 and 222 nm 
do not increase further at a molar ratio of 1:50, A30P requires more that 350 µM of DHA 
(protein/DHA 1:70) to reach the saturation. So accordingly to previous results (Bodner et 
al., 2010), it seems that A30P does not have the same affinity for DHA as the other 
mutants and aS. 
 - 98 - 
 
Fig. 6.4. Ellipticity at 208 nm as a function of DHA/protein ratio. Black circles refer to aS, red 
circles to A30P, green circles to A53T and yellow circles to E46K. 
 
6.2 Proteolytic mapping of the complex protein/DHA 
To define the region(s) of interaction of aS variants with DHA, an approach based 
on proteolytic digestion and mass spectrometry was used as previously done for aS (De 
Franceschi et al., 2009). This strategy relies on the consideration that regions of the 
protein normally available to proteases exhibit limited accessibility when involved in 
interaction with lipids (Fontana et al., 2004; Polverino de Laureto et al., 2006). We used 
proteinase K (pK) (Ebeling et al., 1974), a particularly voracious protease, which displays 
broad substrate specificity to correlate the site of enzyme fission with enhanced 
backbone flexibility or local unfolding of the substrates. Moreover this protease retains 
proteolytic activity in the presence of DHA (De Franceschi et al., 2009). Proteolysis 
experiments were conducted in the absence and in the presence of DHA using a ratio 
with the protein of 1:70 to be sure that the equilibrium between the free and bound 
molecule were shifted towards the bound one. From previous studies, we know that aS 
displays the same pattern of proteolysis in the presence of DHA in ratio 50:1 -70:1 on the 
protein. 
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In the absence of DHA the protein variants are readily fragmented, as already 
observed for aS (De Franceschi et al., 2009), according to the fact that these proteins are 
unfolded in solution and prone to protease attack. A remarkable fact concerns the 
behaviour of A30P. Intact A30P is, indeed, found in the proteolytic mixture after 1 hour of 
incubation with the protease, and after 3 hours of incubation is completely cleaved by pK. 
At variance all other proteins are completely degraded by the protease just after few 
minutes of reaction. The chromatograms RP-HPLC of the proteolytic mixture of A30P and 
E46K with pK in the absence of DHA after 1 hour of incubation are reported in Fig. 6.5 to 
evidence this aspect. 
 
Fig. 6.5. RP-HPLC chromatograms of the proteolytic mixture of A30P and E46K with pK in the 
absence of DHA after 1 and 3-hr of incubation. The fractions are collected and analyzed by mass 
spectrometry to identify the peaks. 
 
The proteolysis of the variants with pK in the presence of DHA is stopped after 5 
min (Fig. 6.6) and 1 hour of incubation (Fig. 6.7), to see the initial and the late sites of 
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fragmentation. In all species the initial sites of proteolysis are located in the protein 
segment 89-92. Indeed, the intact protein is the main species after 5-min of incubation 
and only few peaks of low intensity are visible in the chromatogram. The fractions were 
analyzed by mass spectrometry (Table 6.1).  
 
Fig. 6.6. RP-HPLC chromatograms of the proteolytic mixture of aS, A30P, A53T and E46K with pK in 
the presence of DHA with a molar ration protein:lipid 1:70, after 5 min of incubation. Proteolysis 
were conducted with proteinase K in a E:S ratio of 1:1000. The fractions are collected and 
analyzed by mass spectrometry to identify the peaks.  
 
The main species found in the proteolytic mixture correspond to full length 
protein, and in very low amounts to fragments 1-89 and 1-92 and the complementary 
fragments 90-140 and 93-140, indicating that the proteins are initially cleaved at the 
peptide bonds Ala89-Ala90 and Thr92-Gly93. After 1-hr of proteolysis the predominant 
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product observed for aS is the peptide 1-72 (MM 7299.9 Da) (De Franceschi et al., 2009). 
The fragment 1-89 (MM 8839.7 Da) does not accumulate and it is further cleaved forming 
fragment 1-72. This species remains in the proteolysis mixture also after prolonged (3-hr) 
incubation with the protease (De Franceschi et al., 2009). Fragment 90-140 seems to be 
quite resistant to proteolysis and fragments 93-140, 95-140 and 126-140 are produced in 
minor extent. In the case of E46K after 1-hr of proteolysis the main species are fragments 
1-50 and 1-72 (Fig. 6.7 and Table 6.2), showing a remarkable difference with aS. For A30P 
an unexpected resistance to proteolysis is shown, considering that in the presence of DHA 
there is still intact protein in the mixture after even after 3-hr of reaction with pK. 
Unfortunately we don’t have data regarding the prolonged proteolysis of A53T.  
 
Fig. 6.7. RP-HPLC chromatograms of the proteolytic mixture of A30P and E46K with pK in the 
presence of DHA with a molar ration protein:lipid 1:70, after 1 and 3-hr min of incubation. The 
fractions are collected and analyzed by mass spectrometry to identify the peaks.  
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Fig. 6.8. Scheme of proteolysis. The main cleavage sites for aS, E46K, A30P and A53T with PK are 
reported. 
 
6.3 Aggregation of as variants in the presence of DHA. 
A general consensus is that these aS variants form insoluble fibrillar aggregates 
with antiparallel β-sheet structure upon incubation at physiological temperature and are 
able to accelerate fibril formation. However their precise effects at early stages of the aS 
aggregation process remain unknown. In respect to the tendency to oligomerize, it seems 
that E46K produces an oligomer distribution in which the highest observed oligomer 
order is bigger than that of aS, while A30P produces an oligomer distribution with a lower 
oligomer order than aS (Ono et al., 2011). We have studied the behaviour of the variants 
upon incubation in the presence of DHA. Aggregation process was followed by gel 
filtration (GF), TEM, circular dichroism (CD) and RP-HPLC. The results were compared to 
those obtained for wild type aS.  
The mixtures of proteins and DHA (molar ratio P/DHA 1:50) were analyzed by GF 
chromatography with the purpose of correlating the physical properties of the samples 
with their chemical composition. Aliquots corresponding to different times of incubation 
(from 0 to 48 hr) of the mixture composed of protein and DHA were loaded onto a 
Superdex 75 column. The GF profile shows a major species eluting at 24 min (Fig. 6.9) and 
a minor species (1%) with lower retention time (RT 20 min) for all variants. After 3 h of 
incubation, the fraction of the low RT species increases, and after 48 h this species is the 
main component of the mixture (Fig. 6.9). Comparing the four different proteins, it is 
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evident that a difference resides in the yield of oligomers. A53T has a behaviour quite 
similar to aS. Conversely the peak of oligomers in E46K is quite low and elutes split in 
three forms with different RT. In the case of A30P the yield in oligomers appears higher 
than the others. 
 
Fig. 6.9. Gel filtration analysis. GF chromatograms of the mixture of aS, A53T, E46K and A30P 
with DHA. Aliquots were taken from the mixtures at 3, 24 and 48-hr of incubation. The 
chromatogram relative to mixture just after preparation is also reported.  
 
 
The fractions relative to oligomers were collected and analyzed by TEM, shown in 
Fig. 6.10. TEM analysis showed that the chromatographic fraction corresponding to 
oligomers of A30P and A53T contains heterogeneous population of aggregates in which a 
part has a spherical morphology, with diameters ranging from 15 to 35 nm.  For E46K we 
were not able to obtain better images, so we don’t have definitive results. In the figure, 
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the TEM images of fibrils produced by the variants under the same experimental 
conditions in the absence of DHA are shown on the right. All mutants are able to form 
long and unbranched fibrils in the absence of the fatty acid.  
 
Fig. 6.10. TEM pictures. The aggregation of aS variants in the presence of DHA were analyzed by 
TEM. Pictures are relative to the oligomeric fractions of A30P, E46K and A53T eluted from GF. 
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The aggregation process was also followed by CD (Fig. 6.11) and no 
conformational change was observed, only a partial reduction of the intensity of the CD 
signals as observed for aS, although the spectrum shape does not change over time. 
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Fig. 6.11. CD measurements. Far-UV CD spectra of aS, A53T, E46K, A30P in the presence of DHA 
during aggregation. Spectra were recorded in PBS pH 7.4, at a protein concentration of 5 µM. The 
spectra relative to 0 (solid lines) and 48 (dashed lines) hr of incubation are reported. 
 
The mixtures of proteins and DHA were injected in RP-HPLC. The chromatogram 
corresponding to the starting condition (Fig. 6.12 and Table 6.3) shows two main peaks. 
The first peak is around 18 min and corresponds to the monomeric species, and the other 
peak is centred at 32 min and includes three peaks (RT of 30.5, 32, and 33 min). As 
incubation proceeds, the peak with a RT of 30.5 min corresponding to the oligomeric 
species increases. Of note again the RP-HPLC patterns of the three variants are similar to 
that obtained from aS (Fig. 6.12), but the intensity of the peak relative to the oligomers 
formed by A30P and E46K is lower than the other species. In the case of A30P a 
reasonable explanation is based on the possibility that the oligomers were less stable to 
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the conditions used for RP-HPLC analysis. Further analysis will be done in order to deepen 
these aspects. 
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Fig. 6.12. RP-HPLC analysis. Chromatograms of aS, A53T, E46K and A30P during aggregation in 
the presence of DHA, after 0 (dashed lines) and 48- (solid lines) hours. 
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Table 6.1. Chemical characterization of peptide material corresponding to mayor peaks of 
the chromatograms relative to the fragmentation of aS and its mutants in the presence of 
DHA with pK after 5 min of incubation. 
 
Molecular Mass (Da)  RT
a
 
(min) Found
b
 Theoretical
c
 
Species
d
 
18.4 
 
5633.10±0.11 
5390.01±0.11 
5633.0 
5389.7 
90-140 
93-140 
29.7 7174.57±0.06 7173.7 73-140 
30.1 8846.32±0.74 8845.2 1-89 
30.4 9088.98±0.59 9088.5 1-92 
30.8 14477.41±0.4 14476 1-140+1ox 
31.5 14460.05±0.27 14460 1-140 
18.4 
 
5633.59±0.20 
5390.16±0.11 
5633.0 
5389.7 
90-140 
93-140 
29.6 
8871.96±0.02 
8942.10±0.13 
8871.2 
8942.3 
1-89 
1-90 
29.9 
9115.96±0.26 
8816.91±0.57 
9114.5 
8815.6 
1-92 
57-140 
30.4 14486.34±0.20 14486.2 1-140 
18.7 
 
5632.83±0.10 
5389.76±0.05 
5633.0 
5389.7 
90-140 
93-140 
30.0 9115.56±0.16 9118.5 1-92 
30.4 8876.64±0.09 8875.2 1-89 
30.8 14490.76±0.77 14490.2 1-140 
31.6 14509.58±0.35 14506.2 1-140+1ox 
32.3 14490.76±0.77 14490.2 1-140 
18.5 5185.58±0.02 5185.1 95-140 
19.0 
5632.83±0.10 
5389.76±0.05 
5633.0 
5389.7 
90-140 
93-140 
27.8 7171.30±0.90 7172.7 73-140 
29.8 
8845.12±0.26 
9088.55±0.28 
8844.2 
9087.5 
1-89 
1-92 
30.2 14490.98±0.68 14491.2 1-140+2ox 
30.5 14475.95±0.33 14475.2 1-140+ox 
30.8 14459.75±1.27 14459.2 1-140 
 
a 
Peptides or proteins were purified by RP-HPLC and listed in order of 
retention times (RT). 
b 
Experimental molecular masses determined by ESI-MS. 
c 
Molecular masses calculated from the amino acid sequence of aS. 
d
 Species containing Met residues are present also as oxidized form. 
 
aS 
A30P 
A53T 
E46K 
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Table 6.2. Mass-spectrometry identification of peptide material corresponding to major 
peaks of the chromatograms in Fig. 30 relative to the fragmentation of A30P and E46K in 
the presence of DHA with pK after 1- and 3-hr of reaction. 
 
Molecular Mass (Da)  RT
a
 
(min) Found
b
 Theoretical
c
 
Species
d
 
27.8 7347.29±0.28 
7030.93±0.14 
7346.49 
7031.12 
1-72 ox 
1-69 
27.9 7331.25±0.10 7330.49 1-72 
29.4 8872.86±0.15 8871.23 1-89 
30 
14520.51±0.36 
14537.35±0.98 
14518.22 
14534.22 
1-140 
2ox 
1-140 
30.3 
14488.86±0.28 
14504.60±0.29 
14486.22 
14502.22 
-   
1-140 ox 
 
 
28.4 
5162.84±0.02 
7319.19±0.09 
5661.68±0.57 
5318.98±0.10 
5163.1 
7319.52 
5661.68 
5319.28 
1-50 
1-72 ox 
1-56 
1-52 
29.2 
7303.89±0.63 
8845.47±1.9 
9087.92±0.04 
7303.52 
8844.26 
9087.52 
1-72 
1-89 
1-92 
30.1 14460.360.04 14459.24 1-140 
 
a, b, c, d
 see reference Table 6.1. 
 
A30P 
E46K 
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Table 6.3. Chemical characterization of protein material corresponding to mayor peaks of 
the chromatogram relative to the aggregation of aS and its mutants in the presence of 
DHA. 
 
Molecular Mass (Da)  RT
a
 
(min) Found
b
 Theoretical
c
 
Species
d
 
14508.13 (±0.05) 14508.1 aS 3ox 
14491.8 (±0.5) 14492.1 aS 2ox 
 
 
19.5 14476.1 (±0.3) 14476.1 aS 1ox 
21 14459.92 (±0.01) 14460.1 aS 
14801.9 (±0.05) 14802.1 aS 1ox 326 
14817.1 (±0.7) 14818.1 aS 2ox 326 31 
14831.3 (±0.9) 14834.1 aS 3ox 326 
14522.4(±1.1) 14522.2 A53T 2ox  
17.8 
14554.6 (±0.2) 14554.2 A53T 4ox 
18.5 14506.3 (±0.6) 14506.2 A53T 1ox 
18.9 14490.5 (±0.3) 14490.2 A53T 
31.5 14864.6 (±1.7) 14864.2 A53T 3ox 326 
14464.8 (±0.6) 14459.2 E46K 
14479.1 (±0.6) 14475.2 E46K 1ox 
 
 
17 
 14496.6 (±0.6) 14491.2 E46K 2ox 
31 14791.6 (±1) 14785.2 E46K 326 
14486.9 (±0.2) 14486.2 A30P 
14502.6 (±0.6) 14502.2 A30P 1ox 
14518.6 (±0.3) 14518.2 A30P 2ox 
 
 
 
17.4 
14534.0 (±1.2) 14534.2 A30P 3ox 
17.8 14486.9 (±0.2) 14486.2 A30P 
31.5 14859.8 (±3.2) 14860.2 A30P 3ox 326 
e
32 326.28 (±0.08) 326.24 DHA (-2H) 
33 328.29 (±0.16) 328.24 DHA 
 
a, b, c, d
 see reference Table 6.1. 
e 
Peaks eluted at
 
32 and 33 min correspond to DHA for all analyzed protein. 
 
 
 
 
 
 
 
 
aS 
A53T 
E46K 
A30P 
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7. DISCUSSION AND CONCLUSION 
 There is growing interest in finding a possible link between aS toxicity in 
synucleinopathies and aS-lipid interaction. The precise biological function of aS is still 
under investigation, but it is implicated in a range of interactions with phospholipid 
membranes and free fatty acids. A current hypothesis about its pathological behaviour is 
that the association of aS with oxidized lipid metabolites can lead to mitochondrial 
dysfunction in turn leading to dopaminergic neuron death and thus to Parkinson's disease 
(Ruipérez et al., 2010). aS toxicity might also be related to abnormal membrane 
interactions and alterations in vesicles trafficking (Auluck et al., 2010). Many studies link 
toxicity to the existence of various intermediate structures, such as oligomers originating 
in early stages of aS fibrillation, and their specific interaction with membranes. Such 
intermediates are yet not fully characterized and there are several different possible 
mechanisms of toxicity (Fig. 7.1).  
Fig. 7.1. Schematic representation of interconnectivity between amyloid formation and membrane 
disruption. Top: The process of amyloid-fibril formation. Amyloid formation involves the 
misfolding of soluble proteins into β-sheet oligomers, which further aggregate into protofibrils, 
including ringlike annular protofibrils, and then into amyloid fibrils. Bottom: The role of 
membranes in amyloid formation and toxicity. Soluble proteins bind to membrane surfaces with a 
shift to α-helix structure. The accumulation of proteins on the surface of the membrane induces 
their aggregation. When a critical threshold concentration is reached, a trans-membrane pore 
(annular protofibril) develops in the membrane and enables the leakage of membrane contents. 
As other possible or coexistent mechanisms, annular protofibrils formed in solution may insert 
into the membrane, undefined prefibrillar aggregates may bind to the membrane surface and 
induce membrane thinning, and lipids may be extracted from the membrane and incorporated 
into the developing fibril in a detergent-like process (from Lashuel and Butterfield, 2010). 
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Many evidences are in favour of oligomers able to form membrane pores (Kostka et al., 
2008; Zakharov et al., 2007). A new model of amyloid interaction with membranes by a 
"raft-like" mode of insertion could explain important destabilization of membranes and 
thus amyloid toxicity (Berthelot et al., 2013). Many reports suggest that PUFAs are strictly 
connected to neurological disorders, including Parkinson’s disease (Marszalek & Lodish, 
2005). Specifically, alterations in PUFAs levels have been found related to aggregation of 
aS (Necula et al., 2003; Perrin et al. 2001; Sharon et al., 2003; Assayag et al., 2007). It has 
been proposed that aS could interact with free FAs (Sharon et al., 2001; Broersen et al., 
2006), or, alternatively, with FAs in a micellar or bilayer state (Necula et al. 2003; Lücke et 
al., 2006). Interestingly, It has been shown that elevated brain DHA levels accelerate aS 
accumulation and oligomerization: treating dopaminergic cells expressing aS with 
polyunsaturated fatty acids (PUFAs) induced the formation of stable oligomers whereas 
saturated fatty acids did not. These oligomers were associated with cyto-toxicity, whereas 
the development of Lewy-like inclusions appeared to be protective (Assayag et al., 2007). 
A recent study demonstrated that dietary changes in brain DHA levels affect aS 
cytopathology in mice transgenic for the PD-causing A53T mutation in human aS. A diet 
enriched in DHA increased the accumulation of soluble and insoluble neuronal aS, neuritic 
injury and astrocytosis (Yakunin et al., 2012).  
 We previuosly produced in vitro oligomeric species of aS in the presence of DHA, 
which resulted toxic in cultured dopaminergic cells (De Franceschi et al., 2009; 2011). The 
aim of this thesis is to characterize the main biophysical properties of this type of 
oligomers, in order to explain their possible mechanism of toxicity. Moreover, studies 
about their chemical modification have been conducted, considering also differences that 
may occur between aS and its variants A30P, E46K, H50Q and A53T. 
 
7.1 aS/DHA oligomers characterization 
In the presence of DHA, it is induced the formation of relatively stable oligomers that 
are off-pathway in aS aggregation process (De Franceschi et al., 2011). The first aim of 
this study was to better characterize oligomers structure and shape, in order to correlate 
them with their activity. We have used a number of biophysical techniques such as TEM, 
AFM and DLS. These measurements show that aS/DHA oligomers are a heterogeneous 
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population of species, with diameters ranging from 12-30 nm. Different types of 
oligomers have been described in literature, depending on the conditions of preparation. 
Indeed, different conditions such as the presence of metals or lipids can affect the shape 
and the dimension of oligomers (Paik et al., 2002; Lee et al., 2002). Moreover, studies of 
the kinetics of fibril formation have given important insights into the overall mechanism 
of amyloid assembly, but little is known in any detail about the oligomeric structure 
(Lashuel et al., 2002; Luheshi et al., 2007; Winner et al., 2011). A variety of distinct 
morphologies of aS oligomers have been observed using imaging techniques, such as 
atomic force microscopy or transmission electron microscopy (Conway et al., 2000; Ding 
et al., 2002; Lashuel et al., 2002; Hoyer et al., 2004). Structural studies on aS oligomers 
have also been carried out using FTIR, Raman, CD, and fluorescence spectroscopy (Apetri 
et al., 2006; Goldberg and Lansbury, 2000; Hong et al., 2008; Nath et al., 2010; 
Thirunavukkuarasu et al., 2008), which have revealed the formation of various oligomeric 
structures during aS aggregation, consistent with a progressive increase in β sheet 
structure occurring concomitantly with the formation of more ordered aggregates. 
Oligomers formed in the presence of DHA show a similar size and morphological features 
with those previously described, but they acquire α-helical conformation (De Franceschi 
et al., 2009; 2011). This structure is almost partially lost  after a gel filtration purification 
step. We presume that exchangeable DHA, not the covalently bound one, is removed 
and with it the effect on oligomers structure. Consequently the oligomers acquire a 
partly folded state, significantly different from the natively unfolded structure of 
monomeric aS. These partly folded oligomers are able to acquire again α-helical 
structure upon addition of DHA. This behaviour lead us to speculate about a possible 
structure model of these oligomers, sectioning the structure of oligomers into two parts, 
the N-terminal and the NAC region, and evaluating separately their contribute. In 
monomeric aS, the N-terminal region is essential for membrane recognition and for 
cooperative formation of helical domains. By CD and isothermal titration calorimetry, 
Bartels and colleagues (2010) tested different fragments and domains of aS for their 
binding affinity, concluding that N-terminus results necessary for the membrane-induced 
helical folding and the interaction of the first 25 residues with lipids is driven by 
electrostatic attraction. Transferring this to oligomers, since they in their partly folded 
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state can undergo conformational transition in the presence of lipids and membranes, it 
is reasonable to assume that the N-terminal region, or part of it, is free. 
Another property of aS/DHA oligomers is that they are off-pathway and do not 
proceeds in the aggregation process, even in the presence of membranes. In aS, 
experiments on fragments of NAC have enabled this region as responsible for 
aggregation, in particular  fragment 8-18 of NAC is the smallest fragment that aggregates 
and forms fibrils (El-Agnaf et al., 2002). Furthermore, membranes work as a catalyst of 
aggregation (Berthelot et al., 2013) since membrane-bound aS can generate nuclei that 
seed the aggregation also in vivo (Lee et al., 2002). So it seems that the NAC region 
(residues 61-95) in aS/DHA oligomers is not available or is hidden in their interior. In 
conclusion aS/DHA oligomers have two main structural features: the conformational 
sensitivity to environment for the ability to interact with lipids and to undergo structural 
transition, and secondly the stability under conditions that favours aggregation. The 
overall structure of the oligomers could be stabilized by hydrophobic interactions 
deriving from the association of NAC regions.  
 
7.2 aS/DHA oligomers activity on membranes 
Here we have studied aS/DHA oligomers activity on membranes in an attempt to 
understand their mechanism of toxicity, because the latter, as yet said, is object of 
debate in the literature for the difficulty to define a unifying picture of the toxic activity. 
The controversy springs from both the transient nature of aS oligomers and from the 
many different types of oligomers that have been described. Volles and colleagues 
(2001), demonstrated that protofibrillar aS, in contrast to the monomeric and the fibrillar 
forms, binds synthetic vesicles very tightly via a β-sheet-rich structure and transiently 
permeabilizes these vesicles. An interesting property of aS/DHA oligomers is their ability 
to permeabilize membranes, as verified using a leakage assay from unilamellar 
phospholipid vesicles. By calcein leakage test we demonstrated that aS/DHA oligomers 
destabilize both LUV and SUV composed of negative charged phospholipids. 
Interestingly, vesicles composed of only 50% negative-charged phospholipids show really 
low extent of calcein release after incubation with aS oligomers, even if this kind of 
vesicles is able to induce acquisition of α-helix structure on aS/DHA oligomers, even if 
with a minor extent than that induced by 100% acidic phospholipids. This result is in line 
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with a previously reported behaviour of aS oligomers (Van Rooijen et al., 2008), that bind 
negative charged membranes acquiring α-helix structure. In a similar way, these 
oligomers are not able to induce calcein leakage in vesicles of 50% zwitterionic lipids, 
allowing to conclude that membrane binding of aS does not necessarily lead to vesicle 
permeabilization.  
We tested also the activity of aS/DHA oligomers on dopaminergic cells. Treatment 
with oligomers significantly increases the number of cells internalizing the membrane-
impermeant dye propidium iodide. These results suggest that membranes can be a 
possible target of aS oligomers activity. This can be particularly harmful for neuronal 
cells, where electrical activity and action potential firing are finely regulated by transient, 
voltage-gated channel-mediated variation of membrane potential and intracellular 
calcium concentration. Indeed, increased membrane permeability could result in a 
variety of intracellular processes and leads to cytotoxicity, as well as dissipation of 
sodium and potassium gradients with deleterious impact on electrical neuronal activity.  
Several mechanisms have been proposed to explain oligomers activity on 
membranes. One possible mechanism is that of the pore-like mechanism (Zakharov et 
al., 2007; Kostka et al., 2008; Lashuel and Butterfield 2010). Protofibrils with β-sheet-rich 
structure transiently permeabilizes vesicles and the activity is comparable for aS WT and 
its A53T and A30P mutants (Volles et al., 2001). A thinning effect due to lipid extraction 
from the bilayer has been also reported. aS WT, A53T and the designed A57T mutant 
were found to follow the same mechanism of polymerization and membrane damage, 
involving the extraction of lipids from the bilayer and their clustering around growing α-
synuclein aggregates (Reynolds et al., 2011).  Leakage could be due also to a complete 
disruption of the membrane, reported for mellitin (Bechinger and Lohner, 2006), or a 
transient membrane destabilization, possibly related to the intrinsic instability of the 
bilayer. Indeed, vesicles composed of negatively charged lipids, which are generally used 
for measuring aS-lipid interactions, are unstable to protein adsorption in general (van 
Rooijen et al., 2010). The pore-like hypothesis is especially accepted for those proteins 
forming oligomers or protofibrils with annular or ring-like structure (Butterfield and 
Lashuel 2010). In our case the leakage activity tested on synthetic liposomes shows 
selectivity of markers size, evidencing that the average dimension of the aperture should 
be between 1 and 4 nm (Mazzuca et al., 2010). The enhanced membrane-
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permeabilization activity of amyloid oligomers relative to that of soluble monomers and 
mature fibrils and the reported size dependence with respect to dye leakage from model 
vesicle membranes are considered consistent with the pore-like mechanism (Butterfield 
and Lashuel 2010). Other characteristic are required to assume the formation of pores, 
such as the induction of single-ion-channel currents characteristic of ion-channel or pore-
forming proteins. The activity of aS/DHA oligomers on a planar lipid membrane system 
seems due to a non-specific membrane permeabilization rather than to the formation of 
structured membrane apertures like those previously demonstrated also for monomeric 
aS (Tosatto et al., 2012).  
The complete disruption effect could be excluded by DLS and microscopy 
measurements of aS/DHA oligomers in the presence of phospholipids vesicles. Indeed 
DLS measurements of both LUV and SUV in the presence of aS/DHA oligomers show that 
the vesicles size distribution is modified, but TEM shows no changes to the overall 
vesicles morphology. The reported effect of Triton X-100 on vesicles measured by DLS 
clearly exclude a similar effect by oligomers. In conclusion, aS/DHA oligomers interacting 
with negatively charged membranes induce a perturbation of the phospholipid bilayer 
with the release of encapsulated small molecules. Oligomeric molecules remain 
entrapped on the vesicles, as peripheral membrane proteins, acquiring α-helical 
structure. Damaging of membrane structural integrity seems to be an essential step in 
the cytotoxic activity of aS oligomers formed in the presence of DHA. 
This part of the thesis is object of a publication (Fecchio C., De Franceschi G., Relini 
A., Greggio E., Dalla Serra M., Bubacco L., Polverino de Laureto P (2013) α-Synuclein 
Oligomers Induced by Docosahexaenoic Acid Affect Membrane Integrity. PlosOne 
8:e82732. 
 
7.3. Chemical modification of aS in the presence of DHA 
 The chemical protein modifications, that form under oxidative stress conditions, 
occur on specific amino acid residues. The direct oxidation of proteins by ROS involves 
Lys, Arg, Pro and Thr residues. The secondary reactions with reactive derivatives 
(ketoamines, ketoaldehydes, deoxyosones) produced by sugars oxidation product occur 
especially on Lys, while the formation of adducts of oxidized lipids derived from the 
metal-catalysed oxidation of PUFA involves Lys, Cys and His residues (Esterbauer et al., 
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Fig. 2. Schematic representation of Michael 
addition of 4-HNE on His50, contained in the 
fragment E46-K58. 
1991; Uchida and Stadtman, 1992; Refsgaard et al., 2000; Dalle Donne et al., 2006). In 
the case of aS, the modifications on Lys residues can affect the charge distribution of the 
basic KXKE repeats of the N-terminal region, and so influence the interaction with 
membranes that is primarily mediated by a charge effect (Davidson et al., 1998; van 
Rooijen et al., 2010). One of the main features of aS/DHA oligomers is the chemical 
heterogeneity that derive from the presence of covalently bound DHA and of oxidative 
additional modifications (De Franceschi et al., 2011). In previous studies we detect the 
presence of modification, but we didn’t identify which amino acids are involved, so 
another aim of the present work was to define the modified residues in aS/DHA 
oligomers and eventually the role of these modifications in their activity.  
A first attempt was done to detect the increase of carbonylation (Dalle Donne et 
al., 2006) of aS in the presence of DHA. A reaction with by DNPH was used that have 
demonstrated an increased presence of carbonyls, but unfortunately it was not possible 
to assess which residues were mainly modified. Only a fragment containing the Δ mass of 
180 Da was found and it corresponds to the sequence 24-32. This peptide contains Lys32 
as possible target of carbonylation. However the presence of a single modification does 
not justify the signals obtained in UV and RP-HPLC analyses. It is reasonable that residues 
in the protein are randomly modified and so it is difficult to detect them. 
DHA-adduct is the most evident modification, among the several possible ones, 
so we focused on its characterization. 
Trypsin digestion of the aS/DHA 
oligomers followed by peptide 'finger-
printing' revealed that DHA binds the 
peptide 46EGVVHGVATVAEK58, providing 
an indirect evidence that His50 is 
modified. This could be predictable 
since the reactivity of lipid peroxidation 
products, such as allylic radicals, is 
known and involves Cysteine, Histidine 
and Lysine residues (Uchida et al., 
1997). Moreover, 4-hydroxy-2(E)-
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nonenal, a product of peroxidation of lipids, preferentially binds to His50 on aS (Fig. 2, 
from Trostchansky et al., 2006), or more rarely to Lys60 and Lys69 (Bae et al., 2013; 
Xiang et al., 2013,). His50 results a suitable target for the formation of an adduct with 
DHA. In view of the fact that His50 is preferentially modified by DHA, in comparison with 
the several lysine residues present in the polypeptide chain, we investigated the 
importance of this residue by using a mutant containing a Gln in spite of His in position 
50. Interestingly this specific variant has been recently found in a familiar form of PD. 
H50Q behaviour in the presence of DHA is very similar to that of aS. H50Q acquires α-
helix structure and by limited proteolysis a similar interaction with DHA was evidenced. 
Moreover, also the aggregation process results similar to that of aS and oligomers form. 
Surprisingly, a mass increase of 326 Da is still detectable on the protein, and sometimes 
more than one FA adduct was found, meaning that other residues were modified. This 
result suggests that the position of the modification on aS is not essential for the 
formation of oligomers. The preference for His50 could be due to chemical reasons, since 
the reaction toward His is favoured. Indeed, His50 is surely in excess on reactive DHA, 
that is its radical form, which constitutes about 0.3% of the initial content of FA.  
After His, the binding of DHA can occur at the level of Lysine residues, that are 14 
in the whole protein. It was not possible to detect any modified lysine by finger printing 
analysis of H50Q oligomers. We can explain it considering that it was possible to find 
modified His50 because it was the preferred site of modification. On the contrary, 
without His all the 14 lysines are possible target of DHA binding, leading to the formation 
of a heterogeneous population of H50Q, modified in different lysine residues. As a 
consequence, the extent of modification on a specific lysine is too low to be detectable 
with this kind of analysis.  
Finally the fact that the oligomers obtained from aS and H50Q have the same 
extent of activity on synthetic membrane, allowing to conclude that the position of the 
modification is not essential even for oligomers activity.  
 
7.4 aS variants in the presence of DHA 
 To complete the study, also the other three known mutants found in 
familiar forms of PD (A30P, A53T and E46K) were investigated. In the presence of DHA, all 
mutants acquire α-helix structure in a similar way, but A30P in minor extent. Upon 
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incubation at a molar ratio protein/lipid 1:50, all the proteins form stable oligomers but, 
interestingly, the oligomers formation rate was different, resulting in a minor oligomeric 
content for E46K and A30P. To define the region of aS more directly interacting with DHA, 
proteolysis experiments coupled with mass spectrometry have been performed. aS, as a 
natively unfolded protein, is largely sensitive to proteases because it lacks secondary and 
tertiary structure (Uversky, 2002). As a matter of fact, there are no regions with such 
persistent structure as to hinder protease’s attack. Upon binding to DHA, aS appears to be 
quite resistant to proteolysis, as expected from the fact that the polypeptide has adopted 
an α-helix conformation which strictly involves the first 70 amino acid residues. A 
considerable accessibility of aS polypeptide chain to proteinase K is confined only at the 
level of region 70-90, providing evidence that this segment is the most flexible and 
sufficiently protruded to be protease-sensitive (Hubbard et al., 1994; Fontana et al.,2004). 
Comparing proteolytic patterns of aS and its variants in the presence of DHA, it became 
evident that first cleavage sites are identical for all the proteins, suggesting that the 
overall interaction with membrane is mediated by the same region encompassing the first 
~100 amino acids (De Franceschi et al., 2009). Prolonging the proteolysis to 1 and 3 hr for 
A30P and E46K, it is shown that fragments that accumulate in the proteolytic mixture are 
1-72 for A30P, and 1-50 for E46K. To explain these differences, we can consider the data 
reported  by Bodner et al. (2010).  The mutation of E in K raises the net charge of the first 
100 residues from +4 to +6, resulting in higher affinity for negative charged lipid. By NMR 
it was observed that this fact determines a slower dissociation from lipid. As a 
consequence E46K increase the bound fraction in a SL1 binding mode, in which the first 
10 or 24 N-terminal residues  adopt a stable α-helical conformation upon lipid binding, 
while the lasting ~25-140 residues are dynamically disordered (Fig. 25). A second binding 
state, SL2, populated by aS, engages the whole N-terminal domain until to the residue 
~100. E46K in SL1 state allows the protease to cleave peptide bond H50-G51 located in 
the dynamically disordered region 25-100.   
A30P doesn’t form a canonical α-helix upon binding to lipids, for the presence of 
proline residue. This determines a reduced association rate to lipids and a shift of the 
equilibrium between SL1 and SL2 binding mode towards the SL1 one. Intriguingly the 
A30P is not fragmented at the level of peptide bond H50-G51, since intact A30P is found 
also upon prolonged incubation with the protease. This doesn’t imply necessary presence 
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of regular secondary structure but can be due to a backbone rigidity imposed by proline 
(Polverino de Laureto et al., 2006). In conclusion, in the presence of DHA, the variant 
E46K appears to be highly susceptible to proteases hydrolysis in correspondence of the 
region 50-89, included in the NAC region, while aS in the region 73-89. A30P shows an 
unusual rigidity. However the initial sites of proteolysis clearly indicate that in the 
presence of saturating concentration of DHA, considerable accessibility of the 
polypeptide chains to proteinase K is located to residues 70-90, providing evidence that 
this segment for all variants, by limited proteolysis criteria, is the most flexible and 
protruded to be protease-sensitive. 
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DGKHUHQFHWRDOOWKH3/2621(SROLFLHVRQVKDULQJGDWDDQGPDWHULDOV
(PDLOSDWUL]LDSROYHULQRGHODXUHWR#XQLSGLW
,QWURGXFWLRQ
3DUNLQVRQ GLVHDVH 3' LV WKH PRVW FRPPRQ PRYHPHQW
GLVRUGHUFXUUHQWO\DIIHFWLQJDSSUR[LPDWHO\RIWKHSRSXODWLRQ
ROGHU WKDQ DJH  \HDUV +DOOPDUNV RI 3' DUH WKH ORVV RI
GRSDPLQHUJLF QHXURQV LQ WKH VXEVWDQWLD QLJUD 61 UHJLRQ RI
WKH EUDLQ DQG WKH SUHVHQFH RI F\WRSODVPDWLF LQFOXVLRQV RI Į
V\QXFOHLQD6LQILEULOODUIRUPNQRZQDV/HZ\ERGLHVDQG/HZ\
QHXULWHV>@D6LVDN'DSURWHLQWKDWSUHGRPLQDQWO\H[LVWVDV
XQIROGHG PRQRPHU XQGHU QDWLYH FRQGLWLRQV ,WV VHTXHQFH LV
FKDUDFWHUL]HG E\ DQ DPSKLSDWKLF O\VLQHULFK DPLQR WHUPLQXV
ZKLFK JRYHUQV ELQGLQJ WR OLSLGV DQG LQWHUDFWLRQV ZLWK
PHPEUDQHV >@ E\ D K\GURSKRELF FHQWUDO UHJLRQ 1$& QRQ
DP\ORLGEHWD FRPSRQHQW UHVSRQVLEOH IRU SURWHLQ DJJUHJDWLRQ
DQGȕVKHHWIRUPDWLRQ>@DQGDKLJKO\DFLGLF&WHUPLQDOULFK
LQ3URDQGDFLGLFUHVLGXHV+RZWKHILEULOODUDJJUHJDWLRQRID6LV
UHODWHG WR 3' DQG QHXURGHJHQHUDWLRQ LV VWLOO DQ XQVROYHG
TXHVWLRQ ,Q YLYR DQG LQ YLWUR VWXGLHV VXSSRUW WKH K\SRWKHVLV
WKDW ROLJRPHUV DQG VSHFLHV IRUPHG LQ WKH HDUO\ VWDJH RI
DJJUHJDWLRQ RI D6 UDWKHU WKDQ WKH PRQRPHULF RU ILEULOODU
SURWHLQ UHSUHVHQW WKH WR[LF VSHFLHV LQYROYHG LQ 3' >@
'LYHUVH W\SHV RI ROLJRPHUV KDYH EHHQ GHVFULEHG LQ WHUPV RI
VWUXFWXUH DQG WR[LF DFWLYLW\ ,W VKRXOG EH PHQWLRQHG WKDW WKH
PHWKRGVXVHGIRUWKHSUHSDUDWLRQRIROLJRPHUV LQYLWURVWURQJO\
DIIHFW WKHLUSURSHUWLHVVRXSWRGDWHDUREXVW LQYLWURPRGHORI
WKHPHFKDQLVPE\ZKLFKROLJRPHUVH[HUW WKHLU WR[LFDFWLYLW\ LV
QRWDYDLODEOH
$OWKRXJK WKH SK\VLRORJLFDO IXQFWLRQ RI D6 LV VWLOO SRRUO\
XQGHUVWRRG>@LWDSSHDUVWREHLQYROYHGLQPRGXODWLQJV\QDSWLF
YHVLFOH G\QDPLFV >@ DQG PD\ FRQWULEXWH WR WKH DFWLYLW\ RI
FRQWUROOLQJ V\QDSWLF KRPHRVWDVLVDVVRFLDWHG SURWHLQV >@
6HYHUDOVWXGLHVKDYHUHFHQWO\VKRZQDVWURQJOLQNEHWZHHQD6
DQG IDWW\ DFLGV )$V LQ SDUWLFXODU EUDLQ )$V VXFK DV
DUDFKLGRQLF DQG GRFRVDKH[DHQRLF DFLG '+$ D6 H[SUHVVLRQ
DIIHFWV)$VXSWDNHDQGPHWDEROLVP>@DQGD6LQWHUDFWLRQV
ZLWK SRO\XQVDWXUDWHG IDWW\ DFLGV 38)$V FDQ UDSLGO\ DQG
G\QDPLFDOO\ DIIHFW LWV ROLJRPHUL]DWLRQ DQG IXUWKHU DJJUHJDWLRQ
>@7KHDSSHDUDQFHRID6WR[LFROLJRPHUVLQYLYRKDVEHHQ
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OLQNHGWRWKHSUHVHQFHRIORQJ38)$VLQWKHEUDLQ>@<DNXQLQ
DQG FROOHDJXHV >@ GHPRQVWUDWHG WKDW D '+$ HQULFKHG GLHW
LQFUHDVHV WKHFRQFHQWUDWLRQRI LQVROXEOHD6VSHFLHV LQPRXVH
EUDLQ0DQ\ HYLGHQFHV VXJJHVW D FULWLFDO UROH RI OLSLGV LQ ERWK
3' DQG $O]KHLPHU GLVHDVH VXFK DV FKDQJHV LQ DFWLYLW\ RI
SKRVSKROLSDVH $ DQ HQ]\PH WKDW K\GURO\VHV PHPEUDQH
SKRVSKROLSLGV DQG FDXVHV UHOHDVH RI )$V WKDW KDYH EHHQ
FRUUHODWHG ZLWK EUDLQ LQMXU\ DSRSWRVLV DQG SKRVSKROLSLG
PHWDEROLVPDOWHUDWLRQXOWLPDWHO\OHDGLQJWRQHXURGHJHQHUDWLRQ
$V D FRQVHTXHQFH WKH LQWHUDFWLRQ EHWZHHQ D6 DQG )$V KDV
EHHQ SURSRVHG WR EH D NH\ IDFWRU LQ WKH RQVHW RI
QHXURGHJHQHUDWLRQDQG3'>@
,QSUHYLRXVVWXGLHVZHDQDO\]HGWKHDJJUHJDWLRQSURFHVVRI
D6LQWKHSUHVHQFHRI'+$XVLQJGLIIHUHQWSURWHLQWR'+$PRODU
UDWLRV>@:HGHPRQVWUDWHGWKDW'+$H[HUWVDQLPSRUWDQW
UROH LQ WKH DJJUHJDWLRQ RI D6 UHFUXLWLQJ SURWHLQPROHFXOHV RQ
WKH GURSOHWV VXUIDFH DQG EHLQJ LWVHOI SDUW RI WKH DJJUHJDWHV
VWUXFWXUH 7KH SUHVHQFH RI '+$ WR WKH DJJUHJDWLQJ D6 
PROPRO OHDGV WR WKH IRUPDWLRQ RI VWDEOH ROLJRPHUV WKDW DUH
'062DQG6'6UHVLVWDQWGRQRWELQG7K7DQG ODFNVHHGLQJ
SURSHUWLHV GHPRQVWUDWLQJ WKDW WKH\ DUH RIISDWKZD\ LQ WKH
DJJUHJDWLRQ SURFHVV RI D6 6WUXFWXUDOO\ WKH\ FRQWDLQ ĮKHOLFDO
DQG UDQGRPVWUXFWXUH)XUWKHUPRUH WKHVHROLJRPHUVDUH WR[LF
WR FHOOV FRPSDUHG WR D6 VXJJHVWLQJ WKDW WKH\ DUH SRWHQWLDOO\
UHOHYDQWLQWKHSDWKRJHQHVLVRI3'
,Q WKH SUHVHQW ZRUN ZH FRQGXFWHG H[SHULPHQWV WR WHVW WKH
K\SRWKHVLV WKDW D6 ROLJRPHUV H[HUW WKHLU WR[LF HIIHFW E\
XQGHUPLQLQJ WKH LQWHJULW\ RI OLSLG PHPEUDQHV 7KH LQWHUDFWLRQ
EHWZHHQ D6'+$ ROLJRPHUV ZLWK OLSLG ELOD\HU ZDV VWXGLHG E\
FLUFXODU GLFKURLVP &' WUDQVPLVVLRQ HOHFWURQ PLFURVFRS\
7(0 DQG G\QDPLF OLJKW VFDWWHULQJ '/6 :H VKRZ WKDW
D6'+$ROLJRPHUVELQGWRQHJDWLYHO\FKDUJHGPHPEUDQHVDQG
DFTXLUH DQ LQFUHDVHG DPRXQW RI ĮKHOLFDO VWUXFWXUH 8SRQ
ELQGLQJ WR QHJDWLYHO\ FKDUJHG YHVLFOHV ROLJRPHUV LQGXFH
OHDNDJHRIVPDOOPROHFXOHVVXFKDVFDOFHLQ PZN'DEXW
QRWRI),7&GH[WUDQ PZN'D7UHDWPHQWRIGRSDPLQHUJLF
6+6<< FHOOV ZLWK D6'+$ ROLJRPHUV UHVXOWV LQ LQFUHDVHG
SHUPHDELOLW\WRSURSLGLXPLRGLGH
0DWHULDOVDQG0HWKRGV
'+$DQG IOXRUHVFHLQ LVRWKLRF\DQDWHGH[WUDQ ),7&'H[WUDQ
RI DYHUDJH PROHFXODU ZHLJKW RI  'D ZHUH SXUFKDVHG
IURP 6LJPD &KHP &R 6W /RXLV 02 $OO RWKHU FKHPLFDOV
DQDO\WLFDO UHDJHQWJUDGHZHUHREWDLQHG IURP6LJPDRU)OXND
%XFKV 6ZLW]HUODQG 7KH OLSLGV SDOPLWR\OROHR\OVQ
JO\FHURSKRVSKRFKROLQH 323& GLROHR\OVQJO\FHUR
SKRVSKR
UDFJO\FHURO '23* SDOPLWR\OROHR\OVQ
JO\FHURSKRVSKR/VHULQH 3236 SDOPLWR\OROHR\OVQ
JO\FHURSKRVSKRHWKDQRODPLQH 323(DQG%UDLQ7RWDO/LSLG
([WUDFWZHUHREWDLQHGIURP$YDQWL3RODU/LSLGV$ODEDVWHU$/
DVFKORURIRUPVROXWLRQDQGXVHGZLWKRXWIXUWKHUSXULILFDWLRQ
D6FORQLQJDQGH[SUHVVLRQ
7KHS(7E1RYDJHQSODVPLGZDVXVHGIRUWKHH[SUHVVLRQ
RI UHFRPELQDQW KXPDQ D6 LQ ( FROL %/ '( 7KH
H[SUHVVLRQDQGSXULILFDWLRQRIWKHSURWHLQZHUHFRQGXFWHGXVLQJ
WKHSURFHGXUHSUHYLRXVO\GHVFULEHG>@3URWHLQFRQFHQWUDWLRQV
ZHUHGHWHUPLQHGE\DEVRUSWLRQPHDVXUHPHQWVDWQPXVLQJ
D GRXEOHEHDP /DPEGD VSHFWURSKRWRPHWHU 3HUNLQ (OPHU
1RUZDON &7 7KH H[WLQFWLRQ FRHIILFLHQW RI D6 DW  QP LV
FP0DVHYDOXDWHGIURPLWVDPLQRDFLGFRPSRVLWLRQE\
WKHPHWKRGRI*LOODQGYRQ+LSSHO>@
3UHSDUDWLRQRIROLJRPHUV
7R SUHSDUH ROLJRPHULF VSHFLHV D6ZDV LQFXEDWHG DW  &
IRUXSWRKRXUVDWDSURWHLQFRQFHQWUDWLRQRI0LQ3%6
P01D+32P01D&OP0.+32P0.&O
S+ LQ WKHSUHVHQFHRI'+$P0 WRREWDLQDSURWHLQ
IDWW\DFLGPRODUUDWLRRIXQGHUVKDNLQJDWUSPZLWKD
WKHUPRPL[HU&RPSDFW(SSHQGRUI+DPEXUJ'($OLTXRWVRI
WKH VDPSOHV ZHUH H[DPLQHG E\ WKLRIODYLQ 7 7K7 ELQGLQJ
DVVD\ &' 7(0 JHO ILOWUDWLRQ *) FKURPDWRJUDSK\ DQG 53
+3/& DV SUHYLRXVO\ GHVFULEHG >@ WR YHULI\ WKH LGHQWLW\ DQG
VWUXFWXUH RI WKH ROLJRPHUV DQG WR DVVXUH H[SHULPHQWDO
UHSURGXFLELOLW\7KHLGHQWLW\RIWKHHOXWHGPDWHULDOZDVDVVHVVHG
E\ PDVV VSHFWURPHWU\ FDUULHG RXW ZLWK DQ HOHFWURVSUD\
LRQL]DWLRQ (6, PDVV VSHFWURPHWHU ZLWK D 47RI DQDO\]HU
0LFUR :DWHUV0DQFKHVWHU8.2OLJRPHUVZHUHXVHGDIWHU
SXULILFDWLRQ E\ *) DQG FRQFHQWUDWHG E\ $PLFRQ 8OWUD
XOWUDILOWUDWLRQ . PHPEUDQH FXWRII 0LOOLSRUH %LOOHULFD 0$
86$
&LUFXODUGLFKURLVP
&' VSHFWUD ZHUH UHFRUGHG RQ D - VSHFWURSRODULPHWHU
-DVFR 7RN\R -DSDQ )DU89 &' VSHFWUD ZHUH UHFRUGHG
XVLQJ D  PP SDWKOHQJWK TXDUW] FHOO DQG D SURWHLQ
FRQFHQWUDWLRQRI 07KHPHDQ UHVLGXHHOOLSWLFLW\ >ș@ GHJ
FP GPRO±ZDV FDOFXODWHG IURP WKH HTXDWLRQ >ș@   șREV
05:OFZKHUHșREVLVWKHREVHUYHGHOOLSWLFLW\LQGHJ05:LV
WKHPHDQUHVLGXHPROHFXODUZHLJKWRIWKHSURWHLQ O WKHRSWLFDO
SDWKOHQJWK LQFPDQGF WKHSURWHLQFRQFHQWUDWLRQ LQJP/7KH
VSHFWUDZHUHUHFRUGHGLQ3%6EXIIHUS+
$WRPLFIRUFHDQGHOHFWURQWUDQVPLVVLRQPLFURVFRS\
D6'+$ROLJRPHUVZHUHGLOXWHGWLPHVXVLQJ0LOOL4ZDWHU
DQGȝODOLTXRWVZHUHGHSRVLWHGRQIUHVKO\FOHDYHGPLFDDQG
GULHG XQGHU PLOG YDFXXP 7DSSLQJ PRGH $)0 LPDJHV ZHUH
DFTXLUHG LQDLUXVLQJD0XOWLPRGHVFDQQLQJSUREHPLFURVFRSH
HTXLSSHGZLWK DQ ³(´ VFDQQLQJ KHDG PD[LPXP VFDQ VL]H 
ȝP DQG GULYHQ E\ D 1DQRVFRSH ,9 FRQWUROOHU 'LJLWDO
,QVWUXPHQWV%UXNHU*HUPDQ\6LQJOHEHDPXQFRDWHG VLOLFRQ
FDQWLOHYHUV W\SH2O\PSXV20&/$&762O\PSXV7RN\R
-DSDQZHUHHPSOR\HG7KHWLSRIWKHSUREHZDVRIQP7KH
GULYH IUHTXHQF\ZDVEHWZHHQDQGN+]DQG WKHVFDQ
UDWHZDVEHWZHHQDQG+]7(0SLFWXUHVZHUHWDNHQRQ
D7HFQDL*7ZLQLQVWUXPHQW)(,&RPSDQ\+LOOVERUR25
86$RSHUDWLQJDWDQH[FLWDWLRQYROWDJHRIN96DPSOHVIRU
7(0 ZHUH GLOXWHG  WLPHV DQG D GURS RI WKH VROXWLRQ ZDV
SODFHG RQ D %XWYDUFRDWHG FRSSHU JULG VTXDUH PHVK
7$$%/DERUDWRULHV(TXLSPHQW/WG%HUNV8. IROORZHGE\D
GURSRIXUDQ\ODFHWDWHVROXWLRQZY
Į6\QXFOHLQ2OLJRPHUVDQG0HPEUDQHV
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9HVLFOHVSUHSDUDWLRQ
7RSUHSDUHODUJHDQGVPDOOXQLODPHOODUYHVLFOHV/89689
OLSLGV ZHUH WUDQVIHUUHG LQ JODVV WXEHV &KORURIRUP ZDV
GHK\GUDWHGE\JHQWOHKHOLXPVWUHDPDQGWKHQZDUPHGDW&
WRUHPRYHUHVLGXDORUJDQLFVROYHQW7KHOLSLGILOPZDVK\GUDWHG
ZLWK 3%6 S+  LQ WKH DEVHQFH RU SUHVHQFH RI FDOFHLQ 
P0 RU ),7&GH[WUDQ  P0 DW & IRU  KRXUV ZLWK
IUHTXHQW YRUWH[LQJ 7KHQ LW ZDV VXEMHFWHG WR  F\FOHV RI
IUHH]LQJDQGWKDZLQJ7KHVXVSHQVLRQRIYHVLFOHVZDVH[WUXGHG
WLPHVWKURXJKDQPRUQPSRUHVL]HSRO\FDUERQDWH
PHPEUDQH RQ OLSLG H[WUXGHU 1RUWKHUQ /LSLGV ,QF 9DQFRXYHU
%& LQ RUGHU WR REWDLQ /89V RU 689V &DOFHLQORDGHG DQG
),7&GH[WUDQORDGHG YHVLFOHV ZHUH SXULILHG E\ JHO ILOWUDWLRQ
FKURPDWRJUDSK\6HSKDURVH* WR UHPRYHXQHQFDSVXODWHG
G\H 7KH ILQDO OLSLG FRQFHQWUDWLRQ GHWHUPLQHG DV WRWDO
SKRVSKRUXVZDVFRQGXFWHGDFFRUGLQJWR&KHQHWDO>@
'\QDPLFOLJKWVFDWWHULQJ
7KH VL]H GLVWULEXWLRQ DQG WKH VWDELOLW\ RI YHVLFOHV ZHUH
FKHFNHGE\'/6H[SHULPHQWVSHUIRUPHGRQD=HWDVL]HU1DQR
=6 LQVWUXPHQW 0DOYHUQ ,QVWUXPHQW 8. '/6PHDVXUHPHQWV
ZHUH SHUIRUPHG DW  & LQ 3%6 S+  LQ GXSOLFDWH 'XULQJ
HYHU\PHDVXUHPHQW  UXQVZHUH FROOHFWHG '23* /89 DQG
689 VL]H GLVWULEXWLRQVZHUHPHDVXUHG IRU YHVLFOHV DORQH DQG
DIWHUPLQRILQFXEDWLRQZLWKROLJRPHUV
5HOHDVHDVVD\V
)RU FDOFHLQ UHOHDVH DVVD\ 689 RU /89ZHUH GLOXWHG WR 
0RI OLSLGV$IWHUPLQXWHVRI LQFXEDWLRQ LQWKHSUHVHQFHRI
GLIIHUHQW SURWHLQ VSHFLHV PRQRPHUV ROLJRPHUV ILEULOV
IOXRUHVFHQFHHPLVVLRQDWQPZDVUHFRUGHGDIWHUH[FLWDWLRQ
DW QP0D[LPXP IOXRUHVFHQFHHPLVVLRQZDVREWDLQHGE\
WKH DGGLWLRQ RI  7ULWRQ ; WR GLVUXSW YHVLFOHV 7KH
DYHUDJH YDOXHV RI H[SHULPHQWV SHUIRUPHG LQ WULSOLFDWH ZHUH
H[SUHVVHGDVDSHUFHQWDJHRIWKHPD[LPXPHIIHFWGXHWRWRWDO
YHVLFOHV GLVUXSWLRQ ),7&GH[WUDQORDGHG 689V RU /89VZHUH
LQFXEDWHGIRUPLQXWHVLQWKHSUHVHQFHRIWKHSURWHLQVSHFLHV
DW D ILQDO OLSLG FRQFHQWUDWLRQ RI  0 5HOHDVHG G\H ZDV
GHWHFWHGE\ IOXRUHVFHQFHPHDVXUHPHQWZLWK H[FLWDWLRQDW 
QPDQGHPLVVLRQDWQPDIWHUSXULILFDWLRQRIWKHLQFXEDWHG
VROXWLRQWKURXJK0LFURFRQFXWRIIWRDOORZ),7&'H[WUDQ
HOXWLRQ 7KH PLQLPXP DQG PD[LPXP HIIHFW ZDV REWDLQHG E\
PHDVXUHPHQW RI D OLSRVRPH VROXWLRQ UHVSHFWLYHO\ ZLWK RU
ZLWKRXW7ULWRQ;7KHDYHUDJHYDOXHVRIH[SHULPHQWV
SHUIRUPHGLQWULSOLFDWHZHUHH[SUHVVHGDVDSHUFHQWDJHRIWKH
PD[LPXPHIIHFWFDOFXODWHGDVWRWDOYHVLFOHVGLVUXSWLRQREWDLQHG
ZLWK7ULWRQ;
&HOOSHUPHDELOL]DWLRQDVVD\
7R H[DPLQH ZKHWKHU D6'+$ ROLJRPHUV FDQ SHUPHDELOL]H
FHOO PHPEUDQHV ZH H[SORLWHG WKH DELOLW\ RI SURSLGLXP LRGLGH
3, 0:  'D WR ELQG '1$ DV LQGLUHFW UHSRUWHU RI
PHPEUDQH GDPDJH 'RSDPLQHUJLF 6+6<< FHOOV ZHUH
FXOWXUHG LQ ZHOO SODWHV VHHGLQJ GHQVLW\ a FHOOVZHOO
DQGWZHQW\IRXUKRXUVDIWHUVHHGLQJWUHDWHGZLWK0RID6
PRQRPHURUD6'+$ROLJRPHUV ,PSHUPHDQWG\H3, JPO
DQGFRXQWHUVWDLQG\H+RHFKVWJPOZHUHDGGHG WR
FHOOVVLPXOWDQHRXVO\WRWKHWUHDWPHQW$IWHUDPLQLQFXEDWLRQ
DW & 3,SRVLWLYH FHOOV ZHUH FRXQWHG LQ WKUHH UHSOLFDWH
FXOWXUHVDFTXLULQJDQDYHUDJHRI ILHOGVSHUFXOWXUH
FHOOVILHOG 7KH H[SHULPHQW KDV EHHQ UHSHDWHG  WLPHV
LQGHSHQGHQWO\6DSRQLQJPOZDVXVHGDVSRVLWLYHFRQWURO
RIPHPEUDQHSHUPHDELOL]DWLRQ
$JJUHJDWLRQVWXG\
,QRUGHUWRLQGXFHDJJUHJDWLRQD0VROXWLRQRID6'+$
ROLJRPHUV FDOFXODWHG DV PRQRPHU FRQFHQWUDWLRQ ZDV
LQFXEDWHG LQ  P0 7ULVÂ+&O  P0 1D&O S+  LQ WKH
DEVHQFHRULQWKHSUHVHQFHRI'+$P0PRODUUDWLR
RU'23*689VP0RUP0PRODUUDWLRSURWHLQOLSLG
DQG  DW & XQGHU VKDNLQJ DW  USPZLWK D WKHUPR
PL[HU &RPSDFW (SSHQGRUI +DPEXUJ '( $OLTXRWV RI WKH
VDPSOHVZHUHH[DPLQHGE\7K7ELQGLQJDVVD\&'DQG7(0
7KH7K7ELQGLQJDVVD\VZHUHSHUIRUPHGDFFRUGLQJO\WR/H9LQH
>@XVLQJDȝ07K7VROXWLRQ LQP0VRGLXPSKRVSKDWH
S+  $OLTXRWV  ȝO RI SURWHLQ VDPSOHV FRQWDLQLQJ
DJJUHJDWHVZHUH WDNHQDW VSHFLILHG WLPHVDQGGLOXWHG LQWR WKH
7K7 EXIIHU )OXRUHVFHQFH HPLVVLRQ PHDVXUHPHQWV ZHUH
FRQGXFWHGDW &XVLQJDQH[FLWDWLRQZDYHOHQJWKRI QP
DQGUHFRUGLQJWKH7K7IOXRUHVFHQFHHPLVVLRQDWQP
3ODQDU/LSLG0HPEUDQHH[SHULPHQWV
6ROYHQWIUHH3ODQDU/LSLG0HPEUDQH3/0ZDVFRPSRVHGRI
HTXLPRODUPL[WXUH RI GLROH\OSKRVSKDWLG\OJO\FHURO '23*
DQGGLROH\OSKRVSKDWLG\OHWKDQRODPLQH'23(DQGIRUPHG
RQDQDSHUWXUHLQDȝPWKLFN7HIORQVHSWXPVHSDUDWLQJWZR
FKDPEHUVDVGHVFULEHGLQ'DOOD6HUUDHWDO>@,RQLFFXUUHQWV
ZHUHUHFRUGHGE\DSDWFKFODPSDPSOLILHU9$;QSL7DPP
*HUPDQ\ILOWHUHGDW+]GLJLWDOL]HGDQGDFTXLUHGDWN+]
E\ WKH FRPSXWHU XVLQJ 'LJL'DWD  $' FRQYHUWHU DQG
S&ODPSVRIWZDUH$[RQ,QVWUXPHQWV6XQQ\YDOH&$
5HVXOWV
%LRSK\VLFDOSURSHUWLHVRIROLJRPHUV
D6ROLJRPHUVLQGXFHGE\'+$ZHUHREWDLQHGDVSUHYLRXVO\
GHVFULEHG >@ DQG ZHUH SXULILHG E\ JHO ILOWUDWLRQ IURP
PRQRPHULF D6 DIWHU  K LQFXEDWLRQ >@ 7KH IUDFWLRQ
FRUUHVSRQGLQJWRROLJRPHUVZDVDQDO\]HGE\53+3/&)LJXUH
$UHGOLQHDQGFRPSDUHGZLWK53+3/&SURILOHRIWKHVDPH
VDPSOH EHIRUH LWV SXULILFDWLRQ E\ JHO ILOWUDWLRQ 7KH SHDN 57
 PLQ FRUUHVSRQGLQJ WR '+$ LV ODFNLQJ LQGLFDWLQJ WKDW
H[FKDQJHDEOH'+$LVUHPRYHG0DVVVSHFWURPHWU\)LJXUH$
LQVHWVKRZVWKDWD6PROHFXOHVLQWKHROLJRPHUVDUHFKHPLFDOO\
PRGLILHG IRU WKH SUHVHQFH RI FRYDOHQWO\ ERXQG '+$ DV
SUHYLRXVO\ GHWHUPLQHG >@ 3UHYLRXVO\ 7(0DQDO\VLV VKRZHG
WKDW WKH FKURPDWRJUDSKLF IUDFWLRQ FRUUHVSRQGLQJ WR ROLJRPHUV
KDGDVSKHULFDOPRUSKRORJ\ZLWKGLDPHWHUVUDQJLQJIURPWR
 QP >@ ,Q )LJXUH % WKH QXPEHU VL]H GLVWULEXWLRQ IURP
D6'+$ ROLJRPHUV REWDLQHG E\ '/6 DQDO\VLV LV VKRZQ
LQGLFDWLQJDPHDQVL]HRIQP$)0PHDVXUHPHQWLQVHW
EDVHG RQ KHLJKW GLIIHUHQFHV VKRZV WKH SUHVHQFH RI VPDOOHU
QPDQGODUJHUQPROLJRPHUV
Į6\QXFOHLQ2OLJRPHUVDQG0HPEUDQHV
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6SHFWURVFRSLF DQDO\VLV E\ IDU 89 &' RI ROLJRPHUV DIWHU
SXULILFDWLRQ E\ JHO ILOWUDWLRQ LV UHSRUWHG )LJXUH & 7KH
VSHFWUXPRI ROLJRPHUV UHG OLQH LV VKRZQ LQ FRPSDULVRQZLWK
&' VSHFWUD RI PRQRPHULF D6 FRQWLQXRXV OLQH DQG RI WKH
PL[WXUH RI D6'+$ EHIRUH JHO ILOWUDWLRQ GDVKHG OLQH VHH UHI
 7KLV DQDO\VLV LQGLFDWHV WKDW ROLJRPHUV DFTXLUH D SDUWO\
IROGHGFRQIRUPDWLRQDOVWDWHZLWKDPRGHUDWHFRQWHQWRIĮKHOLFDO
VWUXFWXUH)XUWKHUDGGLWLRQRI'+$WRROLJRPHUVLVRODWHGE\JHO
)LJXUH &KHPLFRSK\VLFDO FKDUDFWHUL]DWLRQRI D6'+$ROLJRPHUVDIWHU WKHLU LVRODWLRQE\JHO ILOWUDWLRQ  $53+3/&RI
D6'+$ROLJRPHUVDIWHUWKHLULVRODWLRQE\JHOILOWUDWLRQUHGOLQHDQGEHIRUHGDVKHGOLQH+3/&DQDO\VHVZHUHFRQGXFWHGXVLQJD
-XSLWHU&FROXPQ[PP3KHQRPHQH[&$86$HOXWHGZLWKDJUDGLHQWRIDFHWRQLWULOH7)$YVZDWHU7)$
IURPWRLQPLQIURPWRLQPLQUHFRUGLQJWKHDEVRUEDQFHDWQP7KHLGHQWLW\RIWKHHOXWHGPDWHULDOZDV
DVVHVVHGE\PDVVVSHFWURPHWU\DQGWKHVSHFWUXPRIROLJRPHUVLVUHSRUWHGLQVHW%'/6IRUSDUWLFOHVL]HHVWLPDWLRQRID6'+$
ROLJRPHUV,QVHW7DSSLQJPRGH$)0LPDJHRIROLJRPHUV6FDQVL]HZDVP=UDQJHZDVQP&)DU89&'RIROLJRPHUV
DIWHUSXULILFDWLRQE\JHOILOWUDWLRQUHGOLQH7KHVSHFWUDRIPRQRPHULFD6DQGD6LQWKHSUHVHQFHRI'+$SURWHLQ'+$DUHDOVR
UHSRUWHG DV UHIHUHQFH ' 7LWUDWLRQ H[SHULPHQW E\ IDU 89 &' RI ROLJRPHUV LQ WKH SUHVHQFH RI LQFUHDVLQJ DPRXQW RI '+$ 7KH
QXPEHUVFORVHWRWKHVSHFWUDLQGLFDWHWKHDPRXQW0RI'+$
GRLMRXUQDOSRQHJ
Į6\QXFOHLQ2OLJRPHUVDQG0HPEUDQHV
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ILOWUDWLRQLQGXFHVDQLQFUHDVHRIWKHLUĮKHOLFDOVWUXFWXUH)LJXUH
' DV REVHUYHG IRU PRQRPHULF D6 >@ 7KH WUDQVLWLRQ
EHWZHHQ SDUWO\ IROGHG VWDWH DQG ĮKHOL[ IROORZV D WZRVWDWH
PRGHO IRU WKHSUHVHQFHRIDQ LVRGLFKURLFSRLQWDWaQP LQ
WKHWLWUDWLRQH[SHULPHQW
2OLJRPHUVLQWHUDFWZLWKQHJDWLYHO\FKDUJHGPHPEUDQHV
,Q RUGHU WR HOXFLGDWH WKH PHFKDQLVP E\ ZKLFK '+$D6
ROLJRPHUV H[HUW WKHLU WR[LF DFWLYLW\ WKH LQWHUDFWLRQ ZLWK PRGHO
PHPEUDQHVKDV EHHQ VWXGLHG&' VSHFWURVFRS\ZDVXVHG WR
GHWHUPLQH WKH HIIHFWV RI OLSLG ELQGLQJ RQ WKH VHFRQGDU\
VWUXFWXUH RI D6'+$ ROLJRPHUV DQG YDULRXV FRPELQDWLRQV RI
FKDUJHGDQGXQFKDUJHGOLSLGVKDYHEHHQXVHG,Q)LJXUHWKH
&'VSHFWUDRID6'+$ROLJRPHUV UHFRUGHG LQ WKHSUHVHQFHRI
689 RU /89 DUH UHSRUWHG D6'+$ ROLJRPHUV LQWHUDFW ZLWK
V\QWKHWLFPHPEUDQHVFRQWDLQLQJQHJDWLYHO\FKDUJHG'23*RU
D PL[WXUH RI QHJDWLYH DQG QHXWUDO SKRVSKROLSLGV DV '23*
323( DQG 3236323& )LJXUH  DVPRUH SURQRXQFHG
PLQLPDDWDQGQPDUHREVHUYHG LQ WKHVSHFWUDXSRQ
ELQGLQJWRWKHVHPHPEUDQHVLQGLFDWLQJDQLQFUHDVHRIĮKHOLFDO
FRQIRUPDWLRQ 689 RU /89 FRQWDLQLQJ QHXWUDO SKRVSKROLSLGV
323&RU323(GRQRW LQGXFHDQ\FRQIRUPDWLRQDOFKDQJHLQ
D6 ROLJRPHUV DVZHOO DV YHVLFOHV FRQVWLWXWHG E\ DPL[WXUH RI
OLSLG H[WUDFWHG IURP EUDLQ )LJXUH  689 DQG /89 ZLWK WKH
VDPHFRPSRVLWLRQH[HUWVLPLODUHIIHFWRQROLJRPHUVVHFRQGDU\
VWUXFWXUH VXJJHVWLQJ WKDW FXUYDWXUH LV QRW D GLVFULPLQDWLQJ
IDFWRU
2OLJRPHUVGRQRWDJJUHJDWHLQWKHSUHVHQFHRIOLSLGV
DQGPHPEUDQHV
0HPEUDQHLQGXFHG RU OLSLGDFFHOHUDWHG ILEULO IRUPDWLRQ RI
DP\ORLGRJHQLF SURWHLQV ZDV IUHTXHQWO\ REVHUYHG >@ 7R
DQDO\]HWKHHIIHFWRIPHPEUDQHVRQWKHDJJUHJDWLRQSURSHUWLHV
RID6'+$ROLJRPHUVD6DQGD6ROLJRPHUVZHUHLQFXEDWHGLQ
WKH DEVHQFH DQG LQ WKH SUHVHQFH RI YHVLFOHV PRODU UDWLR
SURWHLQOLSLGRIDQG7KHDJJUHJDWLRQZDVFRQGXFWHG
LQ WKHSUHVHQFHRI'23*689 VLQFHROLJRPHUVSUHIHUHQWLDOO\
LQWHUDFWZLWK QHJDWLYHO\ FKDUJHGPHPEUDQHV DQG'+$ PRODU
UDWLRSURWHLQIDWW\DFLGDVFRQWURO7KHHIIHFWRIWKHOLSLGV
RQ SURWHLQ DJJUHJDWLRQ ZDV PRQLWRUHG E\ 7K7 IOXRUHVFHQFH
DVVD\)LJXUH7KHDJJUHJDWLRQSURFHVVRID6UHVXOWVVSHG
XS LQ WKH SUHVHQFH RI '23* 689  )LJXUH $ HPSW\
FLUFOHVZKLOHLQWKHSUHVHQFHRI'23*689LVLQKLELWHG
)LJXUH $ HPSW\ WULDQJOHV 7(0 DQDO\VLV VKRZ WKDW LQ WKH
PL[WXUH FRUUHVSRQGLQJ WR D6 LQFXEDWLRQ IRU  GD\V LQ WKH
SUHVHQFHRI689'23*WKHUHDUHLQGLYLGXDOD6DP\ORLG
OLNHILEULOVDVVRFLDWHGWRWKHVXUIDFHRI689)LJXUH$ LQVHW
7KHVL]HDQGPRUSKRORJ\RIWKHVHILEULOVDUHVLPLODUWRWKRVHRI
D6 ILEULOV IRUPHG LQ WKH DEVHQFH RI 689 ,Q ERWK FDVHV D6
IRUPVVWUDLJKWXQEUDQFKHGILEULOVZLWKDZLGWKRI±QP$Q
DGGLWLRQDO IHDWXUH LV WKDW WKHVKDSHRI YHVLFOHV LQFRQWDFWZLWK
ILEULOV LV QRW FKDQJHG ,Q WKH SUHVHQFH RI '+$ DV SUHYLRXVO\
REVHUYHG WKHUH LV QRW IRUPDWLRQ RI D6 DJJUHJDWHV WKDW ELQG
7K7 G\H )LJXUH $ LQYHUWHG EODFN WULDQJOHV ,Q WKH FDVH RI
D6'+$ ROLJRPHUV WKHLU LQFXEDWLRQ LQ WKH SUHVHQFH RU WKH
DEVHQFHRI689RU'+$GRHVQRWUHVXOWLQDQ\LQFUHDVHRIWKH
IOXRUHVFHQFHRI7K7G\HFRQILUPLQJWKHLUQDWXUHRIRIISDWKZD\
LQWHUPHGLDWHV )LJXUH % 7KH DJJUHJDWLRQ SURFHVV ZDV
IXUWKHUPRQLWRUHGE\&'VSHFWURVFRS\FRQILUPLQJWKHSUHVHQFH
RI ȕVKHHW VWUXFWXUH RQO\ IRU 7K7SRVLWLYH ILEULOV GDWD QRW
VKRZQ
2OLJRPHUVLQGXFHSHUPHDELOL]DWLRQRIDUWLILFLDO
PHPEUDQHV
7KHFDOFHLQOHDNDJHWHVWZDVSHUIRUPHGWRGHWHFWFKDQJHVLQ
PHPEUDQHSHUPHDELOL]DWLRQDVUHVXOWRIROLJRPHUVELQGLQJ7KH
DPRXQW RI FDOFHLQ UHOHDVH IURP/89RU689ZDV GHWHUPLQHG
DIWHUPLQRILQFXEDWLRQZLWKWKHROLJRPHUV,Q)LJXUH$WKH
OHDNDJHRIFDOFHLQIURP/89ZDVVKRZQLQFRPSDULVRQZLWKWKH
HIIHFW LQGXFHG E\ PRQRPHULF DQG ILEULOODU D6 :H XVHG /89
FRQWDLQLQJ SKRVSKROLSLGV ZKLFK LQWHUDFW '23* SDUWLDOO\
LQWHUDFW 323&3236 RU GR QRW LQWHUDFW 7%( ZLWK
ROLJRPHUV DV VKRZQ E\&'PHDVXUHPHQWV ,W LV HYLGHQW WKDW
ROLJRPHUV DUH DEOH WR LQGXFH D VLJQLILFDQW G\H UHOHDVH LQ
FRPSDULVRQWRPRQRPHULFD6DQGILEULOV7KHHIIHFWLVVHOHFWLYH
IRU QHJDWLYHO\ FKDUJHG PHPEUDQHV 7KLV HIIHFW ZDV DOVR
DQDO\]HGRQ'23*689XVLQJGLIIHUHQWSURWHLQOLSLGPRODUUDWLR
)LJXUH%7KH OHDNDJHRFFXUV LQDGRVHGHSHQGHQWPDQQHU
DQGUHDFKHVDERXWDWȝ0SURWHLQFRQFHQWUDWLRQ)LJXUH
% LQVHW 7KH SHUPHDELOL]LQJ DFWLYLW\ RI D6'+$ ROLJRPHUV
VKRZV VHOHFWLYLW\ DV D IXQFWLRQ RIPROHFXODU GLPHQVLRQ RI WKH
G\H LQGHHG FDOFHLQ SDVVHV WKURXJK WKH PHPEUDQH LQ WKH
SUHVHQFH RI ROLJRPHUV ZKLOH ODUJHUPROHFXOHV VXFK DV ),7&
GH[WUDQZLWKD6WRNH¶VUDGLXVQPGRQRW)LJXUH&%\
WKHZD\ WKLV YDOXH URXJKO\GHILQHVDQXSSHU OLPLW WR WKHSRUH
UDGLXV
2OLJRPHUVLQFUHDVHSHUPHDELOLW\RIGRSDPLQHUJLFFHOOV
$OWKRXJKZHFOHDUO\VHHWKDWD6'+$ROLJRPHUVDUHFDSDEOH
RISHUPHDELOL]LQJDUWLILFLDOPHPEUDQHVZHQH[WDVNHGZKHWKHU
WKLVDFWLYLW\LVDOVRREVHUYHGLQDPRUHFRPSOH[V\VWHPVXFKDV
WKHFHOOPHPEUDQH:HXVHG3,DFHOOLPSHUPHDQW'1$G\H
WR HYDOXDWH WKH HIIHFW RI ROLJRPHUV WR PRGLI\ PHPEUDQH
SHUPHDELOLW\ RI GRSDPLQHUJLF 6+6<< FHOOV 6+6<< FHOOV
WUHDWHG ZLWK ERWK D6 ROLJRPHULF DJJUHJDWHV SXULILHG E\ JHO
ILOWUDWLRQDQGPRQRPHULFD6ZHUHREVHUYHGZLWKLQKRXU:H
REVHUYHGDPRGHVWEXWVLJQLILFDQW LQFUHDVHRI3,SRVLWLYHFHOOV
XSRQWUHDWPHQWZLWKD6'+$ROLJRPHUVFRPSDUHGWRPRQRPHU
RU YHKLFOH FRQWURO DV TXDQWLILHG E\ RQH ZD\ $129$ ZLWK
7XNH\¶VSRVWKRFWHVW3)LJXUH
2OLJRPHUVGRQRWH[HUWGHWHUJHQWOLNHHIIHFW
7R WHVW WKH SRVVLELOLW\ WKDW D6'+$ ROLJRPHUV ZHUH DEOH WR
FRPSURPLVH WKH LQWHJULW\RI WKHPHPEUDQHE\DGHWHUJHQWOLNH
PHFKDQLVP ODUJH DQG VPDOO XQLODPHOODU YHVLFOHV ZHUH
DQDO\]HG E\ G\QDPLF OLJKW VFDWWHULQJ '/6 DIWHU LQFXEDWLRQ
ZLWKROLJRPHUV IRUPLQXWHVXVLQJDPRODU UDWLRSURWHLQOLSLG
RI  ,Q )LJXUH  WKH QXPEHUV DQG LQWHQVLWLHV VL]H
GLVWULEXWLRQV RI '23* /89 $& DQG 689 %' EHIRUH DQG
DIWHUDGGLWLRQRID6ROLJRPHUVDUHVKRZQ7KHSHDNUHODWLYHWR
YHVLFOHVDORQH VROLG OLQHV LV FHQWHUHGDWQP IRU/89
$DQGDWQPIRU689%7KHPHDQVL]HRIROLJRPHUV
DORQH GDVKHG OLQH LV  QP 7KH DGGLWLRQ RI ROLJRPHUV WR
YHVLFOHV LQGXFHV D FKDQJH LQ WKH VL]H GLVWULEXWLRQ RI YHVLFOHV
JUH\ EDUV GLIIHUHQW IURP WKDW LQGXFHG E\ 7ULWRQ ; $%
EODFN EDUV 6LQFH WKH DGGLWLRQ RI 7ULWRQ UHVXOWV LQ
Į6\QXFOHLQ2OLJRPHUVDQG0HPEUDQHV
3/2621(_ZZZSORVRQHRUJ  1RYHPEHU_9ROXPH_,VVXH_H
)LJXUH   ,QWHUDFWLRQRI D6'+$ROLJRPHUVZLWK OLSLG YHVLFOHVZLWKGLIIHUHQW FRPSRVLWLRQPRQLWRUHGE\ IDU89&'  7KH
VSHFWUD UHODWLYH WR D6'+$ROLJRPHUV DORQH UHG FRQWLQXRXV OLQH D6'+$ROLJRPHUV LQ WKH SUHVHQFH RI 689DWPRODU UDWLR 
GRWWHGOLQHDQGGDVKHGOLQHDQGLQWKHSUHVHQFHRI/89DWPRODUUDWLRGRWWHGGDVKHGOLQHDUHUHSRUWHG
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)LJXUH   $JJUHJDWLRQ VWXGLHV  D6 $ DQG D6'+$
ROLJRPHUV %DJJUHJDWLRQSURFHVVDW& LQ WKHSUHVHQFHRI
OLSLGVIROORZHGE\7K7ELQGLQJDVVD\D6RUD6ROLJRPHUVZHUH
GLVVROYHG LQ  P0 7ULV  P0 1D&O S+  DW D  0
FRQFHQWUDWLRQ LQ RUGHU WR LQGXFH DJJUHJDWLRQ LQ WKH DEVHQFH
EODFN FLUFOHV DQG LQ WKH SUHVHQFH RI '23* 689 DW PRODU
UDWLR  HPSW\ FLUFOHV  HPSW\ WULDQJOHV DQG LQ WKH
SUHVHQFH RI '+$ PRODU UDWLR  LQYHUWHG EODFN WULDQJOHV
7KH H[FLWDWLRQ ZDYHOHQJWK ZDV IL[HG DW  QP DQG WKH
IOXRUHVFHQFH HPLVVLRQ ZDV FROOHFWHG DW  QP 7R EHWWHU
YLVXDOL]HWKHDJJUHJDWLRQWUHQGRID6DQGD6LQWKHSUHVHQFHRI
'23* PRODU UDWLR  WKH GDWD SRLQWV DUH ILWWHG ZLWK D
VLJPRLGDOHTXDWLRQ6LJPD3ORWVRIWZDUH,QVHW7(0LPDJHVRI
SURWHLQPDWHULDOUHODWLYHWRD6DQGD6'+$ROLJRPHUVVDPSOHV
DIWHUGD\VRILQFXEDWLRQLQWKHSUHVHQFHRI'23*689PRODU
UDWLR
GRLMRXUQDOSRQHJ
)LJXUH  /HDNDJH DVVD\V  $ &DOFHLQ HIIOX[ IURP  0
/89 RI GLIIHUHQW OLSLG FRPSRVLWLRQ LQGXFHG DIWHU  PLQ E\
PRQRPHULF ILEULOODU DQG ROLJRPHULF D6 DW D SURWHLQOLSLGPRODU
UDWLRRI %&DOFHLQHIIOX[ IURP0'23*689XSRQ
DGGLWLRQRI LQFUHDVLQJDPRXQW EODFNEDUVJUH\EDUV
GDUNJUH\EDUV0 OLJKWJUH\EDUVRISURWHLQVSHFLHV
,QVHW'HSHQGHQFHRIWKHOHDNDJHIURP0'23*689RQ
WKHFRQFHQWUDWLRQRISURWHLQRUROLJRPHUV7KHHIIHFWLQGXFHGE\
LQFUHDVLQJFRQFHQWUDWLRQRIPRQRPHULFD6LVDOVRUHSRUWHG&
),7&GH[WUDQ OHDNDJH IURP  0 '23* /89 DQG 689
LQGXFHG DIWHU PLQ RI LQFXEDWLRQ E\ D6'+$ROLJRPHUV DQG
D6 /HDNDJH LV H[SUHVVHG DV SHUFHQWDJH RI WKH PD[LPXP
SRVVLEOH HIIHFW LQGXFHG E\ WKH DGGLWLRQ RI 7ULWRQ ;
6WDWLVWLFDO VLJQLILFDQFH ZDV FDOFXODWHG E\ VWXGHQW¶V WWHVW
S
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GLVDJJUHJDWLRQ RI WKH YHVLFOHV LQWRPLFHOOHVZH FDQ FRQFOXGH
WKDW WKHROLJRPHUVGRQRWDFWDVGHWHUJHQWV7RKDYHDEHWWHU
YLHZ RI WKH VL]H GLVWULEXWLRQ RI YHVLFOH XSRQ DGGLWLRQ RI
ROLJRPHUVWKHPHDVXUHPHQWVH[SUHVVHGDVLQWHQVLWLHVDUHDOVR
UHSRUWHG &' 7KH SHDN UHODWLYH WR YHVLFOHV VSOLWV LQWR WZR
SHDNV JUD\ EDUV FRUUHVSRQGLQJ WR WZR YHVLFOHV SRSXODWLRQ
ZLWK LQFUHDVHGFHQWHUHGDWaQPIRU/89DQGDWaQP
IRU 689 DQG GHFUHDVHG VL]H FHQWHUHG DW a QP IRU /89
DQG DW a QP IRU 689 7KLV UHVL]LQJ FDQ EH DVFULEDEOH WR
FOXVWHULQJIXVLRQ RI WKH YHVLFOHV LQ WKH FDVH RI WKH LQFUHDVHG
VL]H RU WR UHPRGHOLQJ LQ WKH FDVH RI WKH VPDOOHU VSHFLHV 2I
LQWHUHVW WKHVDPHH[SHULPHQWZDV IROORZHGE\7(0)LJXUH
() WKDWGRHVQRWHYLGHQFHVXEVWDQWLDOGLIIHUHQFH LQYHVLFOHV
VKDSHDIWHUROLJRPHUDGGLWLRQ
2OLJRPHUVDFWLYLW\RQSODQDUOLSLGPHPEUDQH
D6'+$ROLJRPHUVDWDILQDOFRQFHQWUDWLRQRIQ0DUHDEOH
WR LQFUHDVH WKH FRQGXFWDQFH RI 3/0 FRPSRVHG RI '23*
)LJXUH  3, LQIOX[ LQ GRSDPLQHUJLF FHOOV  6+6<< FHOOV
ZHUH WUHDWHG ZLWK D6'+$ ROLJRPHUV DQG WKH QXPEHU RI 3,
SRVLWLYH FHOOV ZDV FDOFXODWHG DV D SHUFHQWDJH RI WKH WRWDO
FRXQWHUVWDLQHGFHOOV4XDQWLWDWLRQQ FXOWXUHVZLWK ILHOGV
DQDO\]HG SHU FXOWXUH  FHOOV SHU ILHOG HUURU EDUV
LQGLFDWHGWKH6( LQGLFDWHGWKDWD6'+$ROLJRPHUVLQFUHDVHG
WKHSHUFHQWDJHRI3,SRVLWLYHFHOOV6WDWLVWLFDOVLJQLILFDQFHZDV
FDOFXODWHGE\RQHZD\$129$SFRPSDUHGZLWKPRFN
FRQWURORUPRQRPHULFD6
GRLMRXUQDOSRQHJ
'23( XSRQ WKH DSSOLFDWLRQ RI HLWKHU SRVLWLYH RU QHJDWLYH
KLJKSRWHQWLDOVDEVROXWHYDOXHVODUJHUWKDQP9,QRI
H[SHULPHQWVFXUUHQW IOXFWXDWLRQVDSSHDUHGQRQVWUXFWXUHGZLWK
VKRUW OLYLQJ VSLNHVZLWK VPDOO LRQLF FXUUHQWV URXJKO\  S$DW
P9DVUHSRUWHGLQ)LJXUH$7KLVSHUPHDELOL]LQJDFWLYLW\
JHQHUDOO\ GLVDSSHDUHG DIWHU IHZ PLQXWHV ZLWKRXW FDXVLQJ
PHPEUDQHUXSWXUHZLWKSURWHLQFRQFHQWUDWLRQXSWRQ0,Q
RIH[SHULPHQWVDPRUHLQWHQVHFXUUHQWXSWRS$KDV
EHHQ UHFRUGHG DV UHSRUWHG LQ )LJXUH % 6RPHWLPHV PRUH
VWDEOHDSHUWXUHVFDQDOVREHVHHQDVUHSRUWHGLQWKHULJKWVLGH
RI)LJXUH%,QWKLVFDVHWKHFXUUHQWYROWDJHFXUYHKDVDQRQ
RKPLF FKDUDFWHULVWLF ZLWK KLJKHU FXUUHQW DW QHJDWLYH DSSOLHG
YROWDJHV 1RPHPEUDQH GHVWDELOL]DWLRQ KDV EHHQ UHFRUGHG LQ
WKH UHPDLQLQJ  RI H[SHULPHQWV &RQWURO H[SHULPHQWV ZLWK
'+$DORQHXSWRȝ0LQ(W2+GLGQRWVKRZDQ\PHPEUDQH
SHUWXUEDWLRQQRWVKRZQ
'LVFXVVLRQ
7KHUH LV JURZLQJ LQWHUHVW LQ XQGHUVWDQGLQJ D SRVVLEOH OLQN
EHWZHHQ D6 WR[LFLW\ LQ V\QXFOHLQRSDWKLHV DQG D6OLSLG
LQWHUDFWLRQ >@ D6 WR[LFLW\ LV LQGHHG DVVRFLDWHG ZLWK
DOWHUDWLRQLQYHVLFOHWUDIILFNLQJ>@PLWRFKRQGULDOIXQFWLRQ>@
DQG OLSLGV HVSHFLDOO\ EUDLQ )$V ELRV\QWKHVLV DQGPHWDEROLVP
>@ ,QFUHDVLQJ HYLGHQFH VKRZV WKDW ROLJRPHUV RULJLQDWLQJ LQ
HDUO\VWDJHVRID6ILEULOODWLRQDUHUHVSRQVLEOHIRUWR[LFLW\,WKDV
EHHQ VKRZQ WKDW HOHYDWHG EUDLQ '+$ OHYHOV DFFHOHUDWH D6
DFFXPXODWLRQDQGROLJRPHUL]DWLRQ >@ OHDGLQJ WRQHXURWR[LFLW\
>@ :H SURGXFHG LQ YLWUR ROLJRPHULF VSHFLHV RI D6 LQ WKH
SUHVHQFHRI'+$ZKLFKUHVXOWHGWR[LFLQFXOWXUHGGRSDPLQHUJLF
FHOOV>@+HUHZHKDYHVWXGLHGWKHLUDFWLYLW\RQPHPEUDQHVLQ
DQDWWHPSWWRXQGHUVWDQGWKHLUPHFKDQLVPRIWR[LFLW\7KHODWWHU
LVREMHFWRIGHEDWH LQ WKH OLWHUDWXUHIRU WKHGLIILFXOW\ WRGHILQHD
XQLI\LQJ SLFWXUH RI WKH WR[LF DFWLYLW\ 7KH FRQWURYHUV\ VSULQJV
IURP ERWK WKH WUDQVLHQW QDWXUH RI D6 ROLJRPHUV DQG IURP WKH
PDQ\GLIIHUHQWW\SHVRIROLJRPHUVWKDWKDYHEHHQGHVFULEHGD
FRQVHTXHQFHRIWKHYDULHW\RIWKHPHWKRGRISUHSDUDWLRQ,QWKH
SUHVHQFHRI'+$LWLVLQGXFHGWKHIRUPDWLRQRIUHODWLYHO\VWDEOH
ROLJRPHUVWKDWDUHRIISDWKZD\LQD6DJJUHJDWLRQSURFHVV
D6ROLJRPHUVKDYHEHHQGHVFULEHGDVDQQXODUDQGVSKHULFDO
VKDSHG DQG DUH JHQHUDOO\ FKDUDFWHUL]HG E\ EHWDVKHHW
VWUXFWXUHVRPHRIWKHPUHVXOWHGWR[LFWRFHOOV>@%DVHG
RQ 7(0 DQG $)0 PHDVXUHPHQWV D6'+$ ROLJRPHUV VKDUH
VLPLODU VL]HZLWKGLDPHWHUV UDQJLQJ IURPQP$VSHFLILF
GLIIHUHQFH ZLWK ROLJRPHUV GHVFULEHG DERYH UHVLGHV LQ WKH
VHFRQGDU\ VWUXFWXUH D6 LQ WKH SUHVHQFH RI '+$ DFTXLUHV Į
KHOLFDO VWUXFWXUH >@ DQG ROLJRPHUV REWDLQHG XSRQ D6'+$
LQFXEDWLRQKRXUVPDLQWDLQĮKHOLFDOVWUXFWXUH$IWHUDJHO
ILOWUDWLRQ SXULILFDWLRQ VWHS H[FKDQJHDEOH '+$ QRW WKH
FRYDOHQWO\ ERXQG RQH LV UHPRYHG DQG ZLWK LW WKH HIIHFW RQ
ROLJRPHUVVWUXFWXUH&RQVHTXHQWO\SDUWRIWKH'+$GHSHQGHQW
VHFRQGDU\VWUXFWXUH LV ORVWDQGWKHROLJRPHUVDFTXLUHDSDUWO\
IROGHG VWDWH VLJQLILFDQWO\ GLIIHUHQW IURP WKH QDWLYHO\ XQIROGHG
VWUXFWXUHRIPRQRPHULFD67KHVHSDUWO\ IROGHGROLJRPHUVDUH
DEOHWRDFTXLUHDJDLQĮKHOLFDOVWUXFWXUHXSRQDGGLWLRQRI'+$
RU LQ WKH SUHVHQFH RI 689 RU /89 FRQWDLQLQJ QHJDWLYHO\
FKDUJHG KHDG JURXSV $ VLPLODU EHKDYLRU ZDV SUHYLRXVO\
REVHUYHGIRUD6>@ ,QPRQRPHULFD6WKH1WHUPLQDO
Į6\QXFOHLQ2OLJRPHUVDQG0HPEUDQHV
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)LJXUH,QWHUDFWLRQRID6'+$ROLJRPHUVZLWK'23*YHVLFOHVE\'/6DQG7(0'/6DQDO\VLVH[SUHVVHGDVQXPEHUV$%
RUDVLQWHQVLWLHV&'DQG7(0LPDJHV()DUHUHSRUWHG'/6PHDVXUHPHQWVRI'23*/89$&DQG689%'DUHFRQGXFWHG
LQ WKH DEVHQFH RI ROLJRPHUV FRQWLQXRXV OLQHV DQG XSRQ  PLQDGGLWLRQ RI ROLJRPHUV PRODU UDWLR  OLJKW JUH\ EDUV D6
ROLJRPHUVDORQHDUHUHSUHVHQWHGE\GDVKHGOLQHV7KHHIIHFWLQGXFHGE\7ULWRQ;RQ/89DQG689LVUHSRUWHG$%GDUNJUH\
EDUV7(0LPDJHVRI'23*689(RULQWKHSUHVHQFH)RID6'+$ROLJRPHUVZHUHWDNHQDIWHUPLQRILQFXEDWLRQ
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UHJLRQ LV HVVHQWLDO IRU PHPEUDQH UHFRJQLWLRQ DQG IRU
FRRSHUDWLYH IRUPDWLRQ RI KHOLFDO GRPDLQV >@ 6R LW LV
UHDVRQDEOH WR DVVXPH WKDW LQ WKH SDUWO\ IROGHG VWDWH WKH 1
WHUPLQDO UHJLRQ RU SDUW RI LW LV IUHH WR GULYH WKH DVVRFLDWLRQ RI
ROLJRPHUVZLWKPHPEUDQHVDQG OLSLGV2Q WKHRWKHUKDQG WKH
1$&UHJLRQUHVLGXHVVHHPVQRWDYDLODEOHRUKLGGHQLQ
WKHLQWHULRURIWKHROLJRPHULQYLHZRIWKHIDFWWKDWWKHVHVSHFLHV
GRQRWDJJUHJDWHHYHQLQWKHSUHVHQFHRIPHPEUDQHV,QGHHG
WKH PHPEUDQHV FDQ DIIHFW WKH ILEULO IRUPDWLRQ SURFHVV RI D6
DQG RWKHU DP\ORLGRJHQLF SURWHLQV >@ )LEULOODWLRQ FDQ EH
DFFHOHUDWHGRUHYHQPRGXODWHGE\ OLSLGVDQGPHPEUDQHVDQG
WKLVVWULFWO\GHSHQGVRQWKHUHODWLYHSURWHLQOLSLGUDWLR>@,Q
FRQFOXVLRQ D6'+$ ROLJRPHUV KDYH WZR PDLQ VWUXFWXUDO
IHDWXUHV WKH FRQIRUPDWLRQDO VHQVLWLYLW\ WR HQYLURQPHQW IRU WKH
DELOLW\WRLQWHUDFWZLWKOLSLGVDQGWRXQGHUJRVWUXFWXUDOWUDQVLWLRQ
DQG VHFRQGO\ WKH VWDELOLW\ XQGHU FRQGLWLRQV WKDW IDYRU
DJJUHJDWLRQ 7KH RYHUDOO VWUXFWXUH RI WKH ROLJRPHUV FRXOG EH
)LJXUH 3/0H[SHULPHQWV (OHFWURSK\VLRORJLFDODFWLYLW\RI
D6'+$ ROLJRPHUV RQ '23*'23( OLSLG PHPEUDQHV
%XIIHU FRPSRVLWLRQ ZDV .&O  P0 +HSHV  P0 S+ 
3URWHLQFRQFHQWUDWLRQZDVQ0$SSOLHGSRWHQWLDOP9$
RUP9%
GRLMRXUQDOSRQHJ
VWDELOL]HG E\ K\GURSKRELF LQWHUDFWLRQV GHULYLQJ IURP WKH
DVVRFLDWLRQRI1$&UHJLRQV
$QLQWHUHVWLQJSURSHUW\RID6'+$ROLJRPHUVLVWKHLUDELOLW\WR
SHUPHDELOL]H PHPEUDQHV DV YHULILHG XVLQJ D OHDNDJH DVVD\
IURP XQLODPHOODU SKRVSKROLSLG YHVLFOHV DQG LRQLF FXUUHQW
PHDVXUHPHQWV $OVR GRSDPLQHUJLF FHOOV PHPEUDQHV DUH
SHUWXUEHG DV WUHDWPHQW ZLWK ROLJRPHUV VLJQLILFDQWO\ LQFUHDVHV
WKH QXPEHU RI FHOOV LQWHUQDOL]LQJ WKH PHPEUDQHLPSHUPHDQW
G\H SURSLGLXP LRGLGH 7KHVH UHVXOWV VXJJHVW WKDWPHPEUDQHV
FDQEHDSRVVLEOH WDUJHWRID6ROLJRPHUVDFWLYLW\7KLVFDQEH
SDUWLFXODUO\KDUPIXO IRU QHXURQDO FHOOVZKHUHHOHFWULFDO DFWLYLW\
DQG DFWLRQ SRWHQWLDO ILULQJ DUH ILQHO\ UHJXODWHG E\ WUDQVLHQW
YROWDJHJDWHG FKDQQHOPHGLDWHG YDULDWLRQ RI PHPEUDQH
SRWHQWLDO DQG LQWUDFHOOXODU FDOFLXP FRQFHQWUDWLRQ ,QGHHG
LQFUHDVHGPHPEUDQH SHUPHDELOLW\ FRXOG UHVXOW LQ D YDULHW\ RI
LQWUDFHOOXODU SURFHVVHV DQG OHDGV WR H[FLWRWR[LFLW\ DV ZHOO DV
GLVVLSDWLRQRIVRGLXPDQGSRWDVVLXPJUDGLHQWVZLWKGHOHWHULRXV
LPSDFW RQ HOHFWULFDO QHXURQDO DFWLYLW\ 6HYHUDO PHFKDQLVPV
KDYH EHHQ SURSRVHG WR H[SODLQ ROLJRPHUV DFWLYLW\ RQ
PHPEUDQHVVXFKDV WKHSRUHOLNHPHFKDQLVP>@D WKLQQLQJ
HIIHFW GXH WR OLSLG H[WUDFWLRQ IURP WKHELOD\HU >@ D FRPSOHWH
GLVUXSWLRQ RI WKH PHPEUDQH >@ RU D WUDQVLHQW PHPEUDQH
GHVWDELOL]DWLRQ >@ 7KH SRUHOLNH K\SRWKHVLV LV HVSHFLDOO\
DFFHSWHG IRU WKRVH SURWHLQV IRUPLQJ ROLJRPHUV RU SURWRILEULOV
ZLWK DQQXODU RU ULQJOLNH VWUXFWXUH >@ ,Q RXU FDVH WKH
OHDNDJHDFWLYLW\WHVWHGRQV\QWKHWLFOLSRVRPHVVKRZVVHOHFWLYLW\
RIPDUNHUVVL]HHYLGHQFLQJWKDW WKHDYHUDJHGLPHQVLRQRI WKH
DSHUWXUH VKRXOG EH EHWZHHQ  DQG  QP >@ 7KH
SHUPHDELOL]DWLRQ HIIHFW LV LQGXFHG LQ FHOOV MXVW DIWHU PLQ RI
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